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CASSANDRA LUCILLE CLIFT. Uncovering the ‘Hidden Fibrosis’ of Pediatric Congenital 
Aortic Valve Stenosis via Targeted Mass Spectrometry Approaches (Under the direction 
of PEGGI ANGEL and RICHARD DRAKE). 
Congenital aortic valve stenosis (CAVS) affects up to 10% of the world population 
without medical therapies to treat the disease. New molecular targets are continually being 
sought that can halt CAVS progression, particularly in pediatric patients where 
bioengineered solutions are not ideal. Collagen deregulation is a hallmark of pediatric 
CAVS yet remains mostly undefined.  Here, histological studies were paired with high 
resolution accurate mass (HRAM) collagen-targeting proteomics and imaging mass 
spectrometry to investigate collagen fiber production with localized collagen regulation 
associated with human AV development and pediatric end-stage CAVS (pCAVS). 
Histological studies identified collagen fiber realignment and unique regions of high-
density collagen in pCAVS. Proteomic analysis reported specific collagen peptides are 
modified with hydroxylated prolines (HYP), a post-translational modification critical to 
stabilizing the collagen triple helix. Quantitative data analysis reported significant 
regulation of collagen HYP sites across patient categories, providing insight to collagen-
cell receptor binding.  
In addition to chromatographic-based proteomic analysis, Matrix Assisted Laser 
Desorption Ionization imaging mass spectrometry (MALDI-IMS) methods were developed 
to further address the localized structure-function relationship of the extracellular 
matrisome in aortic valve tissue. Here, a novel serial enzyme strategy was developed to 
define the glycosaminoglycome, N-glycome, as well as the collagen and elastin proteome 
xi 
 
from a single tissue section for MALDI-IMS applications. These multimodal MALDI-IMS 
techniques could define unique matrisome profiles based off tissue hemodynamics, as 
well as identify collagen localization unable to be detected by tradition histopathology. 
Finally, as a proof-of-concept study toward biomaterials applications, MALDI-IMS was 
used to localize human collagen-based hydrogels within an infarcted mouse heart, as well 
as analyze its impact on endogenous extracellular matrix (ECM) remodeling.  
The studies presented in this dissertation are the first of their kind to detail the 
collagen types and HYP modifications associated with human AV development and 
pediatric CAVS. Additionally, our findings show evidence for the use of MALDI-IMS in 
assessing the therapeutic application of collagen-based biomaterials. We anticipate that 
this study will inform new therapeutic avenues that inhibit valvular degradation in pCAVS 
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1.1 Valvular Anatomy & Fibrotic Diseases 
1.1.1 Structural Extracellular Matrix in Aortic Valve Development 
Just after the initial heart contractions occur (E16-22 days) in early embryonic 
valve development, the three endocardial aortic cushions form (E31-35 days) and begin 
to elongate as hydrophilic ECM proteins are deposited. At this time, the aortic valves (AVs) 
are primarily composed of the glycosaminoglycan (GAG) hyaluronan (HA), lined by 
endothelial cells [1-5]. Between E35-37, hyaluronan synthase-2 (Hyal2) activity (which 
catalyzes formation of the HA polymer) is elevated, forming a “jelly” in which cells of the 
developing AVs undergo endothelial to mesenchymal transition (EndMT)[1, 5-7]. During 
EndMT, cell populations concurrently proliferate and apoptose, additional ECM is 
deposited, and the endocardial cushion elongates (E37-42 days) [8]. This results in two 
unique populations of cells – valvular endothelial cells (VECs) and valvular interstitial cells 
(VICs). As healthy valves are avascular, VECs are responsible for regulating nutrients and 
biochemical signals from the blood to the VICs [9]. The VICs are responsible for 
organizing, maintaining, and remodeling ECM proteins [10-14]. Studies show proper VEC-
VIC crosstalk is essential to valvular health [15-17]. Additionally, cardiac neural crest cells 
(CNCCs) and second heart field (SHF) precursors migrate to the newly formed 
endocardial cushions, promoting cell apoptosis and ECM regulation of the developing 
valve [13, 18-20]. Recent literature also shows a population of mesenchymal stem cells 
present within the aortic valve [21].  
In late embryonic AV development (E20-39 weeks for humans) the valve leaflet 
stratifies into three distinctive layers – the collagen rich fibrosa, the GAG rich spongiosa, 
and the elastin rich ventricularis. Throughout development, the composition of GAGs 





















































































































































































































































































































such as aggrecan and versican, as well as small leucine-rich proteoglycans such as 
biglycan and decorin, amongst others [22, 23].  Similarly, collagen type distributions 
change over the course of development. While fibril-type collagens I, II, and III are 
dominant in early development, later embryonic and post-natal development involves the 
deposition of network and FACIT type collagens as well (Fig. 1; Section 1.2.1). This data, 
however, is interpreted from mouse studies [22]. Similar studies have yet to be done 
extensively on post-natal human aortic valve tissues. In this review we focus on collagen-
related changes in heart valve development and disease. 
1.1.2 Congenital Aortic Valve Stenosis 
Currently, congenital aortic valve stenosis (CAVS) accounts for 10% of all 
congenital heart defect cases, which affect 1 in 150 people [24]. CAVS progresses as an 
obstructive narrowing of the aortic opening due to enlargement of the AV leaflets through 
deregulated ECM production and results in heart failure. Approximately 90% of all CAVS 
cases are due to bicuspid aortic valve (BAV) [25]. Disease loci associated with BAV have 
been found on chromosomes 18q, 13q, and 5q and while the inheritability of BAV within 
certain families suggest a genetic component, only mutations in NOTCH1 signaling have 
been attributed directly to valvular stenosis [26, 27]. However, other genetic mutations 
have been associated with BAV-aortopathy [28]. Despite other genes being implicated in 
murine models of BAV (such as eNOS and GATA6 mutations), these have not been 
correlated to the valvular stenosis in humans [29, 30]. 
Most CAVS patients (90%) are stable until adulthood, where severe calcific lesions 
are the primary cause of valve replacement. In adult fibrocalcific AVS (FAVS), 
inflammation and adhesion are shown to increase along with mast cell infiltration [31, 32].  
Adult cases also tend to have comorbidities, such as high blood pressure or coronary 
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artery disease, further confounding research [26].  The remaining 10% of all CAVS 
patients are pediatrics, where end-stage is defined by excessive ECM deposition, and no 
calcification (pCAVS) [31, 33]. A main feature of both pediatric and adult CAVS is bicuspid 
aortic valve. The dominant BAV morphology across all patients is the fusion of the right- 
and left-coronary leaflets (71%) [34]. The differences in dominant cusp fusion morphology 
(RL, RN, NL) has not been determined between pediatric and adult calcific CAVS. 
However, right and non-coronary fusion (R-N) are the most common predictor of pediatric 
valve dysfunction and intervention (35% of patients; >4-fold intervention increase) [35]. 
Literature acknowledges a distinct molecular profile between pediatric and adult calcific 
CAVS [31], but the molecular mechanisms behind the rapid progression of pCAVS remain 
to be elucidated. 
1.1.3 CAVS Changes to Valvular ECM Architecture 
A loss of ECM stratification is seen in both pediatric and adult cases of CAVS [31]. 
Hutson et al. set out to quantified changes in collagen architecture associated with adult 
calcific cases of CAVS [36]. Their group showed that collagen content in the GAG-
dominant spongiosa layer doubled in the disease state. Collagen fiber width and density 
also significantly increased, with lysyl oxidase expression also increasing in the diseased 
fibrosa layer [36], however the corresponding post-translational modification (PTM) 
allysine has not yet been defined.  Transcriptional studies in mice have shown that loss of 
crosslinking collagens 5a1 and 11a1 alters expression of fibrillar collagens 1 and 3, 
resulting in AV stenosis [26]. Similarly, CAVS studies of elastin, which crosslinks to 
collagen, has shown increased fragmentation correlated to increased calcification [37]. 
Fragmented elastin has also been seen in pediatric CAVS [31]. Di Vito et al recently 
published an extensive review of ECM alterations in adult calcific valve disease [38]. 
However, differential expression of collagen subtypes remains to be as extensively 
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explored in pediatric cases of CAVS. Our group recently reported that total collagen 
deposition increases in pediatric CAVS, along with  collagen fiber misalignment relative to 
the endothelium, and regions of increased collagen fiber density (or “plaques”), as 
measured by histology [39]. ECM targeted proteomics in this study showed differential 
collagen subtype regulation (in α1(I), α2(I), α1(V), α2(V)) between pCAVS, normal, and 
tricuspid aortic valve insufficiency [39]. 
1.1.4 Hemodynamic Regulation in Aortic Valve Development & Disease 
During late embryonic development and post-natal development, peak shear 
stresses range from 30-1500 dynes/cm2 (with higher values occurring during stenosis), 
and these hemodynamics play a significant role in valve structure [10, 40]. During systole, 
shear stresses are unidirectional and pulsatile, stretching the leaflet, which primarily 
affects the elastin rich ventricularis. Contrarily, the aortic valve during diastole requires the 
stiffer collagen rich fibrosa to maintain structure and function, as oscillatory vortexes 
develop behind the leaflet. The GAG rich spongiosa act as shock absorbers during the 
entire cardiac cycle [41]. Hemodynamics play a role in collagen alignment in the healthy 
valve, which has been shown to align along the circumferential axis, parallel to the 
endothelium [39, 42]. In addition to hemodynamics, emerging subpopulations of VICs and 
differentially expressed genes can play a role in ECM stratification. In the ventricularis, 
Notch1 expression is dominant and may play a role in elastin deposition [1, 43]. In the 
spongiosa layer, BMP2 signaling promotes Sox9 expression and deposition of 
proteoglycans, such as aggrecan, versican, chondroitin sulfate, and decorin [1, 44]. In the 
fibrosa layer, Wnt signaling has been linked to promote the expression of fibroblast related 
ECM components such as fibrillar collagens Type I and III and fibronectin [1, 45].  
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CAVS-mediated alteration in hemodynamics influences all levels of molecular 
expression and feeds forward into deregulating the valvular structure [34]. Velocity field 
analysis has shown that the total kinetic energy, Reynolds shear stress, and viscous shear 
stress are all significantly higher in cases of BAV as compared to the normal tricuspid 
configuration, localized primarily to the fibrosa [41]. In adult calcific CAVS, the fused 
leaflets have a higher incidence of calcific nodule formation compared to the non-fused 
leaflet, correlating to an increase in shear stress [34]. Similarly, ex vivo analysis shows 
that abnormal hemodynamic shear stress may contribute to early adults CAVS 
pathogenesis [46]. During in vitro bioreactor conditioning studies, increased pressure has 
been directly attributed to increased leaflet strain [47]. Studies in VICs under variable 
strain (10, 14, and 20%) show significant increase in [3H]-proline incorporation, indicating 
increased collagen synthesis [47]. These studies offer insight into how the increased shear 
stresses seen in BAV contribute to ECM deposition in CAVS.  
Transcriptional regulation of critical genes differs during strain as well. For 
example, Ku et al showed Col3a1 is significantly upregulated as compared to a steady 
regulation of Col1a1 under strain [48]. Altered differentiation of VICs under strain shows 
an increase in expression of VCAM-1 (responsible for immune infiltration and cell 
migration) and a decrease in osteopontin (shown to be a calcification protectant) [47, 49]. 
During progression of CAVS, VIC undergo activation and become myofibroblast-like cells 
that express matrix metalloproteases (MMPs), cathepsins, and pro-inflammatory 
cytokines which can further stimulate osteogenic differentiation. While enzyme-induced 
turnover of ECM is essential in a healthy valve to maintain homeostasis under shear 
stresses, myofibroblast induced-remodeling is attributed excessive ECM deposition in 
CAVS [50].  To date, all hemodynamic studies have been completed on adult VICs or 
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VICs with osteogenic in vitro conditions, leaving pediatric hemodynamic regulation to be 
elucidated.  
1.1.5 Myocardial Fibrosis and Bioengineered Solutions 
As a proof-of-concept study, Chapter 6 of this dissertation outlines the use of 
targeted imaging mass spectrometry approaches to characterize collagen-subtypes in 
myocardial fibrosis treated with collagen-based hydrogels. While not specific to valvular 
disease, this proof-of-concept study aimed to use targeted imaging mass spectrometry 
approaches to distinguish between collagen subtypes originating from a human-collagen 
derived hydrogel as opposed to the native mouse myocardial fibrosis. To frame the context 
of that study, a brief outline of myocardial fibrosis follows. 
 Coronary artery disease is a common cardiovascular disease that leads to 
myocardial infarction. After an infarct, the myocardium undergoes active remodeling in 
three phases: 1) the inflammatory phase, when neutrophils infiltrate the damaged 
myocardium, secreting anti-inflammatory cytokines; 2) the reparative phase, when 
myofibroblasts replace lost ventricular tissue with ECM; and 3) maturation, when a stable, 
collagen-dense scar is formed [51]. This scar tissue formation is essential to prevent 
rupture of the myocardium, but an over-active fibrotic response leads to cardiac rhythmic 
dysfunction and heart failure [52]. With limited pharmacotherapeutic options, current 
research is aimed at restoring ECM within the infarct myocardium to prevent fibrosis and 
improve cardiac function [53, 54]. Injectable hydrogels are a promising therapeutic 
application to alleviate early stages of pathological myocardial remodeling [55]. Injectable 
biomaterials are composed of either synthetic or degradable matrix and can be seeded 
with therapeutic stem cells, growth factors, particles, and pharmacotherapeutics to 
encourage endogenous repair and provide structure support during healing [53, 55]. 
20 
 
1.1.6 Current Treatment Options and Bioengineered Solutions 
Despite the clinical significance of CAVS, surgical valve replacement and repair is 
still the only available treatment. Mechanical-based engineered valve replacement 
devices are not suitable for young children as they lack any growth potential as well as 
requiring lifelong anti-coagulation therapy[56]. However, in older pediatric cases, there 
has been success with a 55-90% freedom from reoperation at 15 years[57]. Tissue 
engineered valve replacements are currently unavailable in sizes smaller than 19mm,  
making them unsuitable for young pediatric cases. Like mechanical prosthesis, there is a 
lack of growth potential with tissue engineered replacements, but anti-coagulation therapy 
is not required[58]. Survival was reported to be 85% at 10 years, however the rate of 
reoperation is high – 65% at 10 years, with the median longevity being only 7.5 years[57]. 
Homografts are able to retain normal hemodynamic profiles over time, with small sizes 
available for small children. Homografts also do not require anti-coagulation therapy and 
have the added advantage of being more resilient to infection that tissue engineered 
prosthesis, however there is a limited donor pool [57, 59]. Despite these advantages, 
homografts show only a 60% survival at 10 years, and 30% at 20 years, and are not ideal 
for pediatric cases [60].  
The limitations listed above are why the Ross procedure, which switches the native 
pulmonary valve into the aortic valve position, is currently the preferred treatment amongst 
young pediatric cases [61-63]. However, this procedure does not come without 
complications: children having undergone this procedure have a 14.3% mortality rate in 
the first year – after surviving the first year, the likelihood of the child needing an aortic or 
pulmonary reintervention later in life is 15.3% and 27.5%, respectively [57].  
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Mechanisms of failure of pulmonary valves in the aortic position during Ross 
procedures can be inferred from studies regarding proteomic differences between the two 
valves. Ikhumetse et al. found that when pulmonary derived VICs were exposed to cyclic 
aortic pressures, sulfated GAGs as well as collagen synthesis were significantly increased 
[64].  Angel et al aimed to characterize the difference between AV and PV via 
chromatographic proteomic approaches. The study found that only 50% of the proteome 
of the AV is shared with the PV. The PV proteome was abundant in hypoxia associated 
proteins such as H2AX but only sparingly expressed proteins that may be critical to healthy 
AV function, such as MFGe8 and Emilin-1 [65]. The role of PTMs in valvular failure has 
not been extensively explored. 
1.2 Extracellular Matrix: Translational and Post-Translational Regulation in 
Fibrotic Disease 
1.2.1 Collagen Sub-Types 
The collagen superfamily consists of 28 sub-types, all sharing a common structural 
motif – the triple helical domain [66-69]. The triple helical domain of collagen sequences 
contains (Gly-X-Y)n repeats, where X and Y can be any amino acid. Most commonly, X 
corresponds to Proline (in 28% of cases) and Y corresponds to 4-hydroxyproline (in 38% 
of cases) with G-P-HYP being the most common repeating G-X-Y sequences (in 10.5% 
of cases)[69]. 3-hydroxyproline residues are less common that 4-hydroxyproline residues, 
but they have been identified in fibril types collagens, described below.  
The collagen superfamily sub-types can be split into several subfamilies: fibril type, 
FACIT (fibril associated collagens with interrupted triple helices); membrane, multiplexin 
(multiple triple helix domains and interruptions), and other. Triple helical domains within 
these collagen regions are bracketed and intertwined with non-triple helical domains, 
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which include: laminin G-like domains, von Willebrand factor type A domains, fibronectin 
domains, nidogen binding domains, and endostatin domains, amongst others[70].  
Collagen biosynthesis has been most extensively described in fibril type collagens 
[67]. Within the cell, pro-collagen molecules are translated, which consist of an N-terminal 
pro-peptide, and N-terminal telo-peptide, the central triple helical region, a C-terminal 
telopeptide and a C-terminal pro-peptide [66, 67]. Before secretion, these alpha chains 
are post-translationally modified, as described in Chapter 1.2.2. Still in the endoplasmic 
reticulum, once post-translationally modified, an essential protein HSP47 (heat shock 
protein 47) binds to procollagen and acts as a stabilizer and chaperon for extracellular 
secretion, along with other collagen chaperones, such as SPARC [67]. Before collagen 
fibril formation, propeptides of procollagens are cleaved by proteinases – the N-terminal 
propeptide by ADAMTS, and the C-terminal propeptide by BMP-1 (or furin, in the case of 
proα1(V)) [67].  
Fibril type collagens are comprised two classes: major fibrils (type I, II, III) and 
minor fibrils (types V, XI, XXIV, and XXVII) [66, 67]. Fibril subtypes, or “classical collagens” 
form ordered fibrils from precursors or procollagens, comprising of major and minor fibrillar 
collagens. The minor fibrillar collagens serve to regulate fiber length and lateral molecular 
addition[71]. Once assembled, collagen fibrils can range from 15nm to 500nm, depending 
on the tissue of original, with a distinctive banding pattern occurring every 64 to 67nm [67, 
72, 73]. As the name suggests, fibril type collagens associate with FACIT types – IX, XII, 
XVI, XIX, XX XXI, and XXII. These collagens are associated with general ECM 
stabilization and integrity. Membrane collagens are comprised of subtypes XIII, XVII, XXIII, 
and XVII. These are transmembrane proteins with functional interaction both with other 
cell-surface receptors and ECM proteins[74]. Finally, collagens XV and XVIII are 
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multiplexins. This collagen family consists of homotrimers that carry glycosaminoglycan 
chains, so are also proteoglycans[66, 68]. Other proteoglycan collagens are IX, XII, and 
XIV. Diseases of collagen subtypes are further reviewed in section 1.2.7.  
1.2.2 Collagen Post-Translational Modifications 
Extracellular matrix proteins make up the bulk of valvular tissues, and these 
proteins are abundantly post-translationally modified (Fig. 2). Essential post-translational 
modifications of collagen include hydroxylation of proline [75-77], N-glycosylation[77, 78], 
proteinase-initiated cleavage of the N- and C-terminal pro-peptides[77, 79], and oxidation 
of lysine[77, 80]. Hydroxylation is a major PTM of collagens that maintains structural 
integrity of the valve [81]. Hydroxylation of proline and hydroxylation of lysine are the two 
most abundant PTMs of collagen type proteins [69, 82]. These PTMs are necessary for 
the organization of collagen’s triple helix structure as well as its thermal stability[83, 84]. 
In both collagen and elastin, hydroxyproline is a well-regulated modification, with between 
20-24% of prolines being hydroxylated [69]. Prolyl hydroxylases are responsible for 
hydroxylation of proline in elastin as well as collagen, with an X-P-G amino acid sequence 
required substrate in most cases [85]. Elastin studies of the human aorta show that two 




Figure 2: In silico post-translational modification site frequency  analysis of 
valvular structural proteins (collagens and elastin) showing sites PTMs. 




of hydroxylation, suggesting site-specific regulation, however this has not been elucidated 
in the healthy or diseased AV [86]. Similarly, only a single study has attempted to perform 
site specific hydroxyproline mapping in health or  diseased AV [39]. Other PTMs of 
structural ECM in the valve include O- and N-linked glycosylation, phosphorylation, 
allysine via Lysyl Oxidase, and collagen-lysyl intermolecular crosslinking (relative 
abundances via in silico analysis, Fig. 2). 
1.2.3 Collagen Binding Partners 
Collagens in the extracellular space are capability of interacting both to other ECM 
proteins and transmembrane proteins on the cell surface. In the ECM, collagens are 
capable of binding to elastin and glycosaminoglycans (as outlined above and in Chapter 
1.2.4). Cell-Collagen interactions consistent of integrins, glycoprotein vi, dimeric discoidin 
receptors (DDR1 and DDR2), and LAIR-1/2, amongst others. 
Integrins are a major family of cell-adhesion receptors that do not have kinase 
activities[87]. Collagens bind to integrins that contain a β1 subunit via their GFOGER 
sequences (where O is HYP) [67, 88, 89]. Interestingly, there are collagen fragments 
resulting from MMP degradation that are bioactive and capable of binding to several 
integrins (αvβ3, αvβ5 α3β1 α5β1)[67]. When bound to collagens, integrins have been 
shown to act as collagen organizers[72]. Fibril types collagens I-III bind DDR1 and DDR2 
via the GVMGFO motif. Intracellularly, DDRs possess tyrosine kinase activities. 
Extracellularly, DDR1 and DDR2 inhibit collagen fibrillogenesis[90, 91]. Both LAIR-1/2 and 
glycoprotein VI bind to GPO motifs in collagens, with LAIRs having a higher affinity[92]. 
Glycoprotein VI is a platelet-unique membrane glycoprotein. Upon binding to collagen, a 
phosphorylation cascade is initiated by an immunoreceptor tyrosine-based activation motif 
(ITAM) downstream of GpVI, activating platelet binding within tissues[93]. LAIR-1, or 
26 
 
leukocyte-associated immunoglobulin-like receptor, possesses a single extracellular 
domain and binds to collagen as an immune receptor[90, 93]. Knowledge of cell-collagen 
binding domains elucidate further complexities of the extracellular matrix in pCAVS.  
1.2.4 Non-Structural Extracellular Matrix 
This review thus-far, and this dissertation, primarily focuses on the major structural 
ECM protein, collagen, and its role in valvular development ad disease. However, minor 
ECM proteins are critical to valvular development but are unexplored in this dissertation 
work. These proteins can be split into the follow categories: minor structural ECM proteins 
(such as vitronectin, fibronection, periostin, osteonectin, osteopontin, aggrecan); 
basement membrane proteins (laminin, perlecan, nidogen); and ECM remodeling 
proteins, such as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). For 
information regarding these extracellular matrix components in valvular tissues, we point 
the reader to the following reviews and original research papers [42, 94-102].  
1.2.5 Role of PTMs in Cardiac Development and Disease 
The role of PTMs in ECM proteins is largely unknown in pCAVS. While the PTM 
allysine has not been measured directly in CAVS, studies show an increase in the enzyme 
responsible for catalyzing the reactive aldehyde species, LOX [36]. Similarly, PLOD1, the 
enzyme responsible for catalyze hydroxylysine residues in collagen, was found to be 
unchanged in adult CAVS compared to controls [36], however, HYL was not measured 
directly. While hydroxyproline content has been measured in healthy aortic valves, this is 
used as a measurement of insoluble collagen content, not in a site-specific analysis [103, 
104]. Our group recently reported the first study of collagen HYP quantification and site 
mapping with human pediatric CAVS tissue [39]. Overall, a reduction of collagen HYP 
content was seen, particularly in regions within collagen sequence required for integrin 
and glycoprotein vi binding [39]. 
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Potential modifications of intracellular proteins regulated in the heart can include 
both enzymatic (such as acetylation, phosphorylation and ubiquitination) and non-
enzymatic (such as nitrosylation) post-translational modifications. These PTMs have been 
mostly explored in age and aging-related myocardial diseases, but remain largely 
unexplored in pediatric valvular disease. Acetylation of histones 3 and 4 has been reported  
in CAVs and NCAVs from patients, although significantly higher in CAVs patients [105]. 
Similarly, acetylation plays a role in modulating the heart’s response to I/R injury [106]. 
Glycogen Synthase Kinase 3β (GSK3β) – which has been found in cardiac fibroblast and 
implicated in ventricular remodeling – is both phosphorylated and s-nitrosylated in a site-
specific manner relevant to its function in cardiac fibrosis [107, 108]. S-nitrosylation of 
USP9X has been shown to be enriched in NOTCH regulation of valvular calcification [109]. 
Additionally, studies have shown increases in ubiquitin-mediated proteolysis in heart 
failure [110]. While these studies are not specific to ECM proteins, data suggested that 
PTMs may be a potential therapeutic target in cardiac and valvular fibrosis. 
1.2.6 Potential role of Oxidative Stress on ECM PTMs 
Post-translational regulation via oxidation has been pinpointed as having a major 
role in other fibrotic diseases [111]. While inflammatory-derived Reactive Oxygen Species 
(ROS) has been implicated in adult CAVS, ROS is unexplored in pediatric valve disease 
[38]. Similarly, the role of ROS on PTMs in ECM in valvular development nor disease has 
been studied. ROS can alter the expression of ECM both by activating transcription factors 
involved in ECM  protein expression (such as TGFB1) as well as modifying ECM proteins 
post-translationally [111] . Additionally, the hydroxylation of proline and lysine residues of 
collagen is highly redox dependent. Once lysine is hydroxylated, it serves as a synthesis 
starting point for proteins responsible for collagen and elastin crosslinking, such as 
desmosine [82, 111, 112] . Additionally, hydroxylated lysine 2 has been shown to have 
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glycosyl-transferase activity, serving as an anchor for O-glycosylation modification [69, 
82]. In silico analysis of valvular collagen type proteins demonstrates a potential 
abundance of N- and O-glycosylation sites, amongst other PTMs (Figure 2). At high 
concentrations, ROS can initiate catabolization of these carbohydrate entities [111, 113]. 
Previously unexplored in pediatric CAVS, a recent publication by Angel et al. shows that 
N-glycosylation patterns are spatial regulated in aortic valve development and disease, 
with certain sialyted N-glycans being upregulated [114]. At low concentrations, ROS can 
induce GAG-degrading enzymes, such as Hyal2, indirectly effecting ECM turnover [23]. 
Recent studies have shown that GAGs can store growth factors and cytokines in the 
extracellular space; so, indirectly, depletion of GAGs via Hyal2 may modify receptor 
binding and activation [115]. ROS can also induced collagen degrading enzymes, such as 
matrix-metalloproteinase (MMPs), further suggesting a role of oxidative stress in ECM 
remodeling [116].  
1.2.7 Role of ECM regulation and PTMs in Non-Valvular Disease 
PTMs of ECM have been linked to various disease states, not limited to fibrotic 
diseases. While hydroxyproline and hydroxylysine modifications are essential to proper 
collagen fibril formation, over-hydroxylation of the protocollagen chains can delay collagen 
polymerization, resulting in altered additional PTMs, such as glycosylation [69, 82, 117]. 
This perturbs collagen’s triple-helical structure further which in turn contributes to various 
disease states, such as Ehlers-Danlos syndrome and osteogenesis imperfecta [69, 118]. 
Similarly, under-hydroxylation can destabilize collagen’s triple helix, also contributing to 
disease states, as seen in vitamin C deficiencies leading to scurvy [119]. Hydroxyproline 
modifications in collagen amongst other proteins has been implicated in oxygen-sensing 
pathways in cancer cells [120]. Hydroxylysine aldehyde–derived collagen cross-links have 
been found to be upregulated in lung tumor stroma [121]. Kamel et al shows that increased 
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hydroxylation of lysine in collagen increases the proliferation rate of uterine fibroids [122]. 
Additionally, increased tissue stiffness due to over hydroxylation of the ECM may not only 
contribute to progression of tumors and fibrotic diseases but may also influence diffusion 
of drug molecules within the disease microenvironment [123, 124]. For these reasons, 
characterization of not only the ECM, but also its PTMs, are critical for elucidating 
mechanisms of fibrotic diseases, such as pediatric end-stage CAVS.  
1.2.8 Targeting ECM as a Therapeutic Strategy 
Identified therapeutic strategies for adult CAVS, such as targeting of circulating lipid 
levels or osteogenic differentiation of VICs and mineral deposition directly, would not be 
appropriate for targeting the excessive fibrotic build-up of ECM seen pediatric end-stage 
[125]. The late diagnosis of fibrotic diseases limits therapeutic intervention before rapid 
ECM remodeling occurs. The future of fibrotic treatments may rely on proteomic strategies 
to identify new ECM biomarkers, resulting in earlier detection. Walraven and Hinz propose 
in their 2018 review that inhibiting fibrosis will depend on two main strategies: 1) targeting 
the myofibroblasts directly through stimulatory or suppressing cytokines and stimulating 
apoptosis; and/or 2) targeting the fibrotic ECM directly using targeted proteolytic enzymes 
[126].  Currently, the only FDA approved drugs on the market to treat any fibrotic disease 
(idiopathic pulmonary fibrosis) are Nintedanib and Pirfenidone. Previously thought to work 
through kinase-dependent fibrotic pathways [127], a recent study shows that these drugs 
inhibit collagen fibril assembly directly [128]. Another proposed anti-fibrotic therapeutic 
strategy is the targeting of hydroxyprolines via collagen prolyl-4-hydroxylase (CP4H). 
However, CP4H inhibitors lack selectivity – while promising results are seen in vivo, off 
target affects to redox homeostasis and iron metabolism are also seen [129]. Realistically, 
the goal of anti-fibrotic therapies in pediatric CAVS may not be to cure stenosis but instead 
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to delay the severity until patients reach an appropriate age and size for bioengineered 
options to be used without the need for repeated surgeries. 
1.3 Characterization and Identification of the Extracellular Matrisome 
While transcriptional regulation of the valvular ECM has been well characterized, low 
cell density and high ECM content warrant translational level studies. Translational and 
post-translational regulation of these proteins in pediatric CAVS remains to be fully 
elucidated, as the majority of literature focuses on adult calcific cases of CAVS. Acquiring 
information on spatial organization of molecular patterns of ECM proteins and their PTMs 
is essential to defining both disease and development.  
1.3.1 Accessing the Extracellular Matrisome 
The ECM proteome in pediatric valvular tissue has been difficult to characterize 
via conventional tryptic methods due to high levels of intra- and intermolecular crosslinking 
and PTMs. Brioschi et al published a comparative analysis of gel-based and gel-free 
proteomic methods to characterize the human mitral valve proteome, showing large 
variability between the four methods and only 12% of all proteins identified were 
associated with ECM pathways [130]. Schlotter et al used label-free tryptic proteomics 
techniques with isolated VICs and micro-dissected valvular tissues. Amongst other 
findings, they showed that collagen biosynthesis, collagen modification, GAG metabolism, 
and ECM degradation pathways were enriched in the adult CAVS isolates [131].  
While these methods can implicate ECM pathways, ECM proteins specifically are 
not enriched. After years of advancement in valvular proteomic techniques [132, 133], the 
Barderas Lab enriched for ECM proteins in their 2D-LC MS/MS method on calcific AVS 
samples. The group found 13 differentially regulated ECM proteins in the adult calcific 
CAVS samples compared to controls. Of these, biglycan, periostin, prolargin, decorin, and 
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lumican (implicated in collagen fiber assembly) formed a protein-protein interaction 
network cluster. One collagen protein, Col6a1, was identified to be upregulated in adult 
CAVS [134]. Similarly, Bouchareb et al. used guanidine hydrochloride to extract the ECM 
for proteomic analysis, and identified two potential biomarkers of adult calcific CAVS – 
FNDC1 and MXRA5 [135]. While not on native valvular tissue, Syedain et al recently 
performed ECM enriched proteomic analysis on tri-tube valve conduits to analyze their 
regenerative capacity [136]. The Hansen Lab recently did a comparative study of a dozen 
ECM enrichment techniques for proteomics, comparing decellularization, extraction and 
single-shot analysis methods [137]. Outside of valvular biology, Naba et al have published 
several papers regarding proteomic ECM enrichment techniques in cancer tissues. Their 
methods to enrich for and increase identification of ECM peptides consist of: 
decellularizing fresh or frozen tissues; orthogonal fractionation techniques prior to LC-
MS/MS; and including hydroxylation of prolines and lysines as dynamic modifications 
during searches. However, these enrichment methods are limited to fresh or frozen tissue, 
excluding formalin fixed paraffin embedded tissues[138-140]. 
Alternative enrichment approaches used by our group use ECM-targeting 
enzymes, such as collagenase type III and MMP12, to enzymatically enrich for the 
extracellular matrix [39, 141-145]. Bacterial collagenases target cleavage to the triple 
helical regions of proteins[146] – in this way, collagen subtypes as well as other 
extracellular matrix proteins with triple helical regions can be targeted without the need to 
decellularize samples. These studies were applied to valvular tissues for LC-MS/MS 
proteomics, with all proteins identified being of the extracellular matrix, and roughly half 
being collagen subtypes (Chapter 3) [39]. 
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Serum proteomics is a potential source for biomarker discover in tissue diseases 
unable to be biopsied, such as valvular disease. To date, no proteomic analysis has been 
done on serum correlating to pediatric CAVS tissue. However, serum profiling has been 
done for cardiac failure [147, 148] and other fibrotic diseases such as idiopathic pulmonary 
fibrosis [149] and liver cirrhosis [150]. While there are many large-scale proteomic studies 
of serum profiles, ECM proteins are inherently difficult to enrich for [151]. Multimodal -
omics approaches, such as epigenomics, transcriptomics, proteomics, and metabolomics, 
offer promising advantages to traditional characterization techniques, and together moves 
the field away from strictly characterization towards biomarker and pharmacotherapeutic 
target discovery, as well as to inform bioengineered solutions [152, 153].  
1.3.2 Spatial Localization of the Matrisome using Imaging Mass Spectrometry 
Despite advancements in multi-omics techniques listed above, bulk LC-MS/MS 
proteomics still exclude a key variable of disease pathology – spatial localization of 
dysregulated ECM within the tissue microarchitecture. Several mass spectrometry 
techniques exist that link the tissue proteome to its structure. One technique is Matrix-
Assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS). MALDI-
IMS is a robust proteomic technique that spatially maps peptides from histological tissue 
sections. This is traditionally done by spraying the tissue with a thin, uniform layer of 
trypsin that, when analyzed in parallel to high resolution accurate mass proteomics, allows 
for the relative quantitation and localization of tryptic peptides to specific regions of the 
tissue. In addition to tryptic peptides, novel MALDI-IMS and LC-MS/MS techniques have 
been developed to specifically map ECM proteins, that until recently were unable to be 
accessed via conventional proteomic workflows [39, 142, 145, 154-157].  
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Proteomic imaging via MALDI-IMS may allow for greater protein identification and 
improved PTM evaluation compared to antibody-based histology strategies. Angel et al 
outlined the challenges of analyzing cardiac tissues with MALDI-IMS as well as the 
advancements that have been made in the field [158]. Mourino-Alvarez, et al took 
advantage of MALDI-IMS technology to characterize fresh frozen calcific AVS tissue. The 
group was able to visualize m/z peaks correlating to calcified, collagenous, and elastin 
rich tissue areas. Two peptides of interest were from collagen α3(VI) (responsible for 
calcium and collagen HYP accumulation deposited via human osteoblast-like cells) and 
NDRG2 (implicated in p53 mediated apoptosis and mineralization initiation) [159]. 
Recently, several studies have emerged using MALDI-IMS and other imaging mass 
spectrometry methods to characterize molecules associated with healthy and diseased 
aortic valve, such as N-linked glycans [114, 145], lipids [160-162], glycosaminoglycans 
[145], and peptides [145, 154, 158]. With normal and diseased valve tissue samples 
becoming less abundant on the bench due to increases in transcatheter aortic valve 
replacements [163], these multi-modal MALDI-IMS techniques are a promising tool that 
can be used to characterize ECM deposition and post-translational modifications during 














Congenital aortic valve stenosis (CAVS) accounts for 10% of all congenital heart 
defects, which effect 1 in every 150 people[24]. The dominant phenotype of CAVS is the 
fusion of two of the three leaflets, causing a narrowing of the aortic orifice, obstructing 
aortic outflow, leading to left ventricular hypertrophy and heart failure. Despite the clinical 
significance of this disease, no pharmacotherapeutics exist. The clinical paradigm for 
treatment is “watch and wait” until surgical valve replacement and repair is necessary to 
prevent heart failure. Most CAVS patients are stable until adulthood when they develop 
fibrocalcific AVS (FAVS), where the end-stage is valve calcification[164]. However, ~10% 
of all CAVS patients are pediatrics (pCAVS), where end-stage is defined as excessive 
ECM deposition. Bioengineered AV replacements are notably limited for pediatric patients 
due to their inability to grow with the patient, a lifelong requirement of anti-clotting agents, 
and repeated surgeries due to valve failure[57]. There remains a critical need to identify 
pharmacotherapeutic targets in pCAVS that may halt disease progression.  
One knowledge gap is of collagen regulation in valvular disease. Collagens are the 
fundamental scaffolding of valvular structure that influences valvular, and thus cardiac 
function[8, 22]. Healthy AV development involves a stratification of ECM proteins into three 
distinct layers linked to a specific function: the elastin-rich ventricularis, 
glycosaminoglycan-rich spongiosa, and collagen-rich fibrosa (Fig. 3). During beginning of 
systole, pulsatile laminar shear stresses primarily affect the ventricularis – towards the 
end, vortices develop behind the leaflet, putting stress on the fibrosa. During diastole, the 
stiffer collagen-rich fibrosa maintains structure as oscillatory vortexes form behind the 
leaflet and compression occurs. The spongiosa acts as a shock absorber during the 
cardiac cycle[41]. Pediatric CAVS results in the destratification of collagens with other  
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Figure 3: pCAVS progresses as a destratification of the ventricularis 
(elastin; purple), spongiosa (GAGs, blue) and fibrosa (collagen, yellow) 




ECM proteins, making these layers indistinguishable[8] altering valvular function and 
leading to cardiac failure. 
Multiple collagens are known for their cardiac remodeling potential and are 
involved in valvular development[2, 165, 166], yet translational and post-translational 
regulation of these critical proteins due to pCAVS remains unknown. A potential collagen 
PTM target is hydroxylation of proline (HYP) which is known to be critical to proper 
stabilization of collagen’s triple helical structure, with literature evidence suggesting a role 
in cell migration and proliferation[167, 168]. Collagen HYP deregulation has been linked 
to several disease states associated with valvular disorders (i.e., Scurvy, Ehlers-Danlos 
syndrome, Osteogenesis Imperfecta) but has yet to be explored in pCAVS[117, 119, 169]. 
Poorly defined regulation of collagen subtypes’ PTMs associated with pCAVS limits the 
use of targeted anti-fibrotics from being developed yet remain promising towards inhibiting 
the disease[128, 129]. The proposed research is significant because it will precisely 
define molecular mechanisms leading to the rapid dysregulation of collagen 
subtypes in pCAVS, with a focus on post-translational HYP regulation. In the long 
term, the proposed research may identify therapeutic targets to halt pCAVS 
progression, retaining function until bioengineered solutions can be used.  
The work outlined in this dissertation is significant at several levels: 
A1) For the first time, we spatially define expression levels of collagen sub-types and 
HYP peptides in the context of a clinically well-defined cohort of human valve samples, 
with age matched tissues between 4 patient categories: normal, pCAVS, FAVS, and 
non-bicuspid pediatric AV insufficiency (AVI). Completion of the proposed work will 
therefore relate aortic valve pathological ECM structure to clinical function and patient 
hemodynamic profiles defined via echocardiogram. 
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A2) This dissertation outlines foundational work for studying collagen stabilizing PTMs 
in fibrotic cardiovascular disease. Novel information on collagen prolyl hydroxylation 
and network interactions will initiate studies on signaling factors driving collagen 
organization and deposition in CAVS. 
A3) This work focuses on pediatric, as opposed to adult, end-stage CAVS, for which 
pharmacotherapeutic development has a significant clinical impact. We aim to change 
the paradigm of treatment from “watch-and-wait” surgical replacement to biomarker 
identification and early intervention with antifibrotics targeted to specific modifications 
of collagen subtypes, to halt progression until bioengineered solutions are feasible. 
2.2 Specific Aims 
In heart valve biology, organization of the extracellular matrix structure is directly 
correlated to valve function. This is especially true in cases of congenital aortic valve 
stenosis (CAVS), in which extracellular matrix (ECM) dysregulation is a hallmark of the 
disease, eventually leading to left ventricular hypertrophy and heart failure. Most CAVS 
patients are stable until adulthood when they develop fibrocalcific aortic valve stenosis 
(FAVS), where the end-stage requiring valve replacement is valve calcification[164]. 
However, around 10% of all CAVS patients are pediatrics, where end-stage is excessive 
ECM deposition at a young age, when bioengineered valve replacement options are not 
suitable. It is not currently known the underlying molecular mechanism that leads to the 
rapid ECM dysregulation seen in pediatric end-stage CAVS. ECM proteins have been 
shown to be upregulated in FAVS, but current literature acknowledges a distinct molecular 
profile between pediatric CAVS and adult FAVS[31]. There is a critical need to define 
molecular indicators of rapid ECM structural dysregulation in order to develop targeted 
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treatment which halts CAVS progression in pediatric cases, retaining function until 
bioengineered solutions can be used. 
To address this problem, we will determine regulation of basic scaffold collagens and 
aortic valve (AV) structure by defining the ECM proteome. These data will be analyzed in 
a cohort of human AV tissues, with age-matched samples ranging between 2 weeks and 
81 years represented, and AV function clinically defined via echocardiogram. We will use 
a recently developed parallel approach of high-resolution accurate mass chromatographic 
proteomics and imaging mass spectrometry methods that together report expression 
levels and spatial localization of collagens and other ECM proteins from thin tissue 
sections[39, 141-145]. Using these techniques, we will also define specific sites of post-
translational modifications (PTMs) on ECM peptides and map the spatial distribution of 
these peptides across tissues. Our preliminary data suggests that the most abundant 
collagen subtypes are differentially expressed between normal and CAVS tissues, with 
collagens XVI, XVIII, and IV differentially abundant in normal tissues, and collagens I, III, 
and VI in CAVS tissues. Collagen fiber analysis shows that collagen fiber orientation is 
disorganized in CAVS, with a possible role of collagen stability identified, via hydroxylated 
proline (HYP) collagen site mapping. For example, site mapping of collagen α1(III) HYPs 
shows HYP sites are 29% more abundant and differentially localized in normal tissues 
compared to CAVS. Similarly, 60% of the top 10 differentially expressed peptides in 
normal tissues are hydroxylated compared to 30% in CAVS. Our approach is novel, as 
collagen HYP site maps have never been correlated to AV structure or function in normal 
or CAVS tissues. 
Our central hypothesis is that there is a reduction in the extent of proline 
hydroxylation on primary fibril-type collagen sequences which can be localized to 
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valve structural abnormalities within pediatric end-stage congenital aortic valve 
stenosis. Specifically, we propose the following Aims: 
Aim 1: Determine levels of collagen fiber and ECM dysregulation in CAVS tissues 
via conventional histopathological approaches. We hypothesize that increased 
collagen deposition that occurs in CAVS manifests in dysregulated collagen alignment, 
maturity, and density. Histopathological evaluation of collagen will be performed with 
traditional microscopy techniques, such as Picrosirius Red, Movat’s Pentachrome, and 
Second Harmonic Generation Imaging. Results of collagen fiber distribution and density 
can then be correlated to clinical outcome and hemodynamic profile of pediatric CAVS 
patients in development and disease. 
Aim 2: Determine association between differences in HYP sequences from main 
valvular scaffold collagens and pediatric end-stage CAVS. We hypothesize that 
reduction in the number of HYP modifications in primary fibril collagens α1(I), α2(I), and 
α1(III) correlates to the destabilized trilayer organization of the valvular collagen scaffold 
in pCAVS, independent of age at end-stage. High resolution, accurate mass (HRAM) 
tandem mass spectrometry will be used to sequence collagen subtype peptides and 
identify novel sites of hydroxyproline within the collagen sequence. Identified proteins will 
be used to predict regulators of CAVS collagen networks.  
Aim 3: Define spatial localization of collagen HYP sequences relative to collagen 
structural signatures in AV development and pathologies. We hypothesize that 
pathological sites of collagen production within the pCAVS structure involve reduced HYP 
abundance in fibrillogenesis-associated collagen. State-of-the-art imaging mass 
spectrometry (IMS) methodologies, coupled with previously acquired peptides databases 
(Aim 2), will report expression levels and spatial localization of HYP modified collagen 
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peptides, across a clinically well-defined cohort of human AV tissues. These studies will 
define the molecular makeup of pCAVS’ unique collagen signature, including regions of i) 
immature collagen production; ii) collagen fiber realignment; and iii) collagen plaques. 
Goals and Impact: The overall goal of this project is to understand the molecular 
mechanisms involved in the rapid ECM dysregulation seen in pCAVS. A long-term goal is 
to shift the paradigm of pCAVS treatment from “watch-and-wait” until surgical repair is 
necessary, to pharmacotherapeutic intervention at an earlier diagnosis to attenuate 
disease progression. The proposed study will 1) Define histopathological variability in 
collagen deposition between pediatric and adult CAVS patients; 2) identify translational 
and post-translation regulation of collagen subtypes in pCAVS; 3) spatially define collagen 
regulators in pCAVS, 4) identify molecular imaging markers for pCAVS. These studies 
provide a foundation for collagen PTM studies in fibrotic cardiovascular disease. 
2.3 Rationale & Approach 
2.3.1 Specific Aim 1 
Determine levels of collagen fiber and ECM structural dysregulation in CAVS 
tissues. Rationale: ECM proteins have been identified as dysregulated both in pediatric 
CAVS and adult FAVS via destratification of the ventricularis, spongiosa, and fibrosa 
layers[8, 31]. However, a study in human pediatric tissues with this sample size has not 
been performed in order to correlate ECM deregulation to changes in collagen fiber 
alignment, maturity, and density. Studies in breast tissue shows metastatic regions differ 
in collagen fiber maturity, thickness, and orientation[168]. We hypothesize thickened 
collagen fibers (i.e., “collagen plaques”) that correspond to structural anomalies of 
pediatric CAVS are not detected in normal valves. 
Experimental Design: Microscopy-based pathological evaluation will correlate ECM 
structure to clinical function. Serial tissue sections will be analyzed with three stains: (i) 
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Movat’s Pentachrome, for collagen, elastin, and GAGs; (ii) Picrosirius Red (PSR), which, 
under polarized light, which elucidates collagen fiber orientation and thickness; and (iii) 
Herovici, for immature and mature collagen regions.  PSR images will be taken with 
circularly polarized lenses to limit variability due to tissue orientation. Color Deconvolution 
will be done in ImageJ. CT-FIRE software will be used to quantify collagen fiber width, 
length, and angle and create a collagen “fiber score” that can be correlated to HYP 
expression. 
Expected Outcomes: Movat’s Pentachrome Color Deconvolution will quantify ratios of 
collagen, GAGs, and elastin over total stained area and identify the dominantly 
deregulated ECM type in CAVS. Color Deconvolution analysis of polarized PSR and 
Herovici stains will be able to determine statistical differences in collagen maturity and 
thickness between normal and CAVS samples. CT-FIRE collagen fiber analysis will be 
used to annotate vectors corresponding to individual collagen fibers, and create fiber angle 
distribution histograms, as well as quantify the area and distribution frequency of “collagen 
plaques” and determine correlation to disease state. This analysis can be done on varying 
regions of the valve (hinge, belly, and distal tip) in order to elucidate the role of 
hemodynamics on ECM stratification. The successful completion of this Aim will elucidate 
the relationship between ECM type dominance, collagen fiber orientation, collagen 
maturity, and collagen density to CAVS disease state.  
Potential Pitfalls & Alternative Strategies: 1) PSR is not sensitive enough to identify 
collagen plaques. This can be confirmed orthogonally via a) second harmonic generation 
imaging, b) IHC staining of main scaffold collagens I and III , and c) Herovici imaging. 2) 
Statistical limitations may occur due to small sample sizes (5 normal; 12 CAVS, 5 AVI, 4 
FAVS) and biological variability (see Statistical Considerations).  
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2.3.2 Specific Aim 2 
Determine association between differences in HYP sequences from main valvular 
scaffold collagens and pediatric end-stage CAVS. Rationale: Translational and post-
translational regulation of collagen subtypes remains mostly unknown in pediatric or adult 
CAVS. Hydroxylation of prolines (HYP) is a PTM that is critical in stabilizing the triple helix 
of collagen fibers through hydrogen bonding21. Collagen HYP levels are known to drive 
collagen organization in breast cancer, as well as result in changes to cell migration and 
proliferation14,15. Our preliminary data suggests that HYP levels may differ in pediatric 
CAVS as well. We hypothesize that the deregulation in 1) the number of HYP modifications 
in fibril type collagens α1(I), α2(I), and α1(III) correlates to the destabilized trilayer 
organization of the valvular collagen scaffold and is uniformly expressed in pediatric end-
stage CAVS, regardless of age at end-stage. 
Experimental Design: High resolution accurate mass (HRAM) proteomics will be 
performed on an expanding cohort of 26 FFPE tissues (Table 1). The cohort tissues are 
from age-matched patients across 4 categories: normal (n=5), pediatric end-stage CAVS 
(n=11), adult fibrocalcific AVS (FAVS) (n=5), and non-bicuspid aortic valve insufficiency 
(AVI) (n=5). We have previously shown that deglycosylating with PNGase F before ECM 
digestion results in greater peptide identification, with the additional benefit of retaining the 
N-glycan profile for further analysis22. Tissue is then digested with Collagenase Type III 
(COLase3) to detach ECM peptides. The use of COLase3 is a novel technique recently 
developed by our lab to improve upon the limitations of tryptic ECM digest in FFPE tissues. 
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Table 1: Current tissue cohort; continuously expanding via biorepository 
acquisition. normal (n=5), pediatric end-stage CAVS (n=11), adult fibrocalcific 
AVS (FAVS) (n=5), and non-bicuspid aortic valve insufficiency (AVI) (n=5). BSA: 




Label free quantitation LC-MS/MS analysis will be done via data dependent acquisition on 
an Orbitrap Elite mass spectrometer equipped with a LC Packings U3000 nano-LC system 
(Thermo Scientific). CID Tandem mass spectra will be initially searched using MaxQuant 
version 1.6.3.3. MS/MS and then will be re-searched using a subset database of proteins 
identified at 0.05 FDR for Oxidation (Proline), and a peptide probability of 99%. 
Expected Outcomes: The LC-MS/MS data acquired from this Aim will identify an expected 
2500 peptides across 44 ECM proteins from our cohort of AV COLase3 digest samples. 
This peptide data will include corresponding m/z values that will allow us to identify peaks 
from our MALDI-IMS experiments in Aim 3. With the results of this Aim, we will sequence 
collagen type peptides and identify target novel sites of HYP in collagen that are 
differentially expressed in pediatric CAVS. With this same dataset, protein interaction 
networks will be created to determine regulators of CAVS collagen networks (proof of 
concept, Fig. 4[143]). To confirm our LC-MS/MS results, a minimum of one new regulator 
will be evaluated by IHC. Identified peptide targets (both hydroxyprolinated and 
unmodified) will be further evaluated via targeted proteomics for enhanced precision, 
validated quantitation, and sensitivity. Potential Pitfalls & Alternative Strategies. 1) The 
use of nonspecific enzymes such as COLase3 may increase false discovery rate (FDR) 
of protein IDs. We will limit FDRs by using concatenated reverse databases in peptide 
searches, ensuring high peptide probabilities (>99%), and manually inspecting MS/MS 
data. 2) Overall levels of HYP may not differ between disease states. HYP site maps along 
each ECM protein sequence will be performed to probe for specific domains that may 
differ in their HYP levels. 3) PTMs other than HYP are invovled in collagen regulation.  
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Figure 4: As a proof of concept, we show collagen interaction 
networks found by COLase3 proteomics on a tissue section of breast 
cancer, (blue: predicted signaling molecules). This same 
methodology will be applied to discover new signaling molecules 
driving CAVS collagen deposition. (Angel et al, 2018) 
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Secondary searches of the dataset can be performed to identify levels of other PTMs 
associated with crosslinking, such as hydroxylation of lysines. Our method also allows us 
to analyze changes in N-glycosylation. Collaborative labs have also developed an IMS 
method for observing O-glycosylation changes, a PTM directly linked to hydroxylation in 
lysine residues23. 
2.3.3 Specific Aim 3 
Spatially localize HYP containing collagen peptides across healthy AV and CAVS 
tissues. Rationale: ECM stratification into the three layers fibrosa (collagen), spongiosa 
(GAG), and ventricularis (elastin) is part of healthy AV development, influenced in part by 
changing hemodynamics and oxidative stress[23, 41, 48-50, 170, 171]. During 
development, collagen distributions change: fibril-type collagens (COLI, II, and III) are 
present in early development, while network and FACIT type collagens (COLIV, VI, VIII, 
XIV) in late-embryonic/post-natal development. This data, however, is interpreted from 
mouse[22]. Similar studies have yet to be done on human AV. Collagen stability during 
this time, mediated by HYP, plays a critical role in collagen stratification in vivo, directly 
influencing AV function[41]. We hypothesize collagen sequences with HYP increase due 
to normal aging patterns and play a role in stratification; similarly, HYP levels change in 
the distal tip of CAVS valves where highest levels of hemodynamic stress and ECM 
destratification are observed at end-stage in pediatric CAVS. 
Experimental Design: To spatially localize collagen HYP peptides across the valve, Matrix-
Assisted Laser Desorption/Ionization (MALDI) coupled to Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) Imaging Mass Spectrometry (IMS) will be used in parallel with HRAM 
proteomics (Aim 2). Tissues will be prepared in a similar manner as those used for HRAM 
proteomics, but instead will remain on the slide to be imaged via MALDI-IMS. MALDI-IMS 
analysis will be completed with a 7.0 Tesla solariX™ Legacy FT-ICR (Bruker Scientific, 
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LLC) operated in positive ion broadband mode spanning m/z range 500-4000. Images will 
then be visualized in FlexImaging v5.0 and analyzed using SCiLS (Bruker Daltonics). 
MALDI-IMS and HRAM LC-MS/MS data will be linked by accurate mass within ±5 ppm 
mass accuracy. 
Expected Outcomes: It is our hypothesis that there is a unique regulation of collagen HYP 
in the CAVS tissue microenvironment contributing to progression. MALDI-IMS techniques 
used in this Aim will allow us to visualize and relatively quantify in situ peptides from 
collagens localized to AV structure or CAVS pathology. Heat maps of distinct peptides will 
be evaluated for correlation with ECM stains and markers of AV development (Aim 1-2). 
Spatial localization of collagen peptides throughout the AV may provide insight into the 
mechanical mechanism of valve degradation. For example, collagen peptides can be 
mapped to regions known to be particularly dysregulated in CAVS – such as the tip of the 
valve. Preliminary data analyzed via SCiLS segmentation analysis shows that the tip of 
the valve has a distinct molecular profile compared to the belly and the hinge region (Fig. 
5c). This method is also capable of spatially localizing the distribution of collagen HYP 
peptides (Fig. 5d, bottom). 
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Figure 5: MALDI-IMS of collagens in CAVS. A) Hematoxylin, eosin & alcian blue 
stain shows structural features of the tissue. B) COLase3 total ion current by 
MALDI FT-ICR. C) Regionalization of spectral grouping across the valvular 
structure. Each color represents a distinct proteome. D) Examples of collagen 
image patterns found in the same experiment. The COL18A1 peptide represents a 
hydroxylated proline peptide. 
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Potential Pitfalls & Alternative Strategies: 1) Collagen peptide signal is limited due to intra- 
and inter-molecular crosslinking. Sequential enzyme treatment with elastase and other 
MMPs may be used to increase access to collagen peptides22. 2) Spatial mapping may 
indicate no correlation between hemodynamically stressed areas and collagen 
deregulation. An alternative approach is to perform in vitro analysis of cells undergoing 
shear stress via bioreactor conditioning to simulate hemodynamic conditions of CAVS31. 
We would perform MALDI-IMS on cultured cells to detect changes in HYP collagen 
peptides, and N-glycans.  
Statistical Considerations: 
Sample size and power analysis estimation using a two-group t-test indicates a minimal 
sample size of 8 per group will provide 98% power to detect a 2.56-fold change with a 
relative standard deviation of 0.65 due to biological variation. The Type I error probability 
of the null hypothesis is 0.001. The Collaborative Unit at MUSC is a biostatistics and 
















Chapter 3: Collagen Fiber Regulation in Pediatric Congenital 
Aortic Valve Stenosis 
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The following chapter details the histopathological- and proteomics-based 
characterization of the ECM within our pediatric cohort of aortic valve tissues. Our goal 
was to ascertain the dominant ECM constituent being deposited within pediatric CAVS 
patients. Additionally, we aimed to characterize various parameters of the collagen that 
was being deposited – that is, its maturity, density, and orientation. Similarly, via, bulk 
chromatographic proteomic analysis, we aimed to determine collagen-sub type regulation 
within the different disease states. We also aimed to determine differential post-
translational regulation via quantification of the hydroxyproline (HYP) content within the 
collagen peptides identified. The bulk of this chapter was included in a first-author 
manuscript published in Nature Scientific Reports in May 2021[39]. Experiments were 
performed by myself in addition to manuscript writing, data analysis, and final approval. 
Minor editorial and intellectual contributions were provided by co-authors [39].  
4.1 Introduction 
Congenital aortic valve stenosis (CAVS) accounts for 10% of all congenital heart 
defect cases, affecting up to 6 of every 1000 newborns[24]. There are two distinct subsets 
of this disease: 1) pediatric end-stage, characterized by a rapid engorgement of the 
structure with extracellular matrix (ECM); and 2) the more frequently studied adult end-
stage, characterized by fibrocalcific lesions [172]. These defects result in a narrowing of 
the aortic opening, obstructing aortic outflow and leading to left ventricular hypertrophy 
and heart failure. Despite the clinical significance, there are no available therapeutics. The 
patient is managed by “watchful waiting” until deteriorating cardiac hemodynamics 
indicates a need for surgical intervention either through valve replacement or heart 
transplantation [173]. Bioengineered aortic valve replacements are especially limited for 
pediatric patients due to their inability to grow with the patient and lifelong requirements of 
anti-clotting agents, and serial surgeries to replace valves during somatic growth [57]. 
53 
 
There is an ongoing need for identifying therapeutic targets, particularly for the pediatric 
population. 
Collagens form the underlying scaffolding of valvular structure that influences 
valvular function and consequently cardiac function[8, 26, 166, 174-178]. Collagen is 
developmentally regulated and is required for appropriate heart function during somatic 
growth[178-180]. The normal human aortic valve has an ECM trilayer structure defined by 
a high density collagenous fibrosa facing blood outflow, an interior spongiosa composed 
of primarily glycosaminoglycans, and the elastin-rich ventricularis [178, 181]. In the mature 
human valve, a parallel alignment of collagen with valvular endothelium is critical for 
normal function [179, 181], highlighting the importance of collagen organization within the 
trilayer compartments as fundamental to valvular function. Pediatric CAVS produces 
excessive collagen deposition that mixes with other extracellular matrix proteins, creating 
a disorganized ECM structure, altering valvular function and leading to cardiac failure [8, 
182, 183]. Although collagen deregulation is a hallmark of adult and pediatric valvular 
stenosis [184-186] and a potential prognostic and therapeutic target[187, 188], very little 
is known about the complexities of collagen fiber regulation in the human valve. 
In the current study, we test the hypothesis that pCAVS disease mechanisms also 
include dysregulation of collagen fiber arrangements with an altered post-translational 
regulation. A total of 20 human AV tissue specimens with clinical data on AV function were 
evaluated. Histopathological stains paired with microscopy methods were used to define 
collagen fiber changes and collagen variation within the valvular structure. A collagen-
targeting[141, 143, 144, 189] high-resolution accurate mass (HRAM) proteomics 
approach was used to measure collagen type composition and PTM regulation within the 
collagen structure. Protein-protein interaction analyses were done to determine possible 
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upstream regulators relevant to collagen deregulation observed in pCAVS. Upstream 
regulators were validated via immunohistochemistry. Results of this study indicate that 
pCAVS shows fundamental differences in collagen fiber organization, collagen type 
regulation, and regulation of proline hydroxylation of collagens. These studies are the first 
to report specific collagen regulation due to pCAVS, and establish a foundation for new 
translational and post-translational collagen studies in fibrotic cardiovascular disease. 
4.2 Materials & Methods 
4.2.1 Materials 
Xylenes, 200 proof ethanol was from Fisher Scientific (Pittsburgh, PA, USA). 
Acetonitrile, Ammonium Bicarbonate, Calcium Chloride, Formic Acid, and Trizma Base 
were from Sigma-Aldrich (St. Louis, MO, USA). PNGase F Prime was purchased from N-
Zyme Scientifics (Doylestown, PA). Collagenase type III (COLase3) (C. histolyticum) was 
purchased from Worthington Biochemical (Lakewood, NJ, USA). 
4.2.2 Tissue Procurement 
Aortic valve tissue samples were procured through the Vanderbilt Core Laboratory 
for Translational and Clinical Research and the National Disease Research Interchange. 
The aortic valve tissues were collected under the Vanderbilt Pediatric Congenital Heart 
Disease Biorepository, written informed consent was obtained, and the project was 
approved by the Vanderbilt Institutional Review Board (IRB) and the IRB at the Medical 
University of South Carolina. De-identified tissues were obtained during reparative or 
transplant surgeries and characterized by pre-operative function into three patient 
categories: normal tricuspid (normal), pediatric CAVS bicuspid (pCAVS), and aortic valve 
insufficiency tricuspid (AVI). Valvular function is from de-identified complete 2D, color and 
spectral Doppler, or M-mode echocardiogram reports acquired prior to valve resection, 
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replacement or heart transplant. The pCAVS patients were identified as being stenotic, 
predominantly bicuspid, and having mild aortic valve insufficiency. The AVI group only has 
aortic valve insufficiency, but are not stenotic and are all tricuspid. Adult CAVS samples 
(aCAVS) used in the qRT-PCR study showed no calcification by clinical annotation, with 
the except of SKU SB176. Pediatric ages used to stratify the population are based in 
National Institute of Child Health and Human Development (NICHD) pediatric terminology 
defining pediatric age groups in terms of clinical treatment, considering rapid somatic 
growth stages[190]. 
4.2.3 Histological Staining 
The 5-µm thick formalin-fixed, paraffin-embedded tissue sections were stained 
with Picrosirius Red (PSR; Polysciences, Inc., Warrington, PA, USA), Movat’s 
Pentachrome and Herovici (American Mastertech Scientific of StatLab, McKinney, TX, 
USA) following manufacturer’s protocols. Optical light whole tissue scans were done using 
a high-resolution slide scanner (Nanozoomer, Hamamatsu, Japan). Polarized light images 
of PSR were taking with a Spinning Disk CARV II microscopy (BD Biosciences, San Jose, 
CA, USA), and manually stitched together using Photoshop (Adobe, San Jose, CA, USA). 
Movat’s, PSR, and Herovici Color Deconvolution analysis was done using ImageJ[191] 
adjusting for RGB hue threshold color (Movat: Elastin 0-19, 170-255; GAG 80-169; 
Collagen 20-79) (PSR: Thin 46-190; Thick 0.45, 191-255) (Herovici: Immature 0-167; 
Mature 168-255). Percent of each color threshold is represented as a percent of total area 
stained (RGB 0-255). Collagen Plaque analysis was done using ImageJ[191]. Briefly, 
polarized light images were converted to 8-bit and thresholded to include all signal. Images 
were processed with a mean filter of 1 μm and a look-up table of Red/Green was applied. 
Regions of increased collagen fiber density (RIFD) were quantified by thresholding to 
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include the top 50% most dense signal (i.e., “green” component).  Collagen fiber analysis 
(fiber length, width, angle) of PSR birefringent images were converted to 8-bit grayscale 
and analyzed using CT-FIRE[192].  
Second Harmonic Generation (SHG) microscopy was performed on the same 
tissue section used for PSR studies. SHG images were collected with a Spectra-Physics 
InSight X3 dual laser system and excited at 860nm. SHG images and were collected at 
emission 432nm with a 45nm bandpass. SHG multichannel show overlay images collected 
at emission wavelengths: 432nm (±22.5 nm) (cyan; collagen SHG), 518nm (±22.5 nm) 
(green; collagen autofluorescence), 610nm (±35 nm) (red; PSR, elastin, and heme 
structures).  
For immunohistochemistry, tissues were deparaffinized, antigen retrieved at pH 6 
in sodium citate, then stained with HRP/DAB (ABC) Detection IHC Kit (Abcam, 
Cambridge, UK) according to manufacturer’s instructions with the following modifications: 
all incubation times were increased to 15 minutes. Primary antibody BAMBI (polyclonal) 
was diluted 1:100 (Millipore Sigma, St. Louis, MO, USA). IHC stained tissues were 
counterstained with Mayer’s hematoxylin (Electron Microscopy Sciences, Hatfield, PA, 
USA).  
4.2.4 Proteomic Tissue Preparation 
Proteomic studies used tissue sections adjacent to histological studies (~150 μm 
distance). Tissues were 5-µm thick and mounted on standard microscope slides (Tissue 
Tack, Polysciences, Inc., Warrington, PA, USA). For proteomic experiments, slides were 
heated at 60°C for 1 hour then dewaxed as follows: xylenes (3 min, two times), 200 proof 
ethanol (1 min, two times) 95% ethanol (1 min), 70% ethanol (1 min), HPLC water (3 min, 
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two times). Valve surface area was used to determine equivalent amount of tissue and 
valves were scraped with a razor off the slide into centrifuge tubes. 10 mM Tris pH 9 was 
added to each tube to cover the tissue. Tissues were ultrasonicated at 50% energy 
(Fisherbrand 120 sonic dismembrator;Fisher Scientific, Pittsburgh, PA, USA) for 2 minutes 
each and incubated at 60°C for two hours to antigen retrieve formalin-fixed 
crosslinks[193]. Samples were buffer exchanged into water and deglycosylated with 2 μg 
of PNGaseF PRIME (N-zyme Scientifics, Doylestown, PA) for two hours at 38°C at 450 
rpm using a thermomixer (Eppendorf, Hamburg, Germany). Supernatant was removed, 
and samples were buffer exchanged into 10 mmol/L ammonium bicarbonate, 3 mmol/L 
CaCl2, pH 7.25 and treated with 4 μg of Collagenase Type III (COLase3) overnight, 
shaking at 38°C. An additional 4 μg of COLase3 was then added to each sample and 
incubated for 5 hrs at 38°C with mixing at 450 rpm. COLase3 activity of 3 Units/mL was 
confirmed prior to digestion by a colorimetric activity kit (ab196999, Abcam, Cambridge, 
MA). Samples were centrifuged at 16,000 g for 5 minutes at 4°C and supernatant collected 
for proteomic analysis. Samples were purified by C18 STAGE tip[194] (Pierce 
Biotechnology, Waltham, MA) followed by a C18 ZipTip (Millipore Scientific, Burlington, 
MA) according to manufacturer’s protocol. Solutions were modified for STAGE tip using 
90% acetonitrile, 5% formic acid (initialize and elute); 5% acetonitrile, 5% formic acid 
(equilibrate and wash). STAGE-tip eluate was dried down via speed vac and resuspended 
in 0.1% TFA in water. An additional C18 ZipTip according to manufacturer’s protocol 
(Millipore Scientific) and sample resuspended in mobile phase A (2% acetonitrile, 0.2% 




Peptides were analyzed by data dependent acquisition on an Orbitrap Elite mass 
spectrometer equipped with a LC Packing U3000 nano-LC system (Thermo Scientific). 
Peptides were loaded onto a trap column and separated on a 75 μm x 30 cm classic pulled 
tip column (C18-Reprosil-AQ Pur RP 1.9 µm particles, Dr. Maisch, GmbH) at 60°C. The 
gradient was from 5% to 40% solvent B over 180 min, where solvent A was 0.2% v/v 
formic acid in water and solvent B was 98% acetonitrile with 0.2% v/v formic acid. An 
FTMS survey scan was acquired over a mass range of 400-1700 m/z at a resolution of 
60,000 with an automatic gain control (AGC) target value of 106, followed by CID MS/MS 
of the top 10 most intense ions in the ion trap. Dynamic exclusion was enabled with a 
repeat count of 1, repeat duration of 30 s, and exclusion duration of 180 s. Data were 
searched using MaxQuant version 1.6.3.3 [195] against the human database (42,106 
entries downloaded May 5, 2017) and a subset 1783 entries with keywords used 
(collagen, elastin, aggrecan, gelatin, osteonectin, perlecan, plasminogen, and fibronectin).  
Parameters included unspecified proteolytic enzyme, precursor mass tolerance of  20 
ppm, and fragment mass tolerance  0.8 Da. Methionine oxidation, asparagine and 
glutamine deamidation were included as variable modifications. Proteins were identified 
with FDR≤0.05 and at least two peptides. Hydroxylated proline modification site 
localization probabilities were obtained by re-searching MS/MS using a restricted 
database of identified proteins and allowing for dynamic modification proline oxidation. 
Perseus[196] was used for protein and peptide level analyses.  
4.2.6 Protein-Protein Interaction Network Analysis 
Protein identifications were uploaded to Ingenuity Pathways Analysis (IPA; Qiagen 
Inc., https://www.qiagenbio informatics.com/products/ingenuity-pathway-analysis) to 
identify putative regulators of the protein dataset. Networks were calculated using 
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predicted relationships between regulators by p-value ≤ 0.01; a p-value < 1.0 × 10–12 was 
used for inclusion in the network. Upstream Regulator Networks were calculated using 
predicted relationships between regulators (CCR2, COLQ, IGF2BP1); a p-value <1.0 x 
10-18 was used for inclusion of the upstream regulator network. Causal Network analysis 
was done to identify Master Regulators of the data (BAMBI) and a p-value < 1.0 × 10–12 
was used for inclusion in the network. 
4.2.7 Proteomic Data Analysis and Statistics 
Perseus[196] was used for protein and peptide level analyses. Hierarchical 
clustering was performed in Perseus on ANOVA significant peptide intensities via a 
permutation-based FDR of 0.05 and 250 randomizations. Clustering parameters: 
Euclidean distance, average linkage, and k-means pre-processing. Peptide level 
quantification was determined using peak intensities from peptides scoring ≥ 75 after 
median normalization and considered as significant with a minimum two-fold change. 
Relative changes in protein abundance based on normalized protein intensities were 
evaluated by ANOVA and Mann Whitney U test, correcting for multiple comparisons (IBM 
SPSS Statistics, version 25). A Type I error probability of ≤0.1 was used to evaluate the 
significance of the result. MWU-test was used in histological studies to calculate raw p-
values. For this small clinical cohort, p-values of ≤0.1 are reported as trending to 
significance and p-values of ≤0.05 were used determine significant results.  
GO enrichment was performed through Geneontology.org[197, 198]. Genes were 
clustered to cellular component, biological process, or molecular function using Panther 
v14[199] filtered by Fisher’s Exact (FE) p-values <0.001 and false discovery rates (FDR) 
of <0.005. Exported peak intensities are visualized as heatmaps after natural log 
transformation with MultiExperiment Viewer (http://www.tm4.org)[200]. 
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4.2.8 Real Time Quantitative Reverse Transcription PCR 
Aortic valve (AV) specimens were collected at the time of surgery or from an 
explanted heart. Samples were immediately flash-frozen and stored at -80°C till used for 
RNA extraction. Total RNA from AV tissues was isolated using RNeasy Kit (Qiagen, 
Germantown, MD), according to the manufacturer’s instructions. The BAMBI gene 
expression level was validated by quantitative RT–PCR (qRT-PCR) using the Taqman 
method, as previously described[201]. Briefly, cDNA was generated using 100 ng of total 
RNA and High Capacity cDNA Synthesize Kit (Catalog # 4368814 Thermo Fisher 
Scientific). Predesigned BAMBI (catalog # Hs03044164) and GAPDH (catalog # 
Hs02758991) primers were obtained from Thermo Fisher Scientific and the qRT-PCR 
were run in triplicates according to the manufacturer’s instructions. All Ct values were 





Table 2: Descriptive statistics of patient characteristics for all pediatric aortic valve 
(AV) tissue samples featured in the study. Normal AVs are from cardiac transplant 
patients where normal AV function is define by 2D echocardiogram. 2D Echocardiogram 
mean gradients define pre-operative AV function where a normal gradient is defined as 
<5 mmHg, mild stenosis as 5-25 mmHg, moderate stenosis as 25-50 mmHg, and severe 
stenosis as >50 mmHg. BSA: body surface area; C: Caucasian; L: Latino; AA: African 
American; MD: Myxomatous Degeneration. DB43 was included in pCAVS due to stenosis, 
but main diagnosis was Hypertrophic Cardiomyopathy. Pediatric Age Groups are defined 
by National Institute of Child and Human Development: Neonate (0-30d), Infant (1 mo – 





4.3.1 Clinical and Morphological Characteristics of Study Cohort.  
Collagen from human aortic valve samples was studied across four patient 
categories: normal, pediatric end-stage congenital aortic valve stenosis (pCAVS), and 
aortic valve insufficiency (AVI) (Table 2). Age-matched pediatric samples ranged from 
Neonates (2 weeks) to Adolescent (18 years), with an average patient age of 6.75 ± 6.06 
years. Gender was predominantly male (15, 57.7%). The race was primarily Caucasian 
(16, 61.5%). For each patient, serial tissue sections were evaluated for histopathology of 
collagen by multiple staining methods and collagen fiber measurements. Translational and 
post-translational regulation of collagen was investigated by collagen targeted 
proteomics[203] using HRAM proteomics on regions approximately 100 µm in thickness 
adjacent to histological sections. In summary, this cohort represents a suitable 
pathological variation towards probing ECM distribution in human aortic valve 
development and pediatric end-stage disease. 
4.3.2 Pediatric CAVS valves trend to be collagen dominant at a younger age of end-
stage.  
Color deconvolution of Movat’s Pentachrome on the valve cohort was performed 
to determine the dominant ECM type in each patient category (Fig 6A-B, Fig7). Movat’s 
Pentachrome stain showed an ECM trilayer in the normal valves with thickened, 
disorganized ECM due to pCAVS, consistent with previous literature reports on CAVS[8, 
204]. We stratified the pediatric tissues by neonatal to early childhood (0-including 5 years 
of age; rapid growth and development) and middle childhood to early adolescence (age 
6-18 years of age). While differences in elastin can be seen from patient to patient, elastin 




Figure 6: Histology analysis identifies ECM mixing and collagen dominance in 
pCAVS valves at a young end-stage. A. Examples Movat’s Pentachrome staining 
between normal and age matched pCAVS samples. Blue stain corresponds to 
glycosaminoglycan (GAG) regions, dark purple to elastin, and yellow to collagen. Normal 
valves show traditional trilayer structure, while pCAVS valves show lack of trilayer and 
areas of ECM mixing B. Quantification of Movat’s Staining via color deconvolution 
analysis. Blue = GAG, purple = Elastin, yellow = collagen. Shown as a percent of total 
Movat’s stain area. C. Multinomial logistical regression analysis of Movat’s Pentachrome 
Color Deconvolution data shows pCAVS valves are collagen dominant at a younger age 
than normal patients. Variables: ECM dominant category (GAG, elastin, or collagen); 
Patient Category (normal or pCAVS); Age (0-18 years). D-F. Quantification of Elastin, 
GAG, and Collagen (respectively) Movat’s Pentachrome color deconvolution results (Fig. 
1B) comparing two pediatric age groups: young child (Newborn to <6 years of age) and 
Child-Adolescent (6-18 years of age). **p-value 0.008, MWU test. pCAVS GAG decrease 
is concomitant with collagen increase across pediatric age categories G. Scatterplot of all 
data points across Normal, pCAVS, and AVI samples for collagen vs. GAG stain percent 
of total area of Movat’s stain. Bar: 500μm. Spearman’s correlation (R2) -0.96 (p-value 




Figure 7: Movat’s Pentachrome images of all valves studied in Figure 6. DB113 and 
DB32 are included as representative images only, due to delayed acquisition and 




categories (Fig. 6B, D). Pediatric patients in all categories showed decreased 
glycosaminoglycan (GAG) staining over time relative to patient age (Fig. 6E). GAG 
decrease was significant within the pCAVS category compared between two patient age 
groups: young children (77.2 ± 14%; pediatric age < 6 years, n=6) vs children to 
adolescents (30.6 ± 19%; pediatric age >6 years, n=5) (p-value 0.008) (Fig. 6E-F). 
Collagen content increased concomitant with decreasing GAG content over all patient 
groups (Spearman’s correlation -0.96 (p-value <5.62E-8) (Fig. 6G). Interestingly, while 
collagen content progressively increased with age for each patient category, the likelihood 
of a pCAVS valve having a collagen dominant phenotype occurred at a younger age of 
end-stage. Histopathology evaluation revealed that the rate of collagen deposition 
increased by 56% in pCAVS compared to normal AV development. When accounting for 
age by multinomial logistical regression, analysis showed that the probability of a normal 
valve being in the collagen dominant ECM category increased by 32% (p-value 0.034, 
Fig. 6C) for every year of age. In contrast, pCAVS valves showed a trend to having a 
collagen dominant phenotype which increased by 88% (p-value 0.126, Fig. 6C) for every 
year of age. Collagen significantly increased in between pediatric patient age groups (34.7 
± 15.7% age<6 years; 67.4 ± 24.1% age ≥ 6 years, p-value 0.0079) (Fig. 6F). These 
results show that the ECM disorganization of pCAVS involves a progressive collagen 
dominant phenotype concomitant with GAG decreases. 
4.3.3 Pediatric CAVS demonstrate high deposition of immature collagen compared 
to individual age-matched controls.  
Herovici stain was used to assess valvular content of immature/smaller collagen 
fibers (blue) and mature/larger collagen fibers (purple) (Fig. 8-9) [205]. Immature collagen 





Figure 8: Pediatric CAVS demonstrate high deposition of immature collagen 
compared to age-matched controls. A-B. Herovici staining of SKU DB27, a 17-year-old 
normal sample with regions of Hinge, Belly, and Free Margin 10x zoom shown (B). 
Blue=immature. Purple-mature. Normal immature collagen production is localized to the 
ventricularis, while pCAVS immature production becomes increasing dysregulated 
towards the free margin. C-D. Herovici staining of SKU DB16, an age-matched CAVS 
sample with regions of Hinge, Belly, and Free Margin 10x zoom shown in D. E. Patient 
specific breakdown of Herovici color deconvolution analysis. pCAVS patients show 
increased immature collagen production compared to age matched controls. F. Boxplot 
showing quantification of Herovici color deconvolution, showing larger heterogeneity 




Figure 9: Herovici images for valves studied in Figure 8. 
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by pathology, suggestive of a link to mechanics of valve function. In trilayer regions close 
to the hinge region, normal valves and pCAVS showed immature collagen deposition in 
the spongiosa (Fig. 8 A-D). Within the belly of the leaflet,  immature collagen deposition 
aligned with regions of ventricularis delamination. However, pCAVS showed sites of 
pathological mixtures of immature and mature collagen. For example, in SKU DB16, 
immature collagen appears mixed with mature collagen along the ventricularis closer to 
the hinge. The free edge of this valve contains significant mixtures of both immature and 
mature collagen, suggestive of a dynamic production of collagen in this region. By Herovici 
stain, all valves showed immature collagen deposition (Fig. 8F). Averaged across ages at 
end-stage, where there was no significant difference between normal and pCAVS levels 
of immature collagen. However, comparison of same age patients showed increases in 
immature collagen for age matched samples (ex. 19% increase in SKU DB16 vs DB27) 
(Fig. 8E). Overall, the data show that both normal and pCAVS continually produce 
immature collagen with pCAVS showing pathological mixes of both immature and mature 
collagen. 
4.3.4 Pediatric end-stage CAVS valves have greater numbers of collagen fibers with 
localized regions of collagen density.  
Collagen fiber measurements were done by Picrosirus Red (PSR) staining to 
characterize collagen fiber regulation (thickness, density, and alignment) (Fig. 10-11). 
Interestingly, all pCAVS valves showed localized areas of high-density collagen, 
confirmed by second harmonic generation microscopy (Fig. 10A, 11). Collagen fiber 
thickness was not significantly different between normal valves compared to pCAVS or 
AVI. However, larger interquartile ranges were observed in pCAVS (37-81% thick fibers) 




Figure 10: Pediatric end-stage CAVS valves have a greater number of collagen 
fibers with localized regions of collagen density. A. Collagen fiber visualization of 
select pCAVS and normal valves. From left to right: Second Harmonic Generation (SHG); 
SHG multichannel; Polarized picrosirius red (PSR); PSR Regions on Increased Fiber 
Density (RIFD) Masque; Movat’s Pentachrome. Movat’s Pentachrome: blue=GAGs, 
yellow=collagen, and purple=elastin. Scale Bar = 200μm. B. Boxplot showing 
quantification of PSR color deconvolution analysis. C. Patient-specific data of PSR color 
deconvolution analysis. pCAVS and AVI patients show larger heterogeneity across age 
groups compared to normal. D. Boxplot showing quantification of collagen RIFD areas 
normalized to total valve area. *p-value 0.024, MWU test. pCAVS and AVI patients have 
significantly more regions of high collagen fiber density compared to normal patients. E. 
Boxplot showing quantification of total number of collagen fibers as measured by CT-FIRE 
analysis. *p-value 0.014, MWU test.  F-G. Hinge, Belly, and Free Margin (respectively) 
10x zooms of PSR-polarized light signal overlayed with CT-FIRE mask of collagen fibers 
for normal (F; SKU DB27) and pCAVS (Gl SKU DB16) (Fig. 11). H. Polar histogram 
showing frequency distribution of collagen fiber angles from 0-180°, across all normal 
valve samples (left) and pCAVS (right) relative to the endothelium. Normal n=4; pCAVS 




Figure 11: Optical and Polarized Picrosirius Red (PSR) images of valves studied in Figure 
10. RIFD (Regions of Increased Fiber Density) masks are shown. 
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have increased heterogeneity of fiber thickness (Fig. 10B-C). Compared to normal valves, 
both pCAVS and AVI valves demonstrated a significant increase in regionalized collagen 
density normalized by area (p-value 0.024 and 0.019) (Fig. 10A, D). Localized areas of 
high-density collagen fibers did not appear to be specific  to valvular anatomy and 
occurred at different locations within the leaflet. The amount of collagen fibers in pCAVS 
valves was significantly higher when compared to normal valves (2.5-fold more, p-value 
0.014; normalized to cross-sectional area). Fig. 10E). Picrosirius Red staining, in 
combination with CT-FIRE software, was used to determine the collagen fiber angle 
alignment relative to endothelium. Collagen fiber angles in normal valve structures were 
primarily between 150-180° relative to endothelium (SKU DB27, Figure 10F,H), following 
previous observations in normal valve growth[175, 179, 185]. In comparison, the pCAVS 
valves showed a larger distribution of fiber angles (over 0-180° relative to the endothelium) 
along the length of the valve, suggestive of collagen fiber misalignment compared to 
normal controls (Fig. 10G, H). To summarize, the data shows that pCAVS valves are 
characterized by localization of high-density collagens and higher number of collagen 
fibers compared to normal valves. 
4.3.5 Proteomic analysis indicates collagen structure is post-translationally 
regulated in pCAVS.  
A collagen and ECM protein targeted proteomic analysis approach was next 
applied to the valve tissue cohort to understand how collagen fiber regulation corresponds 
with collagen protein structure regulation. The proteomics analysis workflow is 
summarized in Figure 12 and described in Materials and Methods. A focus of the analysis 
was testing for hydroxylated proline (HYP) residues, a collagen post-translational 




Figure 12: Collagenase Type III high resolution accurate mass (HRAM) Proteomics 




Figure 13: Pediatric CAVS valves have reduced HYP, including in collagen-ECM 
binding sites. A. log2(fold change) scatterplot of pCAVS vs. Normal peptides. Red 
squares are HYP containing peptides, grey squares are unmodified peptides. Bold lines 
indicate X+2 and X-2. Top 10 collagen peptides are annotated with corresponding 
sequence and protein shown (A, right). P(X) where X is between 0-1, indicated HYP 
probability at that site. Significantly regulated collagen subtypes differ between pCAVS 
and normal, with non-fibril types (multiplexin, FACIT) differentially regulated in normal. B. 
Representative HYP site mapping for COL1A1, COL1A2, and COL3A1, shown for Normal 
and pCAVS patients (DB27 and DB16, respectively). Normal sample contained more HYP 
sites than age matched controls. Unique HYP sites in Normal (top, red) are found in 
glycoprotein vi and integrin binding motifs. C. Quantification of HYP state of proteins in all 
peptides identified in normal (black) or pCAVS (grey). D. HYP percent in peptides 
containing glycoprotein vi, integrin, or SPARC binding motifs. Loss of HYP may indicate 




























































































































































































organization[69, 206]. From a total of 2985 peptides identified, with 126 peptides were 
differentially expressed between normal and pCAVS by a minimum of 2-fold change (Fig. 
13, Tables 3-4). The majority of altered peptides were from collagen type proteins (87/126; 
69%) and these included site-specific modifications of hydroxylated proline (Figure 13A). 
Hydroxyproline site mapping from age-matched normal and pCAVS valves suggested a 
strong potential for HYP site variation within the triple helical regions on fibril type 
collagens α1(I), α2(I), α1(III) (Fig. 13B). Site occupancy analytics showed 41 HYP sites in 
collage α1(I) were shared between normal and pCAVS valves; the normal valve showed 
5 unique sites of HYP modification while the pCAVS valve showed 8 sites of HYP 
modification that were not detected in normal valves (Fig. 13B). Consistent with data 
across the abundantly changed peptides, normal valve collagen α2(I) and α1(IIII) 
contained more HYP sites than the age-matched pCAVS valve. In collagen α2(I), 41 sites 
were shared with 9 unique HYP sites in normal valve and only 3 unique HYP sites in the 
age matched CAVS sample However for collagen α1(III), the normal AV (SKU DB27) 
showed an additional 16 unique hydroxyproline sites, while 7 unique HYP sites identified 
in the pCAVS valve (SKU DB16; Fig 13B). Among patient groups, the overall percent 
change in HYP content showed more subtle variation (Fig. 13C), yet it is likely that 
regulation at key HYP sites has greater effects on collagen structure organization [69, 
207].  
Specific HYP binding site motifs were evaluated for pCAVS related changes. 
These included motifs for glycoprotein VI (collagen-induced platelet adhesion and 
activation), integrin (cell-surface receptor for collagen)[208] and SPARC (cell invasion) 
(Fig. 13D)[207]. Qualitatively, fibril type collagens α2(I) and α1(V) showed reduced HYP 
in glycoprotein VI binding sites. Similarly, collagen α1(I) demonstrated potential reduction  
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in HYP content for integrin binding sites. Collagen α1(XXI), which was recently found to 
be transcriptionally increased in cardiomyopathy remodeling[209], showed large 
decreases in pCAVS HYP content; in pCAVS, HYPs in known binding motifs of 
glycoprotein VI were undetected in collagen α1(XXI). The analysis of collagen structure 
variation by peptide analytics suggests that collagen HYP site regulation may contribute 
to human aortic valve status. 
4.3.6 Valve status is characterized by a differential ECM proteome with primary 
activities of collagen interaction.  
Protein level analysis was performed on the proteomic data (Fig. 14, Table 5) to 
further evaluate how non-collagen ECM proteins contribute to collagen regulation. 
Proteomic analysis identified a total of 44 ECM proteins, including 18 collagen type 
proteins, many of which have not been previously associated with the human aortic valve 
(Fig. 14A). When measuring total protein abundance, most collagens showed very little 
change between normal and pCAVS, suggesting that regulation at the level of post-
translational modifications may play a larger role in AV collagen organization. However, 
there were multiple ECM proteins associated with collagen regulation detected as 
differentially regulated. The abundance of the proteins fibronectin (FN1) and Transforming 
Growth Factor Beta Induced protein (BGH3; cell-collagen adhesions[210]) were 
significantly increased in pCAVS compared to normal AV (2.5-fold, MWU p-value 0.04; 
3.4-fold, MWU p-value 0.02, respectively). In AVI, collagen α1(I) and FN1 increased 
compared to normal AV tissue (1.6-fold, MWU p-value 0.02; 4.6-fold, MWU p-value 0.03). 
Additionally, the proteomics identified SPARC and VTN proteins only in the pCAVS 





Figure 14: Extracellular matrix proteomics implicates collagen binding and collagen 
organization pathways. A. Aortic valve extracellular matrix proteins identified by the 
collagen-targeting proteomics. A total of 18 collagen proteins were identified with COL1A1, 
COL1A2 and COL6A3 being the most abundant collagens. Protein level quantification, 
which includes all peptides both unmodified and modified, revealed significant differences 
based on valve diagnoses in COL1A1, COL1A2, COL5A1, BGH3, FN1, and COL5A2. * 
Mann-Whitney U adj. p-value <0.05 normal AV compared to pCAVS, † Mann-Whitney U 
adj. p-value <0.05 normal AV compared to AVI, ‡ Mann-Whitney U adj. p-value <0.05 AVI 
compared to pCAVS. B. Gene Ontology Functional classification of non-collagen type 
proteins identified in the proteomics dataset. C. Gene Ontology Fold Enrichment analysis 
of collagen type function by non-collagenous proteins identified by proteomics, Fisher’s 
exact p-value ≤ 1.84E-5, false discover rate ≤ 6.66E-3. Proteins associated with collagen 
binding had the highest degree of fold enrichment, followed by collagen fibril organization. 
D. Upstream analysis of the ECM proteome by Ingenuity Pathways Analysis to identify 
potential regulators that explain directional changes in aortic valve ECM proteins. Primary 
regulators affecting the proteome were C-C Motif Chemokine Receptor 2 (CCR2; Fisher’s 
Exact p-value 1.13E-39), Collagen Like Tail Subunit Of Asymmetric Acetylcholinesterase 
(COLQ; Fisher’s Exact p-value 9.67E-19), (Insulin Like Growth Factor 2 MRNA Binding 




Figure 15: SPARC is enriched in pCAVS valves. 
LOG2FC analysis of differentially abundant genes (A) and 
proteins (B, COLase3 proteomics) showing SPARC 
(highlighted), and fibrillogenesis associated collagens 


































































Table 6: Gene Ontology analysis results of non-collagen type proteins identified via 
Collagenase Type III LC-MSMS Proteomics. P-value is Fisher's exact p-value. FDR: 
false discovery rate 
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Gene ontology analyses identified that 26 of the 29 non-collagen proteins were associated 
with collagen-containing ECM (Fig. 14B-C,  Table 6). Furthermore, very specific groups 
of proteins were involved in collagen binding, collagen fibril organization and collagen 
metabolism (Fig 14B-C). 
To understand potential regulators of the dataset responsible for directional 
expression changes in pCAVS compared to normal, protein interaction networks were 
interrogated (Fig. 14D). While some regulators, such as TGFβ1, are known to be 
associated with ECM remodeling and deposition[211], three novel upstream regulators of 
the collagen proteome were identified that could account for change in expression 
patterns. This included C-C Motif Chemokine Receptor 2 (CCR2; Fisher’s Exact p-value 
1.13E-39), Collagen Like Tail Subunit Of Asymmetric Acetylcholinesterase (COLQ; 
Fisher’s Exact p-value 9.67E-19), and (Insulin Like Growth Factor 2 MRNA Binding Protein 
1 (IGF2BP1, Fisher’s Exact p-value 1.05E-18). Both CCR2 and COLQ1 were implicated 
as inhibited in pCAVS based on directional changes[212, 213]. On the whole, proteomics 
identified new collagen types in the human valve and demonstrated that changes in 
pCAVS structure may identify target regulators of the collagen proteome. 
4.3.7 BAMBI as a Potential Novel ECM Regulator of Pediatric Congenital Aortic 
Valve Stenosis  
To identify master regulators that could be driving previously identified upstream 
regulators of the AV collagen proteome, causal network regulation analysis was 
performed. This analysis expands the scope of the upstream regulator analysis from 
Figure 14 by integrating literature-observed cause-effect relationships (Figure 16, 17A).  
One such master regulator putatively  identified was BMP and Activin Membrane-Bound 




Figure 16: Proteomics based protein-protein interaction networks identify BAMBI 
as a potential master regulator of the collagen interactome in pCAVS. A.Protein-
Protein Interaction network showing relationship BAMBI relative to the ECM proteome and 
key valvular development proteins. B. Quantification of qRT-PCR expression data on 
BAMBI (normalized to GAPDH), between patient categories. One-way ANOVA shows 
significant differential expression between patient categories (*p-value 0.013), with 
significant reduction in pCAVS (MWU *p-value 0.045) and trending reduction in aCAVS 
(MWU *p-value 0.053) compared to normal pediatric patients. (Normal n=2; pCAVS n=12; 
aCAVS n=5) C. Quantification of qRT-PCR expression data on BAMBI (normalized to 
GAPDH) of CAVS patients, compared between pediatric age categories (Infant n=2; 
Young Child n=3; Child n=2; Adolescent n=5; Adult n=6). A suggestive trending decrease 
of BAMBI expression as a function of pediatric age categories is seen (ANOVA p-value 
0.096). D. DAB stain area quantification of BAMBI IHC of select valves in the cohort. E. 
Representative immunohistochemistry staining of BAMBI in a selection of pCAVS and 
normal valves 20x (top) and 40x zoom are shown. BAMBI positive cells appear highly 
localized, shown in dotted lines. Verhoeff van Geison (VVG) staining on the same valve 
section post-IHC study is shown (middle). Movat’s Pentachrome staining of a serial valve 
section (bottom). Positive BAMBI staining in pCAVS corresponds heavily to areas low in 
collagen staining (VVG) and high in GAG staining (Movat’s), while normal valve shows 




Figure 17: Causal network analysis implicating BAMBI and expression analysis. A) 
Causal Network Analysis identifies a potential Master Regulator sorted by highest p-value 
overall and of overlap: BAMBI (BMP and activin membrane-bound inhibitor homolog, p-
value 1.16E-18), based on trending expression patterns. B) Amplification plot of qRTPCR 
experiments in Figure 6b-d. C) Relative standard deviation (RSD) of GAPDH across all 
patient samples, sorted by age of patient. Average RSD is 0.75% ± 0.48%. D) Patient-by-
patient expression (shown via LOG2(2-ΔCt), as normalized to GAPDH expression, 
organized by patient disease category. E) Patient-by-patient expression (shown via 




as both developmentally regulated[214] and a negative regulator of TGFβ1[215, 216]. 
Further studies have found that BAMBI may be biomechanically sensitive, and functions 
to protect murine heart from pressure overload through restraint of TGFβ signaling[217]. 
In this study, BAMBI was identified as having a high p-value of overlap, which unlike z-
score-sorted regulators, is identified independently of the dataset’s regulation weight or 
direction[218]. This preliminary identification of BAMBI was confirmed to have both direct 
and indirect interaction with proteins implicated in valve disease and development, such 
as ACVR1, DVL2, and SMARCA4 (Fig. 16a). Confirmational transcription-level analysis 
was performed on a cohort of fresh-frozen pediatric and adult aortic valve samples (Table 
7, Fig. 16b&c, Figure 17). Adult CAVS samples (aCAVS) used in this study showed no 
calcification by clinical annotation, with the except of SKU SB176. BAMBI expression was 
found to be significantly differentially regulated between patient categories of normal 
pediatric, pCAVS, and aCAVS (ANOVA p-value 0.013), with significant reduction in 
pCAVS (p-value 0.045) and trending reduction in aCAVS (p-value 0.053) compared to 
normal pediatric patients (Fig. 16b). Amongst CAVS patients, there is a suggestive 
trending decrease of BAMBI expression as a function of pediatric age categories (ANOVA 
p-value 0.096) (Fig. 16c). 
IHC staining of BAMBI was performed to visualize translational expression relative 
to ECM staining in age-matched samples (young child age 2-5; adolescent age 12-18) 
(Fig. 6d&e). BAMBI was not abundantly detected in young normal valves (SKU NDRI, 
age 2) nor, in contrast, older adolescent pCAVS valves (SKU DB16, age 17) (Fig. 16d&e). 
In the normal valve sample, BAMBI was observed in ventricularis endothelium and in 




Table 7: Descriptive statistics of patient characteristics for aortic valve samples used 
for rt-qPCR studies (Fig. 15). Normal aortic valves are from cardiac transplant patients 
where normal valve function is defined via 2D echocardiogram. 2D Echocardiogram mean 
gradients define pre-operative valve function where a normal gradient is defined as <5 
mmHg, mild stenosisas 5-25 mmHg, moderate stenosis as 25-50 mmHg, and severe 
stenosis as >50 mmHg. BSA: body surface area; C: Caucasian. DB43 was included in 
pCAVS due to stenosis, but main diagnosis was Hypertrophic Cardiomyopathy 
87 
 
the same tissue section (Fig. 16e, right). BAMBI was also detected in spatially localized 
regions of mixed collagen-GAG, seen in Movat’s Pentachrome staining (Fig. 16e). In 
pCAVS, only certain cells were BAMBI-positive and tended to be within the fibrosa-
spongiosa mixed interstitium of GAG associated regions low in primary collagen (Fig. 16e, 
left, center). These data suggest that future studies on BAMBI may show its contribution 
to regional collagen deposition within the valve structure.  
4.4 Discussion  
Collagen forms the fundamental framework of the aortic valve starting from 
embryonic developmental stages onward; disease-driven changes deform the framework 
and ultimately lead to heart dysfunction[26, 180, 219-221]. In pCAVS, rapid and excessive 
production of ECM components increases leaflet thickness by up to 8-fold, leading to 
pediatric heart failure[183, 184, 222, 223]. Genomic studies, primarily characterized from 
adult end-stage phenotypes, show complex genetics with dissimilar patterns of 
inheritance, genetically heterogenous phenotypes, and multiple chromosomal regions that 
impact the ECM network directly or indirectly[222, 224-226]. Gender may also play a role 
– while bicuspid aortic valve is three times as likely to be found in males, females have 
more collagen deposition and less calcification[227, 228]. Surgical replacement of valves 
is an option in adults, but in children, valve replacements do not grow with the patient, 
leading to heart dysfunction and failure[229, 230]. Directly or indirectly targeting collagen 
production in pediatric end-stage CAVS may be a viable therapy inhibiting the disease, 
but very little is known about translational and post-translational regulation collagen and 
ECM components that form the working structure of the maturing aortic valve. The goal of 
this study was to identify the dynamic collagen regulation that occurs in pCAVS, including 
collagen sub-type regulation, collagen fiber alignment, and regulation of hydroxylated 
proline residues associated with triple helical stability. 
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The ECM trilayer structure was lost in pCAVS and the rate of collagen deposition 
trended to increasing by up to 56% per year compared to normal AV development (Figure 
1). This coincides with previous reports that pCAVS involves overproduction of collagen 
to result in thickened valves [26, 183, 184]. Supporting this, immature collagen fibers were 
detected by staining in all ages of pCAVS localized to regions of mixed collagen and 
elastin, particularly valves that showed hypertrophic commissures. Significantly, the 
pCAVS valves showed that collagen fiber alignment with the endothelium is lost and 
resulted in a random fiber angle relative to endothelium that localized with stains for 
immature collagen fibers. An additional finding was that unique, pathologically confined 
regions of increased collagen density were observed in all pCAVS structures (Figure 3). 
This contrasted with measurements on normal valves in the study that showed where 
collagen fibers were parallel to the endothelium with the fibrosa staining for mature 
collagen fibers. Similar findings in normal human aortic growth have been reported, with 
emergence of collagen fiber alignment parallel to endothelium within maturing 
fibrosa[181]. Previous work in normal human aortic and pulmonary valve has shown that 
fibrosa collagen is circumferentially oriented and that uniformly distributed, densely 
packed collagen fibers emerge with age [179]. Age-related increases in collagen density 
in pCAVS were attributed to an imbalance of normal collagen synthesis and remodeling 
required to maintain appropriate collagen stretch dependent on local hemodynamics 
[179]. We also observed that for valves with aortic valve insufficiency,  higher but more 
variable levels of thick collagen fiber production were observed compared to either normal 
or pCAVS valves, supporting that valvular function is a balance of collagen production and 
collagen degradation[26, 177, 178] with dependence on hemodynamics. Additional but 
unknown effects on collagen production and alignment may result from the cell type and 
density composition within the tissue microenvironment, in addition to the differential 
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effects of hemodynamics throughout the pCAVS structure. Alterations in collagen fiber 
alignment are an important component of the pCAVS end-stage and are a useful target in 
mechanistic studies on the disease. 
Collagen PTMs are numerous and include non-enzymatic glycation, lysine and 
proline crosslinking, N- and O-linked glycosylation, and tyrosine sulfation[69, 231, 232]. 
Here, we focused on hydroxylation of proline (HYP) to understand collagen regulation in 
pCAVS. HYP is a primary collagen PTM that regulates triple helical stability and 
consequently has a large influence on collagen organization in tissue[69]. Regulation of 
HYP sites within the collagen structure alters fiber conformation and integrity and works 
to promote or protect the collagen structure from degradation[69, 232-234]. HYP is 
regulated by co-factors of iron, oxygen, and ascorbic acid, with dependency on nutritional 
status and oxidative stress [24, 69, 234-236]. Cell-specific and disease-specific regulation 
of prolyl hydroxylases P4HA1, P4HA2, P4HA3 drive HYP modification on collagen[236, 
237]. Cell recognition of very specific sites of hydroxylated prolines along the collagen 
fiber results in signaling changes through integrins and the tyrosine kinase receptors 
discoidin domain receptors (DDRs)[238-241]. These cell-fiber interactions influence 
epithelial mesenchymal transition, cell proliferation survival and metastatic expansion[240, 
242-245]. The current study identified up to 15% reduction of HYP content in pCAVS, 
dependent on collagen subtype. However, HYP changes appeared to be site specific. It 
is possible that changes in HYP sites may contribute to the rapid collagen degradation 
and remodeling of pCAVS[69]. Further, the sites of HYP loss in the pCAVS group aligned 
with regions of glycoprotein VI and integrin binding, which require the presence of HYP 
within the sequence. Integrins play a crucial role in cell-ECM interactions, with recent data 
suggesting a key role in dynamic connective tissue remodeling events during wound 
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healing [246]. Glycoprotein VI is a platelet specific glycoprotein that has been shown to 
have affinity for collagen in the dimeric form [247]. It has been reported that adult patients 
with AVS have decreased platelet function and aggregation, however the role of HYP 
content has not been explored as a potential mechanism[248]. This study identifies that 
HYP regulation on primary fibrillar collagens may contribute to intrinsic and extrinsic 
mechanisms of pCAVS and merits focused studies. 
Histological studies identified localized regions of dense collagen formation in 
common with pCAVS. Protein level studies gave insight into the collagen composition of 
the pCAVS deregulated structures. Collagen α2(V) was found to have significant 
increases pCAVS compared to non-stenotic AVI valves. Importantly, collagen α2(V) has 
been reported within heterotypic collagen type I fibrils and plays an essential role in 
regulating fibrillogenesis and the size of collagen fibrils [249]. The histopathological finding 
of high-density collagen fiber regions in pCAVS may be reflective of the increased 
fibrillogenesis. However, to implicate collagen α2(V) directly spatially oriented proteomics 
would be required to understand localization and regulation of the highly density collagen 
sites compared to collagen type composition. With localized molecular biomarker 
identification, these regions of dense collagen fibers provide a potential mechanism of 
early-stage AV fibrosis molecular marker detection in vivo [250]. Amongst non-collagen 
type proteins, the enrichment of proteins associated with collagen binding, collagen fibril 
organization, and basement membrane was consistent with our histopathological findings 
of collagen fiber misalignment and HYP regulation in binding sites. Interestingly, collagen 
chaperone SPARC was found to be enriched in pCAVS compared to normal AV and AVI 
patients, independent of age (Fig. 5a). While never explored in healthy or disease AV, the 
overexpression of SPARC has been reported with under-expression of COL4A1 and other 
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network collagens in myocardium. Increases in SPARC has been linked to endothelial 
dysfunction, possibly via its binding to VCAM-1 and altered integrin interactions 
downstream[251]. Its abundance in pCAVS may suggest endothelial dysfunction. 
Research of healthy and diseased endothelial cell signaling in AV is ongoing, however 
direct correlation between VEC or VIC cell activation and corresponding collagen 
regulation remains to be explored [31, 252, 253]. 
The study identified BAMBI as a novel candidate that may be involved in valvular 
biology. BAMBI is a negative regulator of TGFβ1 signaling[215, 216] and positively 
modulates Wnt/β-Catenin pathways by increasing interactions with frizzled 5 and 
disheveled segment polarity protein 2 (DVL2)[214]. While never studied directly in AV 
disease or development, recent studies suggest that BAMBI is regulated in the 
myocardium to restrain hypertrophy and fibrosis[217]. In the current study, network 
analysis highlighted BAMBI as a predicted node amongst proteins known to be involved 
in valvular development and disease. Interestingly, the initial protein-level staining studies 
demonstrated that the human aortic valve has cell-specific and localized expression of 
BAMBI, particularly within the glycosaminoglycan-rich spongiosa. Furthermore, by 
transcriptional analysis of total valvular content, BAMBI expression appeared to decrease 
in both pediatric and adult calcific CAVS. It is conceivable that decreases in BAMBI may 
play a role in the excess ECM that is a hallmark of pCAVS. However, the role of BAMBI 














Chapter 4: Improving Enzymatic Access of Collagen 
Proteome via MALDI-IMS 
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 This chapter outlines a method developed to improve upon a targeted enzymatic 
method previously developed in the Angel Lab [141]. The Angel Lab developed enzymatic-
based techniques to target the ECM with collagenase type III (COLase3) [203]. These 
methods were found to be appropriate for FFPE tissues and did not require 
decellularization. COLase3 methods have been used successfully in our lab in the past 
on breast, lung, and prostate[157, 189, 254]. However, COLase3 application alone had 
insufficient enzymatic access of valvular tissues to investigate the structure-function 
relationship of the extracellular matrisome in pCAVS sufficiently (Appendix A). To improve 
on MALDI-IMS data quality, a multi-modal MALDI-IMS method was used to remove 
extracellular matrix components potential bound to collagen subtypes (GAGs, elastin) and 
bulky post-translational modification (N-glycans), allow for better enzymatic access of 
COLase3. The bulk of this chapter was included as part of a publications in Analytical and 
Bioanalytical Chemistry (April 2021) and Multiplexed Imaging Mass Spectrometry 
(Springer, in press). Experiments were performed by myself in addition to manuscript 
writing, data analysis, and final approval. Minor editorial and intellectual contributions were 
provided by co-authors[145, 155]. 
4.1 Introduction 
Fibrosis is a process characterized by excessive and disorganized extracellular 
matrix (ECM) involved in many organ diseases but especially heart, kidney, liver, and lung 
diseases. Fibrotic accumulation of ECM diminishes normal tissue function leading to 
obstruction of organ function[126, 255, 256]. This promotes disease progression and 
eventually leads to organ failure. A main challenge in fibrosis research is accessing the 
ECM to understand how ECM proteins yield feedback information promoting disease 
progression.   
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We describe a multiplexed imaging strategy exceptionally useful for fibrosis research that 
reports N-glycan and ECM information from tissue sections after histological staining. After 
histology staining, the tissue is analyzed sequentially for N-glycans and ECM peptides. N-
glycans and ECM peptides are detected as 2D maps across the tissue using matrix-
assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS).  
MALDI IMS is a robust technique that uses mass spectrometry to map molecules 
such as lipids, peptides, proteins and N-glycans from histological tissue samples[257-
260].  MALDI IMS pinpoints molecular expression to groups of cells or regions of pathology 
in a tissue section. Thus, for fibrosis research comparisons may be made from differences 
in pathological regions, e.g., changes in stroma output and organization related to specific 
fibroblast populations compared to normal adjacent cells. MALDI-IMS has been used by 
our group and others to spatially probe thin formalin-fixed, paraffin-embedded (FFPE) 
samples for their N-glycan content by treating the tissue with the enzyme endopeptidase 
F (PNGase F)[161, 254, 260, 261]. Both the N-glycome and tryptic peptides can be 
accessed within the same tissue section[262]. Recently, we developed proteomic 
workflows using collagenase type III to specifically target and report on ECM proteins from 
FFPE tissues. ECM protein targeting by collagenase type III reproducibly reports on 
average 60-75 ECM proteins, including collagen types[141, 263]. Sequence analysis of 
identified ECM proteins revealed that each protein had on average 3.7 sites for N-
glycosylation as depicted by the consensus sequence N-X-S/T≠P. A challenge with 
transferring a sequential approach to serial analysis of N-glycans and ECM from the same 
tissue section is that collagenase type III treatment can disrupt tissue histology. Here we 
describe a strategy that starts by capturing the tissue histology using a standard histology 
stain, hematoxylin and eosin (H&E). Hematoxylin dyes nuclear content dark purple; eosin 
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stains cytoplasm and stroma pink. After digital high-resolution capture of the stain, the 
same tissue section is processed for N-glycan and ECM peptide imaging mass 
spectrometry through sequential application of PNGase F and collagenase type III. 
Specific washing steps are required to remove matrix, enzymes, and the N-glycans 
between enzyme treatments. This multiplexed imaging approach is particularly useful for 
deep mining of ECM information from fibrotic tissue, as one 5 μm thick tissue section 
allows for pathological evaluation of ECM organization by staining as well as N-glycan 
signaling and ECM peptide data. 
The extracellular matrix (ECM) consists of the non-cellular components of tissues 
and provides essential biochemical and biomechanical signaling[264]. The ECM is a 
complex environment of fibrous type proteins – such as collagen, elastin, and fibronectin 
– as well as proteoglycans, which consist of sulfated glycosaminoglycan (GAGs) chains 
covalently bound to a core protein. The GAGs present in the ECM can be sulfated 
(chondroitin sulfate, heparan sulfate, and keratan sulfate) or non-sulfated (hyaluronic acid) 
[265]. The most abundant fibrous proteins are collagen type proteins[264]. Collagens are 
both intra- and inter-molecularly crosslinked with elastin and other proteoglycans at mainly 
lysine residues. These proteins are also abundantly post-translationally modified, with 
hydroxyproline, hydroxylysine, and N- and O-linked glycans[68, 69]. PTMs at lysine 
residues as well as abundant intra- and intermolecular crosslinking of ECM components 
make this environment a unique analytical challenge for mass spectrometry-based 
approaches. To date, no single enzymatic targeting technique can elucidate all 
constituents of the extracellular matrix. 
Enzymatically targeted techniques have been developed recently for multi-omics 
studies and can analyze tissue glycomics, glycoproteomics, and/or proteomics from a 
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single sample[266-268]. These techniques are largely serial LC-MS/MS strategies applied 
to fresh frozen tissue samples. While serial LC-MS/MS techniques allow for a large 
amount of identifications, the link between -omics data and tissue morphological structure 
is lost. Imaging Mass Spectrometry (IMS) methods, however, can be used to visualize the 
spatial distribution of analytes within tissue sections. One such IMS technique is Matrix-
Assisted Laser Desorption/Ionization (MALDI) Imaging Mass Spectrometry (IMS). MALDI-
IMS is a robust proteomic technique that can spatially map tryptic peptides from 
histological tissue sections[263]. This is done by spraying the tissue with a thin, uniform 
layer of trypsin that, when analyzed in parallel to high resolution accurate mass 
proteomics, allows for the relative quantitation and localization of tryptic peptide 
sequences to specific regions of the tissue. Although trypsin-based ECM-IMS techniques 
have been developed, these approaches decellularize fresh, unfixed tissue which is not 
an option for clinically archived formalin-fixed paraffin embedded (FFPE) tissue[269]. 
Novel MALDI-IMS techniques have been developed to enzymatically target ECM proteins 
via collagenase type III (COLase3) and elastase[141, 143], allowing peptide tissue 
mapping of ECM proteins that are largely trypsin-resistant.  
In this study, we used MALDI-IMS techniques to visualize and relatively quantify 
in situ chondroitin sulfate (CS) GAGs, N-glycans and ECM peptides and proteoglycans 
from a single tissue section after serial treatment with enzymes.  PNGaseF has been used 
to release N-glycans from thin FFPE tissue sections followed by MALDI-IMS[260]. 
Recently, PNGaseF and trypsin have been used in tandem, colocalizing the N-glycome to 
the tryptic proteome[262, 270]. Additionally, our lab has combined histological staining 
with MALDI-IMS to map complex ECM proteins in thin FFPE tissue sections[141, 143, 
155]. While other studies have used IMS techniques to analyze GAG fragments[271], we 
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outline here the first enzymatically targeted study of chondroitin sulfate GAGs via MALDI-
IMS techniques. By combining these enzymatic approaches, comprehensive mining of 
protein translational and post-translational information becomes possible. This is 
especially useful for understanding the complex ECM profile as GAG, N-glycan, collagen, 
and ECM peptide data can be analyzed from one FFPE tissue section.  
 
4.2 Materials & Methods 
4.2.1 Materials and Chemicals 
All solutions were prepared using double distilled or HPLC grade water, following all 
necessary safety and waste disposal regulations. Xylenes, 200 proof ethanol was 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Acetonitrile, Ammonium 
Bicarbonate, Calcium Chloride, Formic Acid, EDTA, Trizma Base, and Chondroitinase 
ABC were purchased from Sigma-Aldrich (St. Louis, MO, USA). PNGase F PRIME was 
purchased from N-Zyme scientific (Charleston, SC, USA). Collagenase type III (COLase3) 
(C. histolyticum) was purchased from Worthington Biochemical (Lakewood, NJ, USA). 
Porcine MMP12 (elastase) was purchased from Alfa Aesar (Fisher Scientific, Pittsburgh, 
PA). 
4.2.2 Specimens 
Aortic valve tissue biopsy was procured through the Vanderbilt Core Laboratory for 
Cardiovascular Translational and Clinical Research and the National Disease Research 
Interchange. Tissue procurement for banking was approved by the Vanderbilt Institutional 
Review Board (IRB) and for project use by the Medical University of South Carolina IRB. 
Tissues were fixed overnight in 10% neutral buffered formalin (American Mastertech), cut 
through the central portion of the cusp, and embedded in paraffin blocks.  
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4.2.3 Tissue Preparation & Histology 
Formalin-fixed, paraffin-embedded tissue was cut to 5 μm thick sections via 
microtome and mounted onto microscope slides (Tissue Tack, Polysciences, Inc., 
Warrington, PA, USA) then dehydrated overnight at 37°C prior to storage at room 
temperature. Tissues were stained with Verhoeff Van Gieson (Verhoeff solution for elastin; 
Van Gieson counterstain for collagen), Movat’s Pentachrome (Alcian Blue for GAG, 
Saffron for collagen, Resorcin-Fuchsin for elastin, and Woodstain Scarlet-Acid Fuchsin for 
muscle), or Alcian Blue alone (Polysciences, Inc.), following manufacturer’s protocols. All 
staining protocols included a hematoxylin counterstain. 
For N-glycan and ECM peptide MALDI-IMS studies, FFPE tissues were prepared 
as previously described[141, 260]. Chondroitinase imaging preparation is novel to this 
study. Briefly, a 1 mg/mL Chondroitinase ABC (Sigma Aldrich, St. Louis, MO, USA) 
solution was prepared in 60mM Ammonium Acetate (pH 8 with sodium hydroxide). 
Solution was sprayed with a TM Sprayer M3 (HTX Imaging, Chapel Hill, NC, USA) under 
the following parameters: 15 passes, crisscross pattern, 3.0 mm track spacing, velocity of 
1200 mm/min, and a dry time of zero. Before enzymatic digest, four antigen retrieval 
conditions (20 minutes, 95°C) were studied: 1) EDTA pH 8; 2) Citraconic Buffer pH 3; 3) 
Tris pH 9; and 4) Double antigen retrieval of Citraconic, wash and desiccate, then Tris.  
FFPE aortic valve tissue sections were digested with COLase3 after serial 
treatment with chondroitinase, PNGaseF (N-Zyme Scientifics), elastase, and for MALDI-
IMS experiments. Trypsin (Porcine Pancrease, Sigma Aldrich, St. Louis, MO, USA) was 
applied during preliminary studies to determine the effects of a single enzyme before 
COLase3. Spray conditions for all enzymes were as previously published [141, 260]. 
Samples were digested in high humidity at 37.5°C for either 2 hours (chondroitinase, 
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PNGaseF) or 5 hours (elastase, COLase3). A 7 mg/mL solution of alpha-cyano-4-
hydroxycinnamic acid (CHCA) matrix solution was prepared in 50% acetonitrile and 0.1% 
trifluoroacetic acid (TFA; for chondroitinase, PNGaseF imaging) or 1.0% TFA (for 
elastase, COLase3 imaging). CHCA matrix solution prepared for peptide imaging was 
spiked with a standard of 200 femtomole/L [Glu1]-fibrinopeptide B human (GluFib) (Sigma-
Aldrich, St Louis, MO, USA). CHCA automatic spray conditions included: 79°C, 10 psi, 70 
μl/min, 1300 velocity, and 14 passes with a 2.5 mm offset. Slides for peptide imaging were 
rapidly dipped (<1 second) in cold 5mM ammonium phosphate and immediately dried in 
a desiccator. 
4.2.4 Chondroitin Sulfate Standard Preparation 
A dilution series of digested CS standards were spotted onto a MALDI plate for CS 
peak validation. Standard used was chondroitin sulfate sodium salt from shark cartilage 
(Sigma Aldrich, St. Louis, MO, USA). Dilution shown was 5 µM of CS. Samples were 
brought up in 60 mM ammonium Acetate pH 8 and digested with 4 μg of Chondroitinase 
ABC. Samples were incubated overnight, shaking at 38°C. Samples were spotted with 0.5 
μl of digest solution onto a MALDI plate and sprayed with CHCA as previously described.  
4.2.5 Imaging Mass Spectrometry 
Tissues were analyzed by MALDI-FT-ICR (7.0 Tesla solariX™ Legacy FT-ICR 
(Bruker Scientific, LLC, Bremen, Germany) operated in positive ion broadband mode over 
m/z range 500-4000. Laser settings used were 300 shots/pixel with a 45 µm stepsize.  The 
average laser shot was measured to be approximately 25 µm x 30 µm. A lock mass of 
1570.6768 (GluFib peptide) was used for peptide IMS studies. Images were visualized in 
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FlexImaging v5.0 and analyzed using SCiLS 2017a version 5.00.9510 (Bruker Scientific, 
LLC, Bremen, Germany). All images shown are normalized to total ion current.  
Chondroitin Sulfate fragmentation and ion mobility data was acquired using a 
Trapped Ion-Mobility Time-of-Flight Mass Spectrometer (timsTOF fleX) (Bruker Scientific, 
LLC, Bremen, Germany) equipped with a dual ESI/MALDI source. The samples were 
analyzed in positive ion Q-TOF mode and scanned at a mass range from 500 – 4000 m/z. 
The SmartBeam 3D 10 kHz laser was set to 33% power, scan range of 20 µm for X and 
Y and resulting field size of 24 µm for X and Y. The measured average spot size was 
18.66 µm for X and 19.94 µm for Y. Additional instrument parameters for CS studies 
include: an ion transfer time of 125 s, pre pulse storage time of 25 s, a collision RF of 
4000 Vpp, a collision energy of 15 eV, an ion energy in the quadrupole of 5 eV, a TIMS 
funnel 1 RF of 500 Vpp, a TIMS funnel 2 RF of 500 Vpp and a multipole RF of 500 Vpp. 
After MS acquisition, the data was imported into SCiLS Lab 2020a (Bruker Scientific, LLC, 
Bremen, Germany) and normalized to total ion current. CS peaks were identified by 
accurate mass using a database created in GlycoWorkBench [272].  
Spectra shown were analyzed using mMass version 5.5.0. Putative peptide 
identifications are based on our previously acquired databases from many tissue samples 
on human aortic and same valvular tissues [10-11]. This analysis does not include peaks 
with biologically relevant spatial distribution that have not yet been sequenced. Percent 
fold change was calculated as: 
ln(𝑠𝑒𝑟𝑖𝑎𝑙 𝑒𝑛𝑧𝑦𝑚𝑒 𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)
ln(𝑠𝑖𝑛𝑔𝑙𝑒 𝑒𝑛𝑧𝑦𝑚𝑒 𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)
∗ 100. Here, serial enzyme 
peak intensity is the intensity measured from tissue samples that had undergone serial-





4.1 The Aortic Valve as a Prototype Model Tissue for ECM Analysis 
Human stenotic bicuspid aortic valves were used to develop this method since the 
hallmark of aortic valve stenosis is overproduction of ECM. Histopathological evaluation 
was done as an initial assessment of the tissue. Movat’s Pentachrome (MP) (Fig. 18a, 
1a’), Verhoeff van Geison (VVG) (Fig. 18b, 18b’) and Alcian Blue stain (Fig 18c) show 
elastin, collagen, and GAGs are present throughout the length of the valve leaflet. A dense 
band of collagen can be seen clearly in the medial of the leaflet via the MP stain (Fig. 18a, 
outlined). In the same region, reduced GAG deposition can be seen via Alcian Blue 
staining (Fig. 18c, outlined). Elastin fibers can be seen at higher magnification to be 
present throughout the leaflet, both via MP and VVG staining (Fig. 18a-b). These 
morphological features were used to show GAGs, collagen, and elastin are abundant 
throughout the length of the leaflet and to further validate localization of MALDI-IMS data 
in later figures. 
Potential regulation of collagen PTMs was quantified via in silico analysis (Fig. 18 
d-e). Uniprot Amino Acid Modification database analysis of confirmed sites, similar sites, 
and consensus sequences shows that all collagen-type proteins identified via our 
COLase3 MALDI-IMS and LC-MS/MS method contain at least one N-linked glycosylation 
site (N-X-S/T site, where X is any amino acid besides proline), with as many as 15 sites 
per collagen-type protein. Previous analysis of acquired COLase3 using LC-MS/MS 
methods indicated that 4.8% of all ECM peptides identified in our database are potential 
glycopeptides (146 out of 3024 peptides have an N-X-S/T site) [141, 143]. Additionally, 
PTMs, such as hydroxyproline and hydroxylysine are abundant in collagen type proteins, 





Figure 18: Method development tissue (pediatric bicuspid aortic valve) displays 
aberrant ECM production and post-translational modifications ideal for ECM 
studies. a. Movat’s Pentachrome staining with GAGs in blue, elastin in purple, and 
collagen in yellow. 20x magnification of the square in a is seen in a’. b. Verhoeff van 
Gieson staining with collagen in red/pink and elastin in purple/black. 20x magnification of 
the square in b is seen in b’. c. Alcian blue staining shown GAGs present throughout the 
valve. d. In silico PTM site count analysis of N- and O-linked glycans (d) and 
hydroxyproline, hydroxylysine, and disulfide modifications (e). Uniprot reported sites for 
each protein were obtained from the Uniprot compiled Amino Acid Modification database. 
Both published confirmed sites and sites identified by similarity and consensus sequences 




Figure 19: MALDI-IMS multi-enzyme workflow. A single FFPE tissue section is taken 
through four serial enzyme treatments to target CS GAGs, N-glycans, elastin, and 
collagen and other ECM peptides. Images are acquired via a MALDI-FT-ICR instrument 
between each enzyme treatment. 
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lysine residues prevent conventional tryptic digests from accessing ECM proteins [82, 
273], indicating a targeted enzymatic strategy would be adventageous, including enzymes 
targeting N-glycosylation and proteomics databases searched for hydroxylysine and 
hydroxyproline. 
Aortic valve tissues are comprised of both activated and inactivated valvular 
interstitial fibroblasts – the average size being approximately 5x30μm and 7x10μm, 
respectively. Additionally, these aortic valve tissues studied are relatively low cell density. 
A serial section of the valve sample shown in Figure 18 was measured to have an average 
cell density of 370 cells/mm2 (Appendix F-G). These data suggest that imaging mass 
spectrometry-based methodologies are conducted at an appropriate resolution for ECM-
based studies in these tissues. 
4.2 Imaging Mass Spectrometry Workflow 
An overview of the optimized MALDI-IMS workflow can be seen in Figure 19. 
Optimization of PNGaseF, elastase, and COLase3 have been completed in previous 
studies[141, 155, 260]. Optimization of Chondroitinase ABC for MALDI-IMS included 
investigating antigen  retrieval conditions, concentrations, incubation times, and optimal 
matrix application. Antigen retrieval steps (Citraconic Buffer pH3 and Tris pH9) were 
completed serially before the serial enzyme treatment. Specific washing steps to remove 
analytes were completed to prevent cross-contamination between imaging acquisitions 
[262]. Within this study, no significant reduction in spatial resolution was seen, as 




4.3 Method Optimization for Chondroitin Sulfate Imaging MS 
This method targets chondroitin sulfates (CS) via application of chondroitinase 
ABC. CS is an abundant glycosaminoglycan (GAG) of repeating glucuronic acid (GlcUA) 
and N-acetylgalactosamine (GalNAc) di-saccharides in the extracellular space, and are 
known to be upregulated in cardiac, pulmonary, and liver fibrosis [274-276]. Previous work 
has shown via LC-MS/MS analysis that tissue treated with chondroitinase ABC can be 
used to detect CS chains of 1-3 repeats in multiple sulfation states [268, 277, 278]. Similar 
results were seen in our studies. A single sulfated CS chain as well as two examples of 
multiply-sulfated dimers can be seen in Figure 20a-b. Previous LC-MS/MS-based studies 
have shown that other enzymes targeted to GAGs, such as hyaluronidase and heparan 
lysase, can be used in tandem to chondroitinase ABC to serially access the proteoglycome 
[266]. Ongoing studies aim to incorporate these enzymes into MALDI-IMS multi-enzyme 
workflows. 
An antigen retrieval study was done to optimize the chrondroitinase IMS method 
(Fig. 20a). Antigen retrieval of FFPE tissues reverses protein chemical modification 
induced via formalin [279]. It is known that the pH of the antigen retrieval solution alters 





Figure 20: Chondroitinase ABC MALDI-IMS method is capable of imaging several 
chain lengths and sulfation states of CSs. a.  Antigen retrieval study on serial aortic 
valve tissue sections to determine optimal conditions for MALDI-IMS acquisition. Three 
representative CSs are shown. b. Corresponding peaks to images shown in a, with all four 
antigen retrieval conditions overlayed: EDTA (black); Citraconic (red); Tris (green); 
Citraconic then Tris (blue). 
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playing role [280]. The pH category shown represents pH of different antigen retrieval 
conditions, suggesting differential specificity to CS under different antigen retrieval 
conditions (Fig 20a). Chondroitinase ABC preferentially cleaves CSs, however other GAG 
structural classes are cleaved when the digestion buffer is prepared at different pHs [281]. 
The final antigen retrieval method for the multi-enzyme study was condition #4 (Methods 
2.3, Citraconic then Tris). While other conditions were more optimal for CS imaging,  
antigen retrieval for N-glycan and COLase3 imaging have been already optimized with 
Citraconic, pH 3 and Tris pH 9 buffers, respectively [141, 260]. 
The theoretical mass values for some chondroitinase products had a similar mass 
defect and m/z value as matrix peaks. For example, a single GalNAc-GlcUA chain has a 
theoretical m/z of 379.0794, while CHCA [2M+H]+ has a theoretical m/z of 379.0925 [282]. 
To confirm the peaks chosen did in fact correspond to CSs and not matrix, on-tissue 
fragmentation was performed using MALDI and trapped ion mobility combinations on a 
timsTOF fleX mass spectrometer. Peak m/z 1340.129 was fragmented via CID to obtain 
the MS/MS spectra seen in Figure 21. Serially increasing collision voltages shows a loss 
of sulfate state, chain length, and chain formation with fragmented ions corresponding to 
GalNAc and GlcUA also seen. To further validate this, ion mobility analysis was also 
performed on- and off-tissue. Figure 22 shows that the on-tissue ion mobility data displays 
two unique populations – one corresponding to matrix-only signal taken off tissue, and 
one corresponding to tissue treated with chondroitinase ABC. These experiments were 
also done on spotted CS standards for further validation (Fig. 22). Trapped ion mobility 
analysis can be used in further studies to not only to distinguish between isobaric matrix 
and GAG peaks, but also between isobaric GAG species of differential sulfation states 




Figure 21: Fragmentation of precursor m/z 1339.9 shows evidence of isobaric CS 
peak with matrix. Summed spectra of CID fragmentation across 5400 shots and 
increasing collision voltages between 20-130eV. Summed spectra shows loss of sulfation 
state, chain length, and chain formation with fragmented ions corresponding to GalNAc 




Figure 22: Ion mobility analysis of CS standards and tissue shows unique drift 
populations of matrix and CS species at isobaric peaks. a. Heat map of spotted CS 
standards. b. Heat map of shots taken on-tissue treated with chondroitinase ABC. c.  Heat 
map of shots of matrix only, taken on the same chondroitinase ABC treated slide but off-
tissue. d. Mobilograms for the CS and Matrix drifts shown in (e) for the isobaric peak 




Figure 23: N-glycan signal by PNGaseF was improved by removal of CS GAGs via 
Chondroitinase ABC. a. Three representative N-glycan images with corresponding 
structures. b. Annotated spectra with PNGaseF treated tissue alone (top, black) and 
PNGaseF treated post-CS GAG removal (bottom, red). c. Quantification of the percent 
change in peak signal intensity for all glycans identified. Each point represents an N-
glycan peak with a boxplot of the data shown to the right. 
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4.4 N-glycosylation imaging may be improved by chondroitin sulfate removal 
N-glycosylation patterns were then obtained from the same tissue section, with N-
glycan signal improved by removal of GAGs (Fig. 23a-b). A total of 25 N-glycans were 
identified by MALDI-IMS after CS-removal, while only 10 N-glycans were identified using 
PNGase F alone. Quantification of N-glycan peak intensity shows that N-glycan signal 
was improved by removal of CSs, with a maximum of 9.2% and a mean of 3.7 ± 2.8% 
increase in peak intensity after CS removal, averaged across 32 identified N-glycan peaks 
(Fig. 23c). While many classes of N-glycans were identified (high-mannose, fucosylated, 
sialylated, bisecting), no single class was uniquely affected by removal of CSs. Removal 
of CSs may impact enzyme access of PNGaseF to N-glycosylation sites of small-leucine 
rich proteoglycans (SLRPs). Many SLRPs are found in healthy and stenotic heart valves, 
such as biglycan, decorin, and versican [285]. Studies with decorin show that both CS-
linker and N-glycan sites are present within the primary sequence [281], which could 
potentially affect enzymatic access for analytical purposes.   
4.8 PNGaseF imaging is compatible with Hematoxylin & Eosin pre-treatment 
Another goal of this study was to combine histopathological evaluation with the 
enzymatic methods used to access to the extracellular matrix via MALDI-IMS. A challenge 
with these studies is that tissue histology can be disrupted with enzymes targeting the 
extracellular matrix, such as the elastin and collagenase used in future studies below. Our 
goal was to stain the tissue section with Hematoxylin and Eosin (H&E), take a high-
resolution digital capture, and then use the same tissue section in MALDI-IMS studies 
(Figure 24). Initial studies performed determined the effect of H&E staining on PNGaseF 
treatment. Based on the relative intensity of glycans identified via MALDI-IMS, there was 




Figure 24 Workflow of histology compatible MALDI-IMS method. a. A single FFPE tissue 
section is taken through hematoxylin & eosin staining and then PNGaseF treatment to 
target N-glycans. Images are acquired via a MALDI-FT-ICR instrument after PNGaseF 
enzyme treatment. b. High resolution digital capture of Hematoxylin and Eosin stain of the 
tissue before proceeding with N-glycan and collagen peptide imaging (Figure 23,25). 




Figure 25: Comparison of N-glycan imaging data due to PNGase F application either 
alone or applied after H&E staining. (a) Overall average mass spectrum of PNGase F 
treated tissue (top, black) and PNGase F treated tissue after undergoing H&E staining 
(bottom, red). N-glycan structures corresponding to m/z are shown. (b) Examples of N-
glycan images created as heat maps of the corresponding m/z peak intensity. N-glycan 
structure and m/z are shown left of each image, created using GlycoWorkbench 2.0 [272]. 
Peak 1570.6768 m/z corresponds to the Glu1-Fibrinopeptide B (Glu-Fib) internal standard 






Figure 26:  Detection of elastin peptides by Elastase is improved by PNGaseF and 
Chondroitinase ABC pretreatment. a. Representative images and corresponding m/z 
values of three elastin peptides. b Annotated spectra with elastase alone (top, black) and 
elastase post-CS and N-glycan removal (bottom, green), with corresponding annotations 
in c. Identified peptide counts are out of 48 peptides IDs via acquired LC-MS/MS 
databases. d. Quantification of the percent change in peak signal intensity for all elastin 
peptides identified. Each point represents an elastin peptide peak with a boxplot of the 




compared to PNGaseF alone (Figure 25a). Similarly, representative images show 
comparable spatial distribution of glycans, independent of H&E treatment (Figure 25b). 
4.5 Elastin imaging by elastase is improved after N-glycan and CS removal 
After removal of sugar moieties, we evaluated whether the deglycosylation steps 
improved detection of ECM peptides following elastase or COLase3 digestions (Figure 
26). Preliminary studies determined that the order with which the peptide-cleaving 
enzymes (elastase, COLase3) was applied has little effect on overall peptide signal 
intensity. Elastase was applied to the tissue previously treated with Chondroitinase ABC 
and PNGaseF, with a control tissue treated in parallel with only elastase under the same 
antigen retrieval conditions. The elastase signal was greatly improved by deglycosylation 
and removal of CS. This increase in signal intensity is shown clearly via three 
representative images (Fig. 26a). Without CS and N-glycan removal, 7 putative elastin 
peptides were observed (Fig. 26b-c). With CS and N-glycan removal 42 putative peptides 
were detected, with a 29% increase in average peak intensity (Fig. 26d; Table 8). 
Consistent with histopathological evaluation, elastin peptides were seen 
throughout the length of the leaflet. Interestingly, the area of the leaflet that stained heavily 
for collagen was lower in signal intensity. This could be due to the intermolecular 
crosslinking of collagen and elastin, limiting enzymatic access. Here, initial treatment with 
COLase3 may improve localized elastase signal in these areas. While elastin does not 
contain any consensus sites for N-glycosylation, tropoelastin aggregates can crosslink 
with certain proteoglycans and glycoproteins in the extracellular space [286, 287]. Matrix 
glycoproteins have been thought to play a role in elastin fiber orientation, while 
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Table 8: Putative Peptide IDs of elastin peptides derived from Elastase (MMP12) imaging 
mass spectrometry experiments. Intensity values are normalized by TIC (Total Ion 





Figure 27: Comparison of ECM peptides detected with collagenase type III (C3) 
application after different sequential treatments. C3 was applied alone, after 
deglycosylation of the tissue with PNGase F or after both H&E staining and 
deglycosylation. (a) Overall average mass spectrum of Collagenase Type III treated 
tissue (top, black) and Collagenase Type III treated tissue after undergoing PNGase F 
digest and deglycosylation (bottom, blue). Annotated collagenase peptides and 
corresponding proteins are shown to the right. (b) Overall average mass spectrum of 
Collagenase Type III treated tissue after PNGase F and deglycosylation (top, blue) and 
Collagenase Type III treated tissue after undergoing H&E staining, PNGase F digest and 
deglycosylation (bottom, red). Annotated collagenase peptides and corresponding 
proteins are shown in (c). (d) Examples of collagen peptide images created as heat maps 
of the corresponding m/z peak intensity. Collagen peptide sequence and m/z are shown 
left of each image. Peak 1570.6768 m/z corresponds to the Glu1-Fibrinopeptide B (Glu-




proteoglycans have been implicated in elastin fibrogenesis [287, 288]. These interactions 
may be responsible for decreased enzymatic access of elastase to the fibrotic aortic valve 
tissue without deglycosylation and CS removal. 
4.6 Collagenase peptide imaging is compatible with pre-treatment of other ECM-
targeting enzymes 
Preliminary studies were performed with deglycosylation alone as a proof-of-
concept multi-enzyme strategy with collagen and ECM peptides as the final analyte. Here 
we have shown that deglycosylating tissues with PNGaseF before COLase3 treatment 
allows for capture of both the N-glycome and collagen proteome while improving collagen 
peptide signal versus COLase3-treatment alone (Figure 27a). Similar to previous studies 
with PNGaseF and histopathological evaluations (Figure 25), multi-enzyme studies on 
H&E-stained tissue show that H&E has no detrimental effect on the collagen signal 
(Figure 27b-d). In addition to comparing relative intensities between tissue treatment 
groups, hierarchical clustering analysis was performed to unbiasedly determine if the 
PNGaseF MALDI-IMS signal had a unique spatial distribution and spectral profile as 
compared to the collagenase (Figure 28). 
To expand upon these studies as part of a multi-enzyme strategy including 
chondroitinase ABC and elastase, additional COLase3 experiments were done to 
evaluate the quality of the signal after single enzyme treatments. While removal of certain 
analytes, such as N-glycans improved the COLase3 signal more than others, no single 
enzyme treatment detrimentally effected the COLase3 signal (Fig. 29a-d; 30). Consistent 
with previous studies by our lab, deglycosylation with PNGaseF had the greatest effect on 




Figure 28: Example of image segmentation analysis used to identify shared tissue 
regions between N-glycan and collagen peptides detected by MALDI-IMS on the 
same tissue section. (a) Output of image segmentation analysis performed with a 
combined list of identified N-glycan and collagen peptide peaks from the same tissue 
section. The blue region from N-glycan imaging and orange region from collagen peptide 
imaging display similar regions of interest. (b) Segmentation analysis showing hierarchal 
clustering. N-glycan or image data type are annotated by color. Image segmentation was 




Figure 29: Single enzyme treatment does not detrimentally alter Collagenase Type 
III collagen peptide signal. a. Representative images of COLase3 digests either after 
antigen retrieval only (C3 alone) or after digestion with a single ECM-targeting enzyme 
and analyte removal. From left to right: COLase3 control, post-chondroitinase, post- 
PNGaseF, and post-elastase. Three ECM peaks are shown: collagen 6a3 peptide (top), 
collagen 3a1 peptide (middle), and vimentin peptide (bottom). b-d. Quantification of the 
percent change in peak signal intensity for all COLase3 peptides identified after 
chondroitinase ABC (b), PNGaseF (c), and elastase (d) incubation and analyte removal 
as compared to control. Each point represents a COLase3 peptide peak with a boxplot of 
the data shown to the right. No single enzyme treatment had a significant effect on 




Figure 30: Collagenase peptide imaging is compatible with pre-treatment of trypsin. 
A. Representative images of COLase3 digests either after antigen retrieval only (C3 alone) 
or after digestion with a trypsin. Three ECM peaks are shown: collagen 6a3 peptide (top), 
collagen 3a1 peptide (middle), and vimentin peptide (bottom). B. Quantification of the 
percent change in peak signal intensity for all COLase3 peptides identified trypsin 
incubation and analyte removal as compared to control. Each point represents a COLase3 
peptide peak with a boxplot of the data shown to the right. P* represents hydroxyproline. 
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4.7 Multi-enzyme treatment reproducibly increases enzymatic access to ECM 
peptides 
The same tissue section treated with chondroitinase, PNGaseF and elastase was 
finally treated with COLase3 to image collagen and other ECM peptides (Fig. 31a-d). 
Quantification of signal intensities between the two methods shows an average of 3.1% 
increase in peak intensity (mean across all samples and peptides) (Fig. 31f) and an 82 ± 
15% increase in total number of peptides identified (mean across all samples) (Fig. 31g). 
Peptides containing the PTM hydroxyproline (HYP) were also able to be identified (Fig. 
31a, c). HYP peptides were not uniquely enriched in this method compared to non-
modified peptides. In addition to collagen-type proteins, other ECM peptides were also 
identified, such as the proteoglycans decorin, perlecan, and fibrinogen (Fig. 31b). 
COLase3 has low secondary proteolytic activity, with a primary cleavage site at the Y-G 
bonds of G-X-Y sequence in triple helical protein structures. Because of this, the specificity 
of this enzyme is not limited to collagen-type proteins but many ECM proteins with triple 
helical regions [146]. This study was tested for reproducibility across three different human 




Figure 31: Collagenase Type III collagen peptide signal and reproducibility study 
after removing the Chondroitin Sulfates, N-Glycans, and Elastin peptides. a-c. 
Representative images of COLase3 peptides in three separate aortic valve samples that 
have been digested with the serial enzyme methodology. d. Annotated spectra with of 
COLase3 alone (top, black) and COLase3 signal post-CS-N-glycan-elastin removal, with 
corresponding peptide sequences shown in e. f. Quantification of the percent change in 
peak signal intensity for all COLase3 peptides identified. Each point represents an 
COLase3 peptide peak with a boxplot of the data shown to the right. g. Quantification of 
total number of peptides identified between C3 alone (black) and C3 post-CS-N-glycan-





Figure 32: Aortic Valve tissue sections used for reproducibility studies. a-b. Movat’s 
Pentachrome staining of tissue sections with GAGs in blue, elastin in purple, and collagen 
in yellow. Tissue shown in b has portions of the outflow tract (OT) and aortic wall still 




4.4 Discussion  
The serial application of Chondroitinase ABC, PNGaseF, Elastase, and 
Collagenase Type III, along with specific washing steps, allows for the mapping of the 
complex ECM from the same 5 µm tissue section. This multimodal approach may be 
useful for deep mining of extracellular matrix information from difficult to obtain tissues, as 
one tissue section can be evaluated for 1) pathology via histology 2) CS GAGs, 3) N-
glycans, 4) elastin, and 5) collagens and other ECM peptides. Ongoing studies aim to 
incorporate i) hyaluronidase treatment to visualize hyaluronic acid; ii) endoglycosidase F3, 
to identify core-fucosylated N-glycan structures; and iii) trypsin, to further probe the ECM 
and non-ECM proteome. This multi-enzyme strategy is beneficial in clinical and biomedical 


















Chapter 5: Structure-Function Relationship of Extracellular 





This chapter outlines the localized targeting of collagen type peptides within the 
valve structure. Collagens are the fundamental scaffolding of valvular structure that 
influences valvular function and thus cardiac function. It has been well documented that 
the stratification into the three valve layers (fibrosa, collagen; spongiosa, GAGs; and 
ventricularis, elastin) that is seen in healthy AVs becomes disorganized in CAVS [8, 36, 
204]. Healthy  AV function is heavily dependent on this trilayer ECM structure, regulated 
by developmental cell signaling, hemodynamics, and biomechanical forces [289]. 
However, the translational and post-translational regulation of these critical proteins 
remodeling in pediatric disease remains poorly understood.  
We have previously identified that collagens are the major ECM constituents being 
deposited in pCAVS, concomitantly with GAG loss. However, collagen sub-type regulation 
remains to be explored in a spatially relevant manner, translatable to structure-function 
relationships. There are 28 collagen subtypes, all with unique roles in biomechanical 
structure of tissues, immune infiltration, signaling molecule storage, ECM-targeted 
protease activation, and cell signaling [66, 67]. In human mitral valves, relative 
abundances of collagen subtypes are as follows: Type I, 74%; Type III, 24%; and Type V, 
2% [289].  Similar ratiometric studies have yet to be done in healthy AVs. Similarly, these 
studies may be limited by techniques that inefficiently access non-fibril subtypes. In the 
AV, these fibril-type collagens are primarily distributed in the fibrosa layer to provide 
support against cyclic hemodynamic forces during systole. While it is known that the 
fibrosa layer is lost in pCAVS (Chapter 3), what is unknown is if this destratification is 
correlated to a localized deposition of different collagen subtypes that may contribute to 
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biomechanical instability and further matrix remodeling. This is the topic of the current 
study. 
Spatially defining the collagen proteome in a high-throughput manner remains an 
analytical challenge. Matrix-assisted laser desorption/ionization imaging mass 
spectrometry (MALDI-IMS) is an imaging technique that reports spatial localization and 
relative quantitation of collagen protein sequences, including PTMs, in thin tissue sections. 
Previously, untargeted MALDI-IMS studies have been performed on calcific aortic valve 
samples [159]. While some ECM peptides were identified, the un-targeted nature of this 
study showed more of a proof of concept than a quantitative analysis of the ECM as related 
to valve structure. Our technique, optimized in Chapter 4, allowed for approximately 150 
ECM peptides, primarily from collagen sub-types, to be identified from each valve sample 
(Fig. 31).  
 In this study, we are delineating collagen regulation in a cohort of pediatric and 
adult CAVS samples through interdisciplinary approaches. Microscopic histopathological 
evaluation via picrosirius red staining is used to visualize collagen fiber thickening and 
orientation due to CAVS (Chapter 3). These regions of localized collagen dysregulation 
are being probed for their unique collagen proteome. Peptide sequences and post-
translational modifications (PTMs) are being detailed by parallel MALDI-IMS studies. This 
chapter outlines the first report of collage peptide localization within a pediatric cohort of 
human CAVS samples. Here we have identified specific collagen peptides that colocalize 
with histopathologically identified regions of collagen dysregulation. This study also 
identifies a unique matrisome profile that may be developmentally regulated within the 
aortic valve, independent if disease status. Overall, this chapter outlines a novel 




5.2 Materials & Methods 
4.2.1 Materials 
Xylenes, 200 proof ethanol was from Fisher Scientific (Pittsburgh, PA, USA). 
Acetonitrile, Ammonium Bicarbonate, Calcium Chloride, Formic Acid, and Trizma Base 
were from Sigma-Aldrich (St. Louis, MO, USA). PNGase F Prime was purchased from N-
Zyme Scientifics (Doylestown, PA). Collagenase type III (COLase3) (C. histolyticum) was 
purchased from Worthington Biochemical (Lakewood, NJ, USA). 
4.2.2 Tissue Procurement 
Aortic valve tissue samples were procured through the Vanderbilt Core Laboratory 
for Translational and Clinical Research and the National Disease Research Interchange. 
The aortic valve tissues were collected under the Vanderbilt Pediatric Congenital Heart 
Disease Biorepository, written informed consent was obtained, and the project was 
approved by the Vanderbilt Institutional Review Board (IRB) and the IRB at the Medical 
University of South Carolina. De-identified tissues were obtained during reparative or 
transplant surgeries and characterized by pre-operative function into three patient 
categories: normal tricuspid (normal), pediatric CAVS bicuspid (pCAVS), and aortic valve 
insufficiency tricuspid (AVI). Valvular function is from de-identified complete 2D, color and 
spectral Doppler, or M-mode echocardiogram reports acquired prior to valve resection, 
replacement or heart transplant. 
3.2.3 Tissue Preparation & Histology 
Formalin-fixed, paraffin-embedded tissue was cut to 5 μm thick sections via 
microtome and mounted onto microscope slides (Tissue Tack, Polysciences, Inc., 
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Warrington, PA, USA) then dehydrated overnight at 37°C prior to storage at room 
temperature. Tissues were stained with Verhoeff Van Gieson (Verhoeff solution for elastin; 
Van Gieson counterstain for collagen), Movat’s Pentachrome (Alcian Blue for GAG, 
Saffron for collagen, Resorcin-Fuchsin for elastin, and Woodstain Scarlet-Acid Fuchsin for 
muscle), or Alcian Blue alone (Polysciences, Inc.), following manufacturer’s protocols. All 
staining protocols included a hematoxylin counterstain. 
FFPE aortic valve tissue sections were digested with COLase3 after serial 
treatment with PNGaseF (N-Zyme Scientifics) for MALDI-IMS experiments. Spray 
conditions for all enzymes were as previously published [11, 12]. Samples were digested 
in high humidity at 37.5°C for 5 hours. A 7 mg/mL solution of alpha-cyano-4-
hydroxycinnamic acid (CHCA) matrix solution was prepared in 50% acetonitrile and 1.0% 
TFA. CHCA matrix solution prepared for peptide imaging was spiked with a standard of 
200 femtomole/L [Glu1]-fibrinopeptide B human (GluFib) (Sigma-Aldrich, St Louis, MO, 
USA). CHCA automatic spray conditions included: 79°C, 10 psi, 70 μl/min, 1300 velocity, 
and 14 passes with a 2.5 mm offset. Slides for peptide imaging were rapidly dipped (<1 
second) in cold 5mM ammonium phosphate and immediately dried in a desiccator. 
6.2.5 MALDI-Imaging Mass Spectrometry 
Images were acquired using a Trapped Ion-Mobility Time-of-Flight Mass 
Spectrometer (timsTOF fleX) (Bruker Daltonik, Bremen, Germany) equipped with a dual 
ESI/MALDI source. The samples were analyzed in positive ion Q-TOF mode and scanned 
at a mass range from 600 – 2500 m/z. The SmartBeam 3D 10 kHz laser was set to 8% 
power, scan range of 10 µm for X and Y and resulting field size of 14 µm for X and Y. The 
images were collected with 300 shots per pixel and a 20 m step size in between pixels. 
Additional instrument parameters include: an ion transfer time of 125 s, pre pulse storage 
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time of 25 s, a collision RF of 4000 Vpp, a collision energy of 15 eV, an ion energy in the 
quadrupole of 5 eV, a TIMS funnel 1 RF of 500 Vpp, a TIMS funnel 2 RF of 500 Vpp and 
a multipole RF of 500 Vpp. After MS acquisition, the data was imported into SCiLS Lab 
2020a (Bruker Daltonik) and normalized to total ion current.  
Putative peptide identifications are based on our previously acquired databases 
from many tissue samples on the identical human aortic valvular tissues [10-11]. This 
analysis does not include peaks with biologically relevant spatial distribution that have not 
yet been sequenced with targeted proteomic analysis. 
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5.3 Results & Discussion 
5.3.1 Overview 
A total of 19 human aortic valve tissues were used in this study. Patients were 
categorized as follows: pediatric normal (n=4), pediatric bicuspid AVS (n=10), and adult 
fibrocalcific AVS (n=5). Clinical characteristics can be found in Table 9. Data in this chapter 
includes both histopathological evaluation of the ECM as well as two-dimensional mapping 
of collagen and other ECM peptides via MALDI-Imaging Mass Spectrometry techniques. 
A total of 152 putative peptides were identified in this dataset, with an additional 110 peaks 
that showed biologically relevant spatial distribution that were not identified in our 
database. These peaks may be potential candidates for future experiments in targeted 
proteomics (Fig. 1). The majority of putative peptide identifications were from collagen 
sub-type proteins (55%), with the remaining peptides putatively identified from ECM and 
collagen associated proteins, such as proteoglycans (DCN), ECM glycoproteins 
(Tenascins, Emilin-1, COMP, MFAP4), and proteins associated with cell-ECM binding 
(BGH3, FBN1, ASPN). 
5.3.2 Extracellular Matrix Patterns within Normal Trilayer Aortic Valve Structure 
 Our MALDI-IMS methods outlined in this chapter use collagenase type III 
(COLase3) to enzymatically target proteins with triple helical regions (primarily collagen 
sub-types) from FFPE aortic valve (AV) tissue sections. These studies were performed on 
tissues that had been previously evaluated for ECM distribution and collagen spatial 
regulation (Chapter 3). An example of MALDI-ECM-IMS evaluation of a tricuspid, normal 
pediatric valve can be seen in Figure 33, relative to a serial section stained via Movat’s 
Pentachrome. Three examples of putatively identified collagen subtype peptides can be 
seen, with dominate distribution shown within the fibrosa layer, as expected based on  
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Table 9: Descriptive statistics of patient characteristics for all pediatric and adult 
aortic valve tissue samples featured in the study. 2D Echocardiogram mean gradients 
define pre-operative valve function where a normal gradient is defined as <5 mmHg, mild 
stenosis as 5-25 mmHg, moderate stenosis as 25-50 mmHg, and severe stenosis as >50 





Figure 33: Representative extracellular matrix peptides within normal trilayer 
valvular structure. Top: extracellular matrix profiling via Movat’s Pentachrome staining 
(Blue: GAGs; Yellow: Collagen; Purple: Elastin). Below: Representative MALDI-IMS 
heatmaps of putatively identified ECM peptides within the valve structure. Peptides from 
several collagen subtypes are identified along with other ECM peptides. Bottom right 
shows a potential candidate for targeted proteomics based upon biologically relevant 
spatial distribution patterns. 
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histopathological evaluation. As can be seen, this method can identify peptides from 
multiple collagen subtypes, with putatively peptides from collagens α3(VI), α1(XIV), and 
α1(I) shown. Similarly, this method was able to putatively map post-translationally 
modified peptides, with an example of a hydroxyproline containing collagen α1(I) peptide 
shown. Since COLase3 can target non-collagen type proteins with triple helical regions, 
we were also able to putatively identify peptides from MFAP4 and Prolargin. Interestingly, 
MFAP4, or Microfibril-associated glycoprotein 4, is strongly associated with elastin-fiber 
formation [290] and has been found to be increased in aortic aneurysm patients of bicuspid 
aortic valve [291]. A prolargin peptide (1426.6728 m/z, IPPGVFSKLENLL) was found to 
be abundant within the elastin-rich ventricularis of the normal pediatric AV (Fig. 33). In 
previous studies, small leucine-rich repeat proteoglycans, such as prolargin, were found 
to be associated with elastin fibers and serve in galectin binding [292].  
5.3.3 Uncovering ‘Hidden Fibrosis’ via MALDI-ECM-IMS 
 Conventional histopathological analysis of collagen is done with various stain 
techniques, such as Movat’s Pentachrome, Picrosirius Red, Herovici, and Masson’s 
Trichrome – some examples of which are shown in Figure 34 (left). It has been well noted 
in literature that the mechanism of these stains targets fibril type collagens, and while 
basement membrane collagens may be highlighted with silver-nitrate based stains [293], 
FACIT and other collagen subtypes may be left unstained without targeted affinity-based 
methods. Uncovering fibrosis-associated peptides that may be unstained by conventional 
histology is one application of MALDI-ECM-IMS. Examples of this can be seen in Figure 
34B. In this pCAVS valve, there is a band of tissue that is unstained for collagens but is 
positive for GAGs, suggesting this is not tissue loss during preparation. A serial section of 




Figure 34: MALDI-ECM-IMS identifies putative collagen peptides unstained via 
conventional histology. A) ECM targeted histology stains on serial sections of valve 
tissue studied. SKU DB119 (age 5). Top: Movat’s Pentachrome (Blue: GAGs; Yellow: 
Collagen; Purple: Elastin); Middle: Herovici (Blue: immature collagen; purple: mature 
collagen); Bottom: Picrosirius Red, optical light (Red: Collagen). A band of tissue can be 
seen in PSR and Herovici stains that stains positively for GAGs in MP. B) Segmentation 
analysis of the MALDI-ECM-IMS identified peaks, showing unique proteomes between 
sections positively and negatively stained for collagen in A. C) Representative images of 
peptides that colocalize with regions identified in B. Top: a peptide from fibril-type 
COL5A1. Middle: a peptide from FACIT-type COL14A1. Bottom: Merged image. 
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analysis, there are unique proteomes associated with regions unstained for collagen (Fig 
34B, yellow) and those than positively stain for collagen (Fig. 34B, green). Two 
representative peaks aligning with those segmentation clusters are shown. The fibril type 
collagen peptide (m/z 1343.6910; COL1α1(V), GEKGEPGEAGEPGL) correlates to the 
collagen stain while the FACIT type collagen (m/z 1505.6797; COLα1(XIV), 
LAVLDDGSESEVVTA) correlates to the region unstained by collagen histology 
techniques. This, in combination with Figure 33, shows the application of MALDI-ECM-
IMS to uncover the translational and post-translational regulation of tissues in a spatially 
defined manner, previously inaccessible by conventional histology. 
5.3.4 MALDI-ECM-IMS Putatively Identifies Collagen-Subtype Composition of 
Collagen “Plaques” within pCAVS 
Previous studies used microscopy-based techniques to identify collagen 
signatures uniquely associated with pCAVS – primarily: increased collagen deposition, 
loss of trilayer structure, misaligned collagen fibers relative to the endothelium, and, most 
significantly, increased regions of increased collagen fiber density, or RIFDs. MALDI-IMS 
was used to in this study to determine the collagen-subtype regulation occurring within 
these localized collagen RIFDs. A total of 10 ECM peptides were found to colocalize with 
previously identified RIFDs within a representative pCAVS patient (Table 10). Figure 35A-
B shows the histology-defined RIFD in a pCAVS sample (B), along with the lack of RIFD 
shown in the age matched control (A). Figure 35C shows two representative images of 
MALDI-IMS mapped peptides that colocalize with these regions. Not all peptides that 
correlated to RIFDs were statistically differentially expressed between normal and pCAVS 




Figure 35: MALDI-ECM-IMS identifies putative peptides colocalized with RIFDs. A) 
Picrosirius Red stain of a normal pediatric valve (SKU DB27, age 17). Top: Polarized light 
image; Middle: RIFD mask (see Chapter 3); Bottom: Optical light image. B) PSR stain on 
age-matched pCAVS valve (SKU DB16, age 17). Top: Polarized light image; Middle: RIFD 
mask (see Chapter 3); Bottom: Optical light image. White arrows show RIFDs. C) 
Representative MALDI-IMS data of two putatively identified peptides that colocalize with 
RIFDs in DB16 (B). D) Maximum intensity values for all RIFD colocalized peaks identified, 
DB27 and DB16 shown. E) Segmentation analysis on all peaks identified within these two 

















































































heatmap mapping of these colocalized peptides that there are regions of increased 
intensity that qualitatively differ from normal valves (Figure 35C, Table 10).  
This technique shows the importance of considering the spatial localization of a 
proteome. While all 10 RIFD colocalized peptides were identified in both the normal and 
pCAVS age matched control samples (Table 10) – with no statistical difference in the 
mean intensity of these peptides across the tissue – there were specific areas of increased 
localization within the pCAVS samples that directly overlaps with RIFDs identified in a 
previous study (Chapter 3). This can be visualized in the representative images (Fig. 35C), 
as well as seen in maximum intensity quantification of two samples shown (Fig. 35D). 
Certain peptides show high maximum intensity with pCAVS’ RIFD and relatively low 
intensity within normal valves, such as 785.3833 mz (COLα1(III), GLPGTGGPPox; 21.6% 
increase in maximum intensity from normal age-matched control), 1323.7799 m/z 
(COLα1(III), GPLGIAGITGARGLA; 43% increase) and 1480.7511 m/z (COLα2(I), 
GKEGPVGLPoxGIDGRPox; 46% increase).  
As expected, 6 out of the 10 RIFD colocalizing peptides were putatively identified 
to be derived from fibril collagens, (I, III, and V). However, 4 peptides were putatively 
identified from network-associated collagen α3(VI) as well as non-collagen proteins 
tenascin-c, lumican, and vimentin. The proteoglycan lumican has been previously 
explored for its role in limiting collagen fibrillogenesis [294-296], but may also play a role 
in increasing myocardial collagen production during pressure overload [297]. Small 
Leucine Rich Proteoglycans (SLRPs) such as lumican have been identified as having a 
critical role in spatiotemporal ECM remodeling in the developing mouse valve cusp [38, 
298], however, its role in human valve disease remains unexplored. Interestingly, the ECM 
glycoprotein tenascin-c has been previously implicated endothelial function in healthy 
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valves, as well as in the progression of human aortic valve stenosis when found within 
deeper layers of the valve structure [299], similar to spatiotemporal patterns identified in 
this study. 
Segmentation analysis was performed on these two age-matched samples to 
determine if there were unique proteomes associated with RIFD colocalized regions, as 
well as between age-matched healthy and diseased valvular tissues (Fig. 35E). This 
analysis showed that when considering both intensity and localization, there are collagen 
proteome clusters unique to previously identified RIFDs (purple, Fig. 35E). Similarly, the 
distal tip of the normal valve (Fig. 35E, yellow), which has been shown to under stronger 
hemodynamic forces and more actively remodeling, appears to share a similar proteome 
to the length of the age-matched pCAVS valve sample (Fig 35E, yellow).  
 Unexpectedly, a peptide from non-fibril type collagen VI (m/z 1211.6196; 
GGAVPIGIGIGNAD) was found to colocalize within regions of RIFDs and collagen fiber 
misalignment within the adolescent pCAVS valve studied above. This peptide was 
visualized within all AV samples as well (Fig. 36).  Following the trend seen in the pCAVS 
valve sample above, this peptide was found to be abundant in regions previously identified 
as RIFDs as well as stained for collagen maturity via Herovici (Fig. 36, arrows). 
Colocalization analysis, applied to this spatial distribution within the valve cohort, 
putatively identified 21 other peptides that overlapped with regions of collagen maturity 
and RIFDs, similar to the 1211 m/z distribution shown in Fig. 36 (Table 11). Of these 
peptides, 33% (7 out of 21 identified peptides, Table 11) were also putatively identified to 
be from collagen VI, suggesting a role for collagen type VI in RIFD formation.  
Collagen type VI is a unique member of the collagen family that forms a 




Figure 36: Distribution of COL6A3 peptide aligns with regions of mature collagen 
deposition and RIFDs in several pCAVS valves. A) Imaging data of a COL6A3 peptide 
found to colocalize with DB16 in Figure 35 (m/z 1211.620; GGAVPIGIGIGNAD). White 
arrows show RIFDs identified in B and C. B) Herovici stained serial sections of AVs studied 





Table 11: Putatively identified peptides that colocalize with COL6A3 peptide 1211 
m/z. Colocalization analysis was done on all valve studied (Table 9). Colocalization 
threshold was 0.65. 
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associated with roles as diverse and biomechanical stabilization to protecting against 
oxidative stress, depending on the tissue of origin [300]. In the heart, ColVI has been found 
to be increased in myocardial infarction mouse models, with a suggested role in cardiac 
remodeling post-infarction [301]. While the role of ColVI has been described in endocardial 
cushion development [302] and early VIC migration [303], its role in valve disease has not 
been explored. The MALDI-IMS studies outlined here do not necessary give mechanistic 
insight into the formation of RIFDs in pCAVS, but they do define molecular targets that 
should be explored in future studies. 
5.3.5 ECM Profiling shows Developmental Regulation within Aortic Valves 
With limited differences in pCAVS vs normal within the whole-tissue proteome, we 
explored developmental differences based on pediatric age categories defined by National 
Institute of Child and Human Development: Neonate (0-30d), Infant (1 mo – 2 yrs), young 
Child (2-6 yrs), Child (6-12 yrs), Adolescent (12-18 yrs). Our previous research (Chapter 
3) has shown significant ECM regulation occurring in early periods of pediatric 
development (young pediatric, age 0-5 yrs) compared to later stages of pediatric 
development (older pediatric, age 6-18).  
Segmentation analysis was done on all ECM peptides identified within the valve 
cohort to determine if unique peptide clusters exist between young pediatric, old pediatric, 
and adult patients, independent of disease (Fig. 37). Previous studies have shown a 
unique inflammatory and cell-signaling profile between pediatric and adult populations of 
AVS [31], however ECM profiling remained limited between these two pathologies. It is 
clear in the segmentation analysis shows that there ECM proteomes that are unique to 
adult fibrocalcific samples as compared to the pediatric cohort; however, differences 




Figure 37: Segmentation analysis of the AV cohort on all peptides identified. Results 
show a unique proteome between adult CAVS samples (bottom, purple clusters) and 
pediatric samples (top, middle). Pediatric samples show similar proteome distributions, 
however RIFDs show unique clusters (green, light yellow). 
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Differential expression analysis was performed between young and old pediatric 
AVs via ROC-AUC. A total of 104 peptides were found with the generous threshold of 0.65 
used within previous studies. Narrowing the threshold to 0.70 identified a total of 14 
putative peptides to be differentially expressed between young and old pediatric AVs, data 
from which were used for further analysis (Table 12, Figure 38). A representative putative  
peptide from collagen α1(XVI) (m/z 1068.511, PGPoxPGRGVQGP, AUC = 0.704; Note Pox 
is a putative HYP site in need of confirmation) that is differentially expressed between 
pediatric age groups can be seen in Figure 38A. Interestingly, peptides that showed 
developmental regulation tended to show dissimilar distribution patterns to those 
correlation to RIFDs – this can be clearly seen by lack of distribution along the endothelial 
RIFDs seen in pCAVS SKU DB41 (age 14), and interstitial RIFDs seen in SKUs DB16 
(pCAVS age 17) and DB117 (pCAVS age 12). Collagen α1(XVI) is a FACIT type collagen 
that aligns well with the fibrosa in healthy tri-layer valves (Fig. 38A, top). Interestingly, this 
FACIT collagen also aligns within regions highlighted by another FACIT collagen peptide, 
shown in Figure 34 within DB 119 (COLα1(XIV), pCAVS age 5). 
 To further show that these peptides identified via ROC-AUC analysis could 
unbiasedly differentiate between young and old pediatric patients independently of 
disease category, hierarchical clustering analysis was done (Fig. 38B). It can be seen 
here, with the exception of SKU DB43 (pCAVS age 0.15) and SKU DB18 (pCAVS age 6), 
these peptides can unbiasedly cluster pediatric patients by age category (Fig. 38B). 
Interestingly, the patient that was misclassified within the “older pediatric” cluster (SKU 
DB43, age 0.15), is a tricuspid pCAVS patient that was included in this study due to their 
severe stenosis. When reviewing the segmentation analysis in Figure 37, this patient has 




Table 12: ROC-AUC identified peptides to be differentially expressed between young 





Figure 38: ECM Profiling shows Developmental Regulation within Aortic Valves. A) 
Representative image of a HYP containing collagen peptide (m/z 1068.511; COL16A1, 
PGPoxPGRGVQGP) that was identified to be differentially expressed between pediatric 
age groups, independent of disease. Note: HYP site requires confirmational proteomic 
studies. B) Hiearchical-clustering analysis of all peptides identified via ROC-AUC to be 
differentially expressed between pediatric patients (Table 12). These results show ROC-
AUC identified peptides can unbiasedly cluster patients by pediatric age group. C) 
Boxplots of mean intensity for significantly differentially expressed peptides, as 




peptides (outlined in Fig. 38C) appear to be increased in the young pediatric population 
that decrease in expression as valve development progresses. One unexpected peptide 
of interest is m/z 1316.673 (COLα1(II), LGSQVGLMPGSVGPV). While collagen II is not 
the dominant fibril type collagen within cardiac tissues, there are early studies outlying its 
role in embryonic valve morphogenesis [304]. 
5.3.6 Conclusions 
This Chapter outlines the application of MALDI-ECM-IMS to determine collagen 
sub-type regulation within localized regions of histologically defined collagen 
dysregulation. Similarly, large -omics datasets such as those acquired with this technique 
have the potential to unbiasedly classify valve samples dependent on pediatric fibrotic vs. 
adult fibrocalcific CAVS valve samples. However, more work needs to be done to 
investigate the subtle translational and post-translational regulation between normal 
pediatric and pCAVS AVs. This study shows that unique ECM peptides may be 
developmentally regulated within the aortic valve structure. Collagen subtypes within this 
study are known to interaction with proteoglycan families as well as elastin, as outlined 
above. This technique may be used together with multi-enzyme studies outlined in 
Chapter 4 to colocalize collagen subtypes directly with spatial regulated GAGs and elastin. 
Similarly, these studies lay the foundational work for those exploring cell-ECM interactions 
within AVs. These techniques that may be applied for future studies are outlined in detail 
within Chapter 7. 
Defining unique peptides that correlate to RIFDs may aid in the discovery of 
molecular markers to be used clinically. Similar studies have been done targeting renal 
and myocardial, lung, and liver fibrosis via MRI, PET and CT imaging [250]. The long-term 
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goal of the studies outlined in this dissertation is to identify ECM biomarkers of pCAVS 
that may be targets for pharmacotherapeutic development to slow the disease 
progression. However, these same targets may be used to diagnose the disease before 
the onset of heart failure identified via irregular hemodynamics and electrophysiology, 
most commonly diagnosed by echocardiography and doppler [61]. Similarly, these ECM-
targeted proteomics applications may be useful to correlate our finding here with on-tissue 
pCAVS profiles to future studies with serum-derived from patients, in order to develop 
minimally invasive diagnostics for the progression of fibrotic cardiac disease, potential 
before the onset of cardiac perturbances. Overall, this chapter outlines the value in 










Chapter 6: Evaluation of Therapeutic Collagen-Based 
Biomaterials in the Infarcted Mouse Heart by Extracellular 
Matrix Targeted MALDI Imaging Mass Spectrometry 
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This chapter outlines a proof-of-concept study using the developed ECM-targeted 
MALDI-IMS techniques towards biomaterial applications of fibrotic cardiac disease. In this 
study, we aimed to use MALDI-IMS to both 1) investigate the ability of this technique to 
distinguish between the spatial distribution of hydrogel injected collagen peptides as 
compared to endogenous mouse tissue; and 2) use MALDI-IMS and proteomics to explore 
the effects of therapeutic-based collagen hydrogels on endogenous remodeling of the 
infarcted mouse heart. The bulk of this chapter has been submitted as a manuscript in the 
Journal of the American Society for Mass Spectrometry and is under review at the time of 
submission of this dissertation. 
6.1 Introduction 
Collagen is a natural, degradable polymer found in the extracellular matrix (ECM) 
that is widely used in therapeutic biomaterial applications due to its biocompatibility, cell 
adhesion promotion, and cell permeability [305-307]. One application of biomaterials is in 
the treatment of myocardial infarction (MI), which if left untreated leads to the formation of 
non-contractile scar tissue and potentially heart failure [53, 55, 308, 309]. Collagen has 
been studied as a biomaterial for injectable hydrogels to repair heart tissue damage post-
MI, with the goal of limiting scar formation [310]. A previous study took advantage of 
human collagen subtypes as a component of the injectable hydrogel [310]. However, 
recent literature suggests that peptides, as opposed to whole proteins, provide a promising 
therapeutic advantage, as full-length human collagen is difficult to synthesize and stabilize 
due to extensive post-translational modifications [311, 312]. For this reason, determining 
which peptides within the protein used in purified collagen protein hydrogels are most 
efficacious may contribute to more applicable therapeutics. Recent studies show that 
peptide-based biomaterials can mimic the function of their full-length protein counterparts, 
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are easier to produce, can be derived from human origin, reducing autoimmune effects, 
and can similarly contribute to structural cell-recognition motifs [313, 314].  
Several imaging techniques have been developed over the years to analyze 
biomaterials in tissues. Fluorescence and MRI imaging techniques have been used to 
trace injected collagen ex vivo as well as in vivo at low penetrative depths [315, 316]. 
These techniques, however, require labeling of the injected material. Imaging Mass 
Spectrometry (IMS) can analyze the spatial distribution of molecules without labeling. 
Recent advances in this field have been applied to biomaterials research, using ionization 
techniques such as Secondary Ion MS (SIMS), Matrix Assisted Laser Desorption 
Ionization (MALDI), and Desorption Electrospray Ionozaion (DESI), amongst others [317]. 
These IMS techniques have been used to detect synthetic polymeric biomaterial and 
nanoparticles in vitro [317-320]. IMS is not only capable of analyzing the biomaterial itself, 
but also potential interactions with the treated tissue [321]. To date, however, the majority 
of studies have been on biomaterial surface analysis [317]. A soft-ionization technique, 
such as MALDI-IMS, is arguably one of the most appropriate methods for natural polymer 
detection in situ due to minimal fragmentation, allowing for more information from a 
complex substrate such as tissue.  
MALDI-IMS is a robust technique that is able to identify endogenous or 
enzymatically derived peptides in tissue sections [322]. However, proteomics-based 
techniques to evaluate ECM-based biomaterial interactions in surrounding tissues have 
been limited due to poor detection of ECM proteins. This is due to their low abundance 
and inter- and intra-molecular crosslinking. Recently, our lab has developed a 
collagenase-based ECM-targeted MALDI-Imaging Mass Spectrometry (ECM-IMS) 
methodology that may be used sequentially with other enzymatic imaging strategies [39, 
142, 145, 154-157]. In the current study, we utilize this method to elucidate the distribution 
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and therapeutic effects of collagen-based biomaterials on extracellular matrix remodeling 
in the infarcted heart, as well as identify potential therapeutic collagen peptides to be 
evaluated in future studies. 
 
6.2 Materials & Methods 
6.2.1 Materials and Chemicals 
All solutions were prepared using double distilled or HPLC grade water, following 
all necessary safety and waste disposal regulations. Xylenes, 200 proof ethanol were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Acetonitrile, ammonium 
bicarbonate, calcium chloride, formic acid, and Trizma base were purchased from Sigma-
Aldrich (St. Louis, MO, USA). PNGase F PRIME was purchased from N-Zyme scientific 
(Charleston, SC, USA). Collagenase type III (COLase3) (C. histolyticum) was purchased 
from Worthington Biochemical (Lakewood, NJ, USA).  
6.2.2 Preparation and characterization of collagen hydrogel 
Collagen hydrogels were prepared as previously described by McLaughlin et 
al.[310]. Brielfy, a 1% collagen solution was prepared by dissolving lyophilized 
recombinant human collagen type I or type III (rhCI and rhCIII, from Fibrogen) in 10 mL of 
ultra-pure ddH2O. Chondroitin sulfate (CS; Wako), N-ethyl-N-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) were added to produce a final 
mixture with a mass ratio of 1:4:0.5:0.3 for collagen:CS:NHS:EDC. Before the final step of 
the hydrogel preparation, after EDC/NHS crosslinkers have been added but before NaOH 
addition to a pH of 7.4, 20 µL of AlexaFluor 594-NHS conjugate (Thermofisher) was added 
to label the hydrogels (25 nmol of dye/gel). The materials were prepared on ice using an 
enclosed system that allows homogenous mixing. 
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6.2.3 Animal Experiments 
All procedures were approved by the University of Ottawa Animal Care Committee 
and performed according to the National Institute of Health Guide for the Care and Use of 
Laboratory Animals. Myocardial infarction (MI) was induced in 8 to 9-week-old female 
C57BL/6 mice (Charles River) and treatment delivery was performed using an established 
protocol [323, 324]. Briefly, mice were anesthetized (2% isoflurane), intubated, and the 
heart was exposed via fourth intercostal thoracotomy. At 1-week post-MI (baseline), mice 
were randomly assigned to receive treatment of PBS (control), rhCI or rhCIII matrices, 
delivered in 5 equivolumetric intramyocardial injections (10μL each site, 50µL total) 
through a 25G needle using an ultrasound-guided closed-chest procedure. Mice were 
sacrificed by terminal anesthesia at 2 days post-treatment (9 days post-MI) and hearts 
were collected and frozen in OCT for histological sectioning.  
6.2.4 Tissue Preparation and Histology 
Frozen tissue sections of mouse hearts injected with AF594-labeled hydrogels or 
PBS (10 µm thick) were cut via cryostat. A section approximately 2.16 mm from the apex 
was used in the present study. Fresh frozen mouse heart tissue sections were fixed briefly 
in 4% paraformaldehyde and stained with DAPI counterstain (Sigma-Aldrich, St Louis, 
MO, USA). Sections were mounted with Dako Fluorescent mounting medium (Agilent 
Technologies, Santa Clara, CA, USA), coverslipped, and sealed with clear nail polish. 
High resolution digital captures were taken of IHC stained mouse heart sections before 
MALDI-IMS studies of the same slide. Slides are imaged using a Leica Aperio Versa slide 




For N-glycan and ECM peptide MALDI-IMS studies, FFPE tissues were prepared 
as previously described [154, 325]. Briefly, after staining, AF594-labeled hydrogel 
detection, and coverslip removal, tissues were cleared of potential remaining OCT and 
mounting media with the following washing steps: 1 min Xylene, 2x 1 min 100% ethanol, 
1 min 95% ethanol, 1 min 70% ethanol, 2x 1 min HPLC water. Tissues were then antigen 
retrieved in Citraconic Buffer pH 3 and 10mM Tris pH 9 [154, 325]. Tissue sections were 
then digested with Collagenase Type III (COLase3) after deglycosylation with PNGaseF 
(N-Zyme Scientifics) for MALDI-IMS experiments [145, 155]. Enzyme solutions were 
sprayed with a TM Sprayer M3 (HTX Imaging, Chapel Hill, NC, USA) under the following 
parameters: 15 passes, crisscross pattern, 3.0 mm track spacing, velocity of 1200 
mm/min, and a dry time of zero.  
COLase3 treated samples were digested in ≥80% relative humidity at 37.5°C for 5 
hours. Matrix was 7 mg/mL solution of alpha-cyano-4-hydroxycinnamic acid (CHCA) 
solution, prepared in 50% acetonitrile and 1.0% TFA, spiked with a standard of 200 
femtomole/L [Glu1]-fibrinopeptide B human (GluFib) (Sigma-Aldrich, St Louis, MO, USA). 
CHCA automatic spray conditions included: 79°C, 10 psi, 70 μL/min, 1300 velocity, and 
14 passes with a 2.5 mm offset. Slides for peptide imaging were rapidly dipped (<1 
second) in cold 5mM ammonium phosphate and immediately dried in a desiccator. 
6.2.5 MALDI-Imaging Mass Spectrometry 
MALDI-IMS analysis was via a 7.0 Tesla solariX™ Legacy FT-ICR (Bruker 
Scientific, LLC) operated in positive ion broadband mode over m/z range 600-2500. Laser 
settings used were 200 shots/pixel with a 75 µm stepsize. A lock mass of 1570.6768 
(GluFib peptide) was used. Images were visualized in FlexImaging v5.0 and analyzed 
using SCiLS (Bruker Scientific). All images shown are normalized to total ion current. 
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Spectra shown were analyzed using mMass version 5.5.0. A filter of 10 ppm mass error 
was used for this study. Target peptides were were further fragmented by on-tissue 
MALDI-MS/MS and analyzed for ion mobility to confirm post-translational modification site 
occupancy via CID on a timsTOF fleX as previously described (Bruker Scientific, LLC) 
[145]. 
6.2.6 Proteomic Tissue Preparation 
Tissue was prepared as previously described [39]. Briefly, tissues were antigen 
retrieved and deglycosylated as described above. One slide with 6 serial sections per slide 
was used per treatment group. Tissue was scraped off the slide and ultrasonicated at 50% 
energy (Fisherbrand 120 sonic dismembrator; Fisher Scientific, Pittsburgh, PA, USA) for 
2 min each in 10 mM ammonium bicarbonate 1 mM CaCl2 (pH 7.4). Tissues were 
incubated with 2 μg of Collagenase Type III overnight and centrifuged to collect 
supernatant for proteomic analysis. Samples were purified by C18 STAGE tip (Pierce 
Biotechnology, Waltham, MA) according to manufacturer’s protocol. STAGE-tip eluate 
was dried down via speed vac and resuspended in mobile phase A (HPLC water). 
6.2.7 Proteomics 
Peptides were analyzed data dependent acquisition on a timsTOF fleX equipped 
with a nano-HPLC (nano-Elute, Bruker Daltonics). Peptides were loaded onto a trap 
column and separate on a 75 μm x 25 cm classic pulled tip column (Aurora C18 1.6um 
particles) at 50°C. The gradient was from 2 to 80% solvent B over 105 min, where solvent 
A was HPLC water and solvent B was acetonitrile. Parallel accumulation serial 
fragmentation (PASEF) scan mode and TIMS were enabled in positive ion mode. TIMS 
accumulation time was fixed to 2 ms with a cycle time of 100 ms, covering a mass range 
of 100–1700 m/z and a 1/K0 range of 0.6-1.6 Vs/cm2. 
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Data was searched using MSFragger with IonQuant [326] (v3.2; Fragpipe v15.0) 
against the mouse extracellular matrix database (downloaded February 26, 2021), a 
subset database of 2976 entries with keywords used (collagen, elastin, aggrecan, gelatin, 
osteonectin, perlecan, plasminogen, and fibronectin). Parameters included unspecified 
proteolytic enzyme, precursor mass tolerance of ± 20 ppm, and fragment mass tolerance 
± 0.8 Da. Methionine oxidation, and proline hydroxylation were included as variable 
modifications. Proteins were identified with FDR ≤ 0.05 and at least two peptides. Scaffold 
v5 was used for protein and peptide level analyses. 
6.2.8 Bioinformatics 
Normalized peak intensities were evaluated by ANOVA and Mann Whitney U test, 
correcting for multiple comparisons (IBM SPSS Statistics, version 25). A Type I error 
probability of ≤0.1 was used to evaluate the significance of the result. For this proof of 
principle study, p-values of ≤0.1 are reported as trending to significance and p-values of 
≤0.05 were used determine significant results. AUC p-values are reported as the maximal 
discriminative power at the centroid. Peaks reported as significantly regulated were 
identified via SCiLS (v. 2017a). Exported peak intensities are visualized as heatmaps after 
natural log transformation with MultiExperiment Viewer (http:/mev.tm4.org) [327]. 
6.2.9 Peptide synthesis 
GRPoxGEVGPoxP, GRPGEVGPoxPox, and GRPoxGEVGPPox peptides were 
synthesized using the Liberty Blue (CEM) automated microwave peptide synthesizer 
(where Pox is HYP). Fmoc protected amino acids were purchased from CEM. HYP were 
purchased from BACHEM. To 2-Chloro trityl resin (ProTideCl-TCP(Cl) resin, CEM), the 
first aminoacid was loaded under microwave (90ºC), DIEA (1M) and KI (0.125M) for 10 
minutes with twice coupling. Next, Fmoc deprotection was carried out with 20% piperidine 
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at 90°C for 60s while standard coupling cycles using DIC/Oxyma Pure were run at 90°C 
for 240s. Peptides were cleaved from the resin and deprotected with 92.5/2.5/2.5/2.5% 
v/v TFA/TIS/EDT/H2O at 42°C for 30 minutes and then precipitated in -20°C diethyl ether. 
Crude peptides were dried under vacuum overnight and purified by RP-HLPC in a Waters 
1525EF semi-preparative system with a 21.6x250 mm C18 column at 20 mL/min. Peptide 
purity and identity was confirmed via RP-UPLC-UV/MS in a Waters Acquity UPLC Xevo 
TQD using a 2.1x100 mm UPLC BEH C8 column. A purity of 95% was determined through 
UV peak analysis. The theorical monoisotopic mass for the 3 peptides is equal to 896.4 
Da. For the peptide GRPoxGEVGPoxP mass spectrometry results gave the most abundant 
peaks of 449.3 m/z [M-2H+] and 897.4 m/z [M-H+] for an experimental mass of 896.4 Da. 
For the peptide GRPGEVGPoxPox mass spectrometry results gave the most abundant 
peaks of 449.4 m/z [M-2H+] and 897.6 m/z [M-H+] for an experimental mass of 896.6 Da. 
For the peptide GRPoxGEVGPPox mass spectrometry results gave the most abundant 
peaks of 449.3 m/z [M-2H+] and 897.4 m/z [M-H+] for an experimental mass of 896.4 Da 
(Fig. 46). 
6.3 Results & Discussion 
6.3.1 Study design and hydrogel region of interest analysis 
In this study, mice with myocardial infarction (MI) were treated at 7 days post-MI 
with either a Collagen Type 1 (rhCI) or a Collagen Type 3 (rhCIII) hydrogel [310]. Two 
days after hydrogel treatment, mouse hearts were harvested, frozen, and sectioned for 
tandem histology and MALDI-IMS studies (Fig. 39). Injected human collagen hydrogels 
were fluorescently labeled prior to injection and analyzed via immunofluorescence. 
Microscopy based analysis of tissues identified the potential site of hydrogel injection as 




Figure 39: Mouse model study design and multimodal imaging mass spectrometry 
workflow. a. Timeline of mouse model. 9-week old mice were induced with myocardial 
infarction. 7-days post-surgery, collagen hydrogel or PBS control was injected into the left 
ventricle. 2-days post injection, hearts were harvested. b. Region of interest (ROI) 
annotation of heart sections in relation to fluorescently labeled human hydrogel signal. BZ: 
Border Zone; LV: Left Ventricle; RV: Right Ventricle. Scale bar shown is 1 mm. c. 
Simplified workflow of tandem high resolution fluorescent microscopy and collagenase-




Figure 40:  Representative sections with ROI annotations from all mice included in this 
study (n=3 per treatment group). All mice were confirmed to have a Left Ventricular 
Ejection Fraction of <50% for initial injury. representative annotated tissue section for each 
biological replicate shown across three patient categories: PBS injected control, rhCI 
hydrogel, and rhCIII hydrogel. Annotated regions include HIS (hydrogel injection site), 
Infarct (region of myocardial infarction, identified via previous studies (McLaughlin, 2019); 
BZ (border zone, region immediately adjacent to infarct), and remote (region furthest from 




and the remote region (intact myocardium) (Fig. 39-40). These microscopy-based 
observations were used to create regions of interest (ROIs) for downstream MALDI-IMS 
analysis of collagen and other ECM peptides (ECM-IMS) (Fig. 39c). While downstream 
peak-picking was performed unbiased of microscopy-based observations, ROIs were 
used to further evaluate collagen-type peaks of interest in relation to hydrogel specificity. 
6.3.2 Fibrillar collagen homology sequences are more abundant in hydrogel 
injection sites 
A challenge of this study is that humans and mice have 93-94% homology between 
collagen sequences (for the collagen subtypes used for hydrogel injections: collagen α1(I), 
α2(I), and α1(III). To determine specificity of hydrogel-derived human collagen sequences, 
the localization capability of MALDI-IMS was leveraged with multiplexed histopathology-
based studies in conjunction with on-tissue peptide sequencing via MALDI-MS/MS. 
Overall, 22 Collagen Type I putative peptides (9 COLα1(I), and 13 COLα2(I)) were 
identified; 11 of all collagen type I putative peptides identified contained sequences 
homologous between human and mouse (Fig. 41a, Table 13). Additionally, ECM-IMS 
analysis identified 18 human COLα1(III) peptides, with only 5 being homologous between 
human and mouse sequences (Fig. 41a, Table 13). Amongst these, pathological ROI 
analysis identified four collagen type I peaks that were differentially regulated in rhCI-
injected hearts, specifically at the infarct ROI (Table 13). Similarly, two COLα1(III) peaks 
were differentially expressed between PBS-control and rhCIII-injected hearts (Table 13). 
Two representative images of Collagen Type 1 in rhCI hearts and COLα1(III) in rhCIII 




Figure 41: Human collagen peptides with mouse homology are more abundant in 
hydrogel injection sites. a. Total number of putative human peptide identifications from 
hydrogel injected tissues as a function of collagen subtype for collagens injected.  b. 
Representative collagen type 1 peaks as visualized in rhCI injected hearts as compared 
to PBS controls. Average intensity levels measured between all samples studied are 
shown in (c). d. Representative collagen type 3a1 peaks as visualized in rhCIII injected 
hearts as compared to PBS controls. Average intensity levels measured between all 
samples studied are shown in (e). n=3. Six tissue sections were visualized for each 





Table 13: MALDI-IMS mapped human hydrogel peptides, showing both peptides that are 
unique to the human proteome as well as those that share mouse and human homology 
sequences. For those with human specific sequences, the corresponding mouse peptide 




Table 14: Significantly Differentially Expressed human hydrogel derived peptides (ROC 
AUC); infarct ROI comparisons. 
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Average intensity levels of peaks shown in representative images were quantified across 
all tissue sections studied (Fig. 41c,e). Overall, ROI annotation and differential intensity 
distributions were able to identify putative peptides corresponding to the site of hydrogel 
injections. 
6.3.3 ECM-IMS identifies human-specific collagen sequences in hydrogel injected 
mouse hearts 
An example of a significantly increased peptide identified that aligned uniquely to 
the collagen α1(I) human sequence is shown in Figure 3 (rhCI 1128.5681 m/z; 
GPPSAGFDFSF). ECM-IMS analysis was also able to identify the mouse peptide 
corresponding to this human sequence (1130.4789 m/z, +1.9108 m/z; GPPSGGYDFSF) 
(Fig. 42a-b). As can be seen in Figure 3, the peak corresponding to the mouse peak is 
equally present in the PBS control and rhCI hydrogel tissue. However, the corresponding 
human specific peptide is significantly more abundant in the rhCI-injected heart (AUC at 
infarct 0.689, p-value 0.013). A similar result is seen for a COLα1(III) peptide sequence in 
the rhCIII-treated heart (AUC at infarct, 0.923, p-value 0.008) (Fig. 42c-d). Importantly, 
m/z 1128 and m/z 844 were not identified in the mouse-database identified peptides via 
LC-MS/MS (Fig 43, Table 15). Finding these human-proteome unique peptides provides 
further evidence of biomaterial localization via MALDI-ECM-IMS. While fluorescent label-
based microscopy techniques may be able to identify the site of injection, ECM-IMS 
identifies unique peptides within the hydrogel that may be contributing to endogenous 
ECM remodeling and improved cardiac function, as seen in tandem studies on the same 





Figure 42: Collagen peptides unique to human proteome have differential 
distribution to corresponding mouse peptides. Species differentiating amino acids are 
underlined in bold within the sequence. a. Representative collagen type 1 peaks as 
visualized in rhCI injected hearts as compared to PBS controls are shown for the human-
specific collagen sequence (left) and corresponding mouse sequence (right). Average 
intensity levels measured between all samples studied are shown in (b). c. Representative 
collagen type 3a1 peaks as visualized in rhCIII injected hearts as compared to PBS 
controls are shown for the human-specific collagen sequence (left) and corresponding 
mouse sequence (right). Average intensity levels measured between all samples studied 
are shown in (d). n=3. Six tissue sections were visualized for each biological replicate. 
Different representative samples are used to show reproducibility across n’s. Note: 




Figure 43: Collagen targeted proteomics investigates endogenous mouse ECM 
remodeling. a. Venn Diagram showing the number of proteins identified in PBS control, 
rhCI hydrogel, and rhCIII hydrogel samples. b. Hierarchical clustering of protein level Fold 
Change (Infarct/Remote) values for each treatment group. c. Hierarchical clustering of LC-
MS/MS identified mouse peptides mapped via MALDI-IMS studies. ROI intensity for infarct 
and remote is shown for each treatment group. d. Representative image of a COL3A1 





Table 15: MALDI-mapped endogenous mouse ECM peptides identified via LC-
MS/MS proteomics. *Mouse peptides that share homology sequences with human 
peptides (+) were mapped via MALDI-ECM-IMS, but were not used for the endogenous 




6.3.4 On-tissue MALDI tandem MS peptide sequencing provides evidence towards 
identifications and PTM site occupancy 
Within the differentially regulated COLα1(I) peptides identified, one peptide had 
potential for differential HYP sites. HYP is a post-translational modification necessary for 
collagen triple helix structural stability. The putative HYP containing peptide, with a 
COLα1(I) peak at m/z 897.4448 (GRPoxGEVGPoxP, where Pox is HYP; AUC = 0.686, p-
value 0.018); this peptide has one hydroxylated proline, with three potential variants at 
isobaric peaks. To identify fragments associated with each HYP variant, on-tissue 
fragmentation was performed MALDI MS/MS to identify specific fragments relating to each 
variant (Fig. 44a-b). On-tissue, the primary HYP variant identified was in proline positions 
1 and 2 (1,2; GRPoxGEVGPoxP), with 17 unique fragment peaks out of the 30 peaks 
identified. However, this experiment showed a mix of peptide variants, with 1,3 and 2,3 
variants also being identified (Fig. 44b) 
HYP site occupancy in the hydrogel-derived 897 m/z peptide were putatively 
identified but were investigated further using synthesize peptide standards (Fig. 44c-e). 
The three synthesized peptide variant standards were also investigated via trapped ion 
mobility, to distinguish the three isoforms of the 897 m/z peptide by their collisional cross-
section (Fig. 44f). An additional unmodified COLα2(I) peptide m/z 1508.7727 
(GPAGARGSDGSVGPVGPA; AUC 0.690), was also targeted for on-tissue fragmentation 
(Fig. 45). These preliminary results have tentatively identified putative peptides, as 
validated by on-tissue MALDI-MS/MS, that may be promising candidates for use in 




Figure 44: Supplementary Figure S2. On-tissue MALDI-IMS provides evidence of 
peptide sequence validation and hydroxyproline site occupancy. a. Table showing 
potential fragment ion m/z depending on hydroxyproline site localization positions of P1-
P2, P2-P3, or P1-P3. b. Annotated MALDI-MS/MS spectra produced by CID fragmentation 
on tissue. Identified b (blue) and y (red) ions are shown. Precursor ion is 897.4425 m/z, 
corresponding to a hydroxyproline containing COL1A1 peptide. P#: observed site of HYP 
(Pox) positions. There are 2 potential Pox sites out of 3 available prolines within the 
sequence. c-e. Annotated MALDI-MS/MS spectra produced by CID fragmentation of 
synthesized peptide standards of the three potential HYP site localizations (Supp. Fig 
S4). f. Ion Mobility study of the three synthesized peptides standards shown in c-e (and 
Supp. Fig. S4). An additional study was done of the three combined standards spotted 
(“cocktail”) as well as on-target summed acquisition of the three standards spotted 




Figure 45: On-tissue MALDI-IMS provides evidence of peptide sequence validation 
and hydroxyproline site occupancy. a. Annotated MALDI-MS/MS spectra produced by 
CID fragmentation. Identified b (blue) and y (red) ions are shown. Precursor ion is 




Figure 46: Confirmation of the synthesized peptide mass. a. Mass Spectrometry data 
of the synthesized peptide GRPoxGEVGPoxP, b. synthesized peptide GRPGEVGPoxPox, 
and c. synthesized peptide GRPoxGEVGPPox. Mass Spectrometry analysis was performed 
in a Waters ACQUITY UPLC XEVO TQD with a column 2.1x100 mm BEH C8, and a flow 
rate of 0.5 mL/min, a gradient of 2% to 95% of Acetonitrile in 9 minutes, and constant 0.1% 
of Formic Acid. 
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6.3.5 Collagen-based biomaterials effects on endogenous mouse ECM remodeling 
To further identify endogenous mouse ECM proteins were differentially regulated 
with hydrogel treatment, we performed parallel chromatographic proteomic experiments 
on macro dissected regions, infarct and remote. In these studies, created mouse ECM 
databases were used to earmark endogenous mouse peptides in serial sections of tissue 
used in the ECM-IMS studies. A total of 33 proteins were identified, with 42 percent (14 
out of 33) proteins being collagen subtypes, varied across families of fibril, network-
associated, FACIT (fibril-associated collagen with interrupted triple helices) and  
multiplexin (Fig. 43a-b, Fig. 44, Table 15). Peptides putatively identified from non-
collagen type proteins were implicated in pathways related to collagen biosynthesis and 
chain trimerization, GAG biosynthesis, and ECM degradation (Supplemental Table 17). 
Proteins were investigated as a function of fold change between each treatment’s Infarct 
ROI vs. Remote ROI (Fig. 43b).  
These proteomic experiments were then used to create a mouse ECM peptide 
database to apply to the MALDI-IMS dataset. Of the 62 mouse peptides mapped in the 
MALDI dataset, 39 peptides contained sequences unique to mouse and were used for 
further analysis (Fig. 43c-d, Table 17). Infarcted and Remote regions show unique 
unbiased clustering based on ECM peptide regulation (Fig. 43c). Within the infarcted 
region, rhCI and rhCIII hydrogel treated mice show similar endogenous peptide expression 
as compared to PBS treated control mice (Fig. 43c). Of these 39 endogenous mouse 
peptides, 8 were found to be differentially regulated amongst treatment groups (Table 14). 
Figure 43d shows a representative image of one of these peptides (m/z 1534.7613; 
COLα1(III) GPPoxGTAGIPoxGARGGAGPoxP) via MALDI-IMS mapping. Here, unique 




Figure 47: Protein Fold Change intensity values of Infarct/Remote ROIs for each 
treatment group (PBS control, rhCI hydrogel, rhCIII hydrogel). Raw values can be seen in 
Table 16. Proteins are organized by collagen subtype (FACIT: Fibril associated collagen 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 17: Pathway annotations for non-collagen type proteins identified in LC-MS/MS 




Table 18: Significantly Differentially Expressed Endogenous Mouse Peptides (ROC 
AUC); whole heart and infarct ROI comparisons. AUC thresholds of this study were 0.6. 
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compared to hydrogel distribution in previous figures. Interestingly, this COL3A1 peptide 
appears to be localized only to healthy remote tissue in PBS treated control, while being 
more homogenously distributed in hydrogel treated samples. Together, these studies 
show the utility of MALDI-IMS to localize both human hydrogel-specific peptides and 











Chapter 7: Conclusions and Future Directions 
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7.1 Conclusions & Limitations 
While ECM dysregulation in CAVS has been identified in the past, no approach to 
date has effectively elucidated dysregulation in specific collagen subtypes or collagen 
PTMs in pediatric end-stage CAVS. The majority of CAVS studies have involved adult 
end-stage fibrocalcific tissue samples, not pediatric end-stage caused by rapid ECM 
deposition. Current studies rely primarily on transcriptional analysis, such as qPCR and 
RNA-Seq, the results of which are not necessarily relevant to the translational level. On 
the protein level, collagen assays, such as the hydroxyproline assay, only measure total 
insoluble collagen content, not HYP levels or collagen subtypes directly. 
Immunohistochemical analysis, while translational, is limited to measuring only a few 
collagen types per tissue, and colocalization with prolyl-4-hydroxylase antibodies cannot 
map to the peptide level. Accordingly, there remains a critical need to provide in-depth 
characterization of valvular development and disease to inform therapeutic interventions. 
In a recent editorial comment on this point, Atkins et. al. discuss the need for in-
depth characterization of clinically relevant human valvular tissues samples [328]. They 
suggest the need for large-scale molecular screening that take advantage of multi-omic 
technologies. Further, the group references a recent study by Schlotter et. al. that takes 
advantage of localized proteomic analysis to use the “normal adjacent” tissue within a 
diseased valve as a control, due to the clinical lack of phenotypically normal samples [131]. 
Accordingly, the field of valve disease is shifting the paradigm from characterization 
towards a mechanistic understanding of the structure-function relationship of valve 
pathology in CAVS. 
To address this need, this dissertation outlines the use of a novel mass 
spectrometry-based methodology to report on expression levels and spatial localization of 
dozens of collagens and other ECM proteins and peptides, as well as PTMs, from human 
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valve tissue sections. By identifying not only collagen subtypes, but also the specific sites 
of their differential HYP levels and the location where they are deposited within the tissue, 
we aimed to detect innovative targets for pharmacotherapeutics that may slow the 
progression of pediatric valvular fibrosis in CAVS.  
The completion of Specific Aim 1 (Chapter 3) found via histopathological 
approaches that human pCAVS aortic valves have a unique tissue-associated collagen 
signature at end-stage: 1) the collagen-rich fibrosa layer is mixed and undefined; 2) 
collagen deposition rate increases by 56% per year of age compared to normal AV 
development; 3) there are dysregulated regions of immature collagen production; 4) 
collagen fibers misalign relative to the endothelium; and most notably 5) there are regions 
of high-density collagen fiber “plaques.” From these data, we hypothesized that 
translational regulation of collagen sub-types would differ in pCAVS tissues. To test this 
hypothesis, chromatographic-based proteomics approaches were used in Specific Aim 2. 
Interestingly, this data showed a reduction in non-fibril-type collagens associated with 
healthy endothelium, such as multiplexins (α1(XVIII)), network forming (α1(IV), α2(IV)), 
and FACIT-type collagens (α1(XIV), α1(XVI)), while fibrillogenesis-associated collagens 
(α1(V)) and chaperones (SPARC) were upregulated. Interestingly, but not unexpectedly, 
we found post-translational regulation of these collagen sub-types differed as well. We 
identified that collagen hydroxyproline (HYP), a post-translational modification (PTM) 
necessary for stabilizing the collagen triple helix, is significantly decreased in pCAVS. 
Further, the sites of HYP loss in collagens α1(I) and α1(III) in pCAVS aligned with regions 
of glycoprotein VI and integrin binding, which require HYP within the sequence. This 
suggests an influence of HYP in pCAVS on cell-ECM interactions.  
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The studies outlined in Specific Aim 1 and Specific Aim 2 (Chapter 3) were the first 
to identify a tissue associated collagen signature unique to pediatric end-stage aortic valve 
stenosis, which includes highly localized regions of dense and misaligned collagen fibers 
within the valve structure. Additionally, this is the first quantitative and structural report of 
collagen hydroxyproline, or HYP, in valve development and disease. These data establish 
the groundwork for future studies examining the spatial regulation of collagen HYP within 
valvular structures and in relation to signaling factors driving collagen organization and 
deposition in pCAVS.  
Specific Aim 3 aimed to correlate the spatial distribution of these deregulated 
collagen subtypes and PTMs relative to structural abnormalities identified via 
histopathology. However, further method development needed to be performed on our 
established MALDI-ECM-IM techniques to sufficiently access fibrotic valvular tissues. 
These developed methods, outlined in Chapter 4, detailed the serial application of 
Chondroitinase ABC, PNGaseF, Elastase, and Collagenase Type III, along with specific 
washing steps, in order to improve enzymatic access of the extracellular matrisome. This 
technique allowed for the mapping of the complex ECM from the same 5 µm tissue 
section. Here, one tissue section was evaluated for 1) pathology via histology 2) CS GAGs, 
3) N-glycans, 4) elastin, and 5) collagens and other ECM peptides. Multimodal ECM 
studies such as these are particularly useful on human valvular studies, where patient 
samples may be limited. We found that the removal of non-collagen ECM components 
improved enzymatic access of collagenase-derived peptides by as much as 40% per 
peptide. Additionally, there was an 82% increase in total number of collagenase peptides 
identified after serial removal of GAGs, N-glycans, and elastin, as compared to 
collagenase alone. Successful completion of these method-development studies (Chapter 
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4) allowed for us to use MALDI-ECM-IMS to probe the structure-function relationship of 
the extracellular matrisome in pCAVS (Specific Aim 3, Chapter 5). 
Chapter 5 outlines the results of our spatiotemporal mapping of collagen peptides 
across a cohort of normal pediatric, pediatric CAVS, and adult fibrocalcific CAVS tissues. 
Specific Aim 3 initially set out to test the hypothesis that there is differential HYP regulation 
on collagen peptides correlated to valve structure in pCAVS. While HYP containing 
collagen peptides were not found to have significantly different distribution within the 
valves structure compared to normal tissues, we did identify collagen subtype regulation 
as correlated to histopathologically defined regions of ECM dysregulation. Primarily, 
multiple peptides from collagen VI were found to localized with regions of increased fiber 
density. This study outlines the role of a collagen subtype, currently understudied past 
ages of embryonic valvular cushion development, within fibrotic valve disease. 
Additionally, this study outlines potential collagen and other ECM peptides that appear to 
have developmentally based regulation, independent of disease status. And finally, 
consistent with previous literature, we find a unique collagen proteome associated with 
fibrocalcific adult CAVS as compared to pediatric samples. 
In studies described is Chapter 6, this dissertation expands upon the initially set-
after Specific Aims to outline novel applications of our developed MALDI-ECM-IMS 
methods towards cardiovascular biomaterial characterization. ECM-IMS of collagen-
based biomaterial therapeutics enabled complex protein and PTM expression data 
analysis, which were localized to surrounding pathological regions and within the 
biomaterial injection site (Chapter 6). The use of MALDI-IMS in this study was able to 
localize and identify peptides within hydrogel injected tissues, as well as identify potential 
endogenously differentiated extracellular matrix proteins. While this study focused on 
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imaging of the collagenous component of the injected biomaterials, glycosaminoglycans 
such as chondroitin sulfate (also within the hydrogel studied, Chapter 6) and recombinant 
elastin proteins are other common components of hydrogels that could potential be 
examined using the methods outlined in Chapter 6. Serial-enzyme ECM-targeted 
strategies used on-tissue may be beneficial to better understand therapeutic mechanisms 
of complex hydrogel mixtures [145]. These and future studies may provide evidence and 
insight for which hydrogel-derived peptides are most efficacious at promoting healing in 
the initial wound environment before therapeutic hydrogel degradation. 
One limitation of our pCAVS study (Chapters 3 and 5) was the sample size of the 
cohort. Pediatric tissues inherently are difficult to obtain with a past national average of 
only 40% of families consenting for tissue use and donation [329]. Actual figures in specific 
regions may be lower[330]. This limitation similarly effects pediatric human aortic valve 
interstitial cell studies, as these require fresh samples for immediate cell isolation [331, 
332] as opposed to the resected valves that are available through tissue banks. These 
limitations also prevented in-depth population studies of the cohort, including influences 
of gender, ethnicity, and socioeconomic status. Nevertheless, this is the largest collagen 
study to date on valve tissue with pediatric end-stage aortic valve stenosis. Future 
investigations to extend studies from this small clinically-relevant cohort will be critical to 
understanding how developmental timing of valvular interstitial cell signaling influences 
spatial distribution of collagen fiber production. 
Overall, this dissertation used novel ECM targeted mass spectrometry techniques 
in order to elucidate the roll of collagen translation and post-translational regulation in 
pCAVS, with potential application to therapeutic biomaterials. By identifying specific 
collagen type peptides with deregulated HYP levels in CAVS, we will lay the groundwork 
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in new studies on signaling factors driving collagen organization and deposition in CAVS 
as well as other fibrotic diseases, driving novel anti-fibrotic pharmaco-therapeutic 
development. We anticipate that this data will inform functional testing of cell-based 
mechanisms regulating collagen HYP, the generation of new mouse models of valve 
disease, and improvements in the development of collagen biomaterials used in in 
vitro valve disease models and bioengineered valve replacements. 
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7.2 Future Directions 
Many findings in this thesis lay the groundwork for mechanistic studies examining 
the functional implications of translational and post-translational regulation of the 
extracellular matrisome in pediatric CAVS. A major advantage of working with formalin-
fixed paraffin embedded tissue samples is the ability to collect clinically relevant, human 
tissue samples from continuously expanding biorepositories, as done in this dissertation 
work. A limitation, however, is the static nature of fixed tissue, which hinders dynamic 
mechanistic studies. Potential future studies building upon our findings are discussed in 
this subchapter. 
Our quantitative proteomic studies were able to map the collagen PTM HYP to cell-
binding domains within the collagen sequences, however the role of ECM signaling was 
not investigated directly. The ECM has been shown to regulate signaling in three main 
ways that may be explored in future studies: 1) matricellular signaling, via cell surface 
receptors; 2) matricrine signaling, where the ECM serves as a reservoir for growth factors; 
and 3) mechanical signaling, where ECM affects stiffness, strain, and other biomechanical 
factors [42, 96]. Studies advancing our work beyond characterization towards ECM-
signaling regulated mechanisms are outlined below. 
Chapter 3 elucidates the potential role of matricellular signaling in pCAVS that 
could be explored. In a healthy valve, VECs form a barrier between interstitial collagen 
and circulating factors. However, as mentioned in Chapter 1, CAVS is associated with 
endothelial barrier dysfunction [333]. This potentially may lead to increased exposure of 
interstitial collagen subtypes that are capable of binding to platelets and subsequence 
thrombus deposition. We found that motifs of glycoprotein VI binding in primarily fibril type 
collagens showed a reduction of HYP, suggesting the potential for reduced glycoprotein 
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VI binding. While unexplored in pediatric cases, It has been reported that adult patients 
with AVS have decreased platelet function and aggregation; however the role of HYP 
content has not been explored as a potential mechanism directly [248]. Based on our 
research, investigating the role of collagen hydroxyproline and glycoprotein VI binding in 
pCAVS may be of value. Similarly, our studies find a reduction in HYP in domains of fibril 
type collagen reported to bind to integrins. Integrin α2β1 has been mostly shown to affect 
platelet aggregation and mast cell functions [246, 334]. Interestingly, mast and 
inflammatory cell infiltration is seen in adult CAVS [335-339] but is unexplored or unseen 
in pediatric cases [31]. Additional experiments may incorporate our findings of HYP 
reduction in integrin binding motifs with the impact on integrin signaling and immune cell 
infiltration. 
 Future studies may build upon our finding of differential localization of collagen 
HYPs site in CAVS to determine potential mechanisms of this reduction. Essential co-
factors that regulate collagen HYP include iron, oxygen, and ascorbic acid, along with 
nutritional status and oxidative stress [69, 234, 340]. Wu et. al. recently found that ascorbic 
acid promoted quiescence in VICs [341]. Interestingly, organized and aligned deposition 
of collagens I and III were promoted. These studies were performed in 3D hydrogel 
cultures of porcine VICs and may further suggest a difference between “good” and “bad” 
ECM deposition in the context of valve disease [341]. Similar studies may be done in 
freshly isolated pediatric VICs. An alternative avenue to measure mechanisms of 
decreased HYP in pCAVS may be to explore other essential co-factors as well as the role 
of prolyl hydroxylases.  
While not outlined in this dissertation, co-authored works within the Angel Lab 
investigated other collagen post-translational modifications involved in matricellular 
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signaling, such as N-linked glycosylation [114]. Within this work, we examined the relative 
abundance and localization of N-linked glycans within the pCAVS cohort (Appendix D-E). 
We found that pCAVS valve demonstrated a primarily core-fucosylated phenotype. Within 
normal valve samples, core-fucose N-glycans aligned with the GAG-rich spongiosa, 
however this layer-specific architecture is lost in pCAVS. Interestingly, core-fucose N-
glycans have been associated with TGFβ signaling, with a reduction in core-fucosylation 
shown to attenuate renal fibrosis [342, 343]. This has yet to be explored in valvular 
disease. These data, along with recent literature, is suggestive of the need for further 
matricrine signaling focused research in pCAVS. 
 As suggested via extracellular localization studies outlined in Chapter 5, known 
hemodynamic-biomechanical signaling may have a potential localized role in matrix 
remodeling. Additionally, our histopathological studies show an increase in immature 
collagen localized regulation in pCAVS as well as an increase in regions of dense collagen 
fibers (Chapter 3; Figure 8-9). Further, this dissertation showed that pCAVS can be 
characterized by collagen fiber misalignment relative to the endothelium (Chapter 3, 
Figure 10).  These suggest the need for future studies in the role of biomechanical 
signaling   ̶ as well as MMPs and TIMPs   ̶ on collagen deposition, degradation, and 
alignment in pCAVS, as our findings are suggestive of active collagen remodeling. 
Interesting work is being done on the role of MMPs, TIMPs, and matrix remodeling in the 
context of cardiac fibrosis by the Richardson Lab. Their group uses systems-based 
approaches to study localized regional heterogeneity of collagen orientation within the 
cardiac structure, as well as mechanical signaling induced remodeling regulation [344, 
345]. Similar systems studies may be done to translate this work to our findings in collagen 
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alignment heterogeneity in valvular disease, as a function of hemodynamic induced 
mechanical strain.  
Independent of valvular biology, this dissertation outlines MALDI-IMS methods that 
have promising applications in ECM biology and biomaterials. An advantage of the multi-
enzyme ECM-targeting strategy outlined in Chapter 4 is that multiple analytes can be 
mapped to the same spatial coordinates which synergistically increases molecular 
information obtained from a single tissue section. Our work has shown that serial 
application of these enzymes does not impair the quality of the signal of the following 
enzyme, and it some cases it improves it. This workflow on a single tissue section allows 
for deep tissue mining of the extracellular matrix as well as colocalization and correlation 
studies between analytes. Work by Heijs et al described an elegant bioinformatic approach 
to colocalize N-glycan tissue maps to tryptic glycopeptide mapping [13]. A similar 
technique could be used in this current study not only for collagenase and elastin peptides 
but also for N-glycans and CS GAGs.  
Multi-enzyme studies targeting GAGs as developed in this dissertation (Chapter 4) 
may be useful in elucidated the role of matricrine signaling in CAVS. Chondroitin Sulfate 
GAGs have been shown to increase bioavailability of latent TGFβ in smooth muscle cells, 
while heparan sulfate GAGs have been reported to increase Fibroblast Growth Factor 
signaling [96, 346, 347]. This has yet to be explored in valvular development or disease. 
However, proteoglycans biglycan and decorin have been associated with increasing TGFβ 
and other growth factors in valves, which resulted in increased calcification [348]. 
Interestingly, TGFβ has also been implicated in valvular EndMT [5], although the role of 
surrounding ECM has not been elucidated.  
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Additionally, serial enzyme methods developed here may have advantages for 
proteoglycan-peptide analysis. For example, digestions with chondroitinase ABC leaves 
behind a disaccharide and linker tetrasaccharide attached to the core protein that is later 
cleaved with COLase3 [36]. This unsaturated linker could be used in future studies to 
determine potential GAG-linker sites on identified CS-proteoglycan peptides (e.g., 
decorin, biglycan) [27]. While currently unexplored, this same linker-tracking methodology 
may be applicable with heparan sulfate proteoglycans and hyalectan proteoglycans, which 
are also detected via our COLase3 digest methodology. 
Similarly, research done in this dissertation may inform strategies for imaging of 
COLase3-produced glycopeptides. Previous studies have shown that PNGase F digestion 
combined with 18O water may be used to demark occupied sites of N-glycosylation on a 
tryptic glycopeptide [37]. For ECM analysis, this strategy combines PNGase F digestion 
in 18O water followed by COLase3 to understand site occupancy of ECM glycopeptides. 
An additional strategy incorporates another enzyme, endoglycosidase F3, into this 
workflow. Endoglycosidase F3, which cleaves N-glycans directly above the core fucose-
N-acetylglucasamine structure, creates an effective tag for core fucosylated N-
glycopeptides [38, 39]. While not yet applied to glycopeptide imaging studies, this mass 
shift has shown to be a trackable linker in glycopeptide LC-MS/MS workflows [38]. 
Future work may be done to use multi-enzyme MALDI-IMS techniques developed 
in this dissertation to probe cell-ECM interactions on-tissue. Our preliminary proteomics 
studies show that HYP is not only reduced in pCAVS but is specifically reduced in collagen 
domains critical to cell-ECM binding (Fig. 13). The healthy AV is comprised of two cell 
types: valvular interstitial cells (VICs) and valvular endothelial cells (VECs). VIC activation 
is known to play a role in ECM disorganization in both adult FAVS and pediatric CAVS[31, 
192 
 
32]. Similarly, VEC dysfunction is well established in adult CAVS but underexplored in 
pCAVS. Published studies show an increase in collagen 2 and collagen 10 in calcified 
adult valves, along with osteochondrogenic markers such as p-SMAD 1/5/8 and 
Runx2[31]. However, the field recognizes a distinct cell activation profile between pCAVS 
and FAVS[31]. While activation markers specific to pCAVS have been identified[31], no 
work has been done to define the relationship between cell activation and surrounding 
ECM deposition in pCAVS. 
Our lab has shown a decrease in endothelial-derived collagen peptides and, in 
contrast, an increase in fibril-type and fibrillogenesis-associated collagen peptides in 
pCAVS (Chapter 3, Fig. 13). Interestingly, chaperone SPARC – found be associated with 
increasing collagen fibrillogenesis, pro-collagen post-translational regulation and reduced 
collagen-integrin binding – was also enriched in pCAVS. (Chapter 3, Fig. 14). Further, 
HYP sites in SPARC binding motifs are maintained in pCAVS (Chapter 3, Fig. 13). All of 
these data suggest that there may be distinct cellular markers, such as SPARC, that 
correlate to localized ECM regulation.  
One method to explore this is histology directed MALDI-IMS [349]. A 
representative workflow of this method is outlined in Figure 48. In this method, 
immunohistochemistry staining is done on-tissue to identify positively and negatively 
stained cells of interest. Then, high resolution scans can be taken to capture the 
histological profile and define regions of interest (ROIs) corresponding to positively and 
negatively stained cells. Tissues will then be taken through the MALDI-IMS protocol with 
ROIs targeted to identify each cell’s corresponding ECM niche by identifying modified and 
unmodified ECM peptides. Preliminary data shows that this method can be used to identify 
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differentially distributed HYP containing collagen peptides between cell markers, such as 
PTEN in breast pathologies [350].  
Relevent to these studies, histology direct MALDI-IMS could be used to identify 
the distinct molecular profiles of differentially activated VICs. Similarly, the relative ECM 
deposited by VECs and VICs could be characterized to identify molecular mechanisms of 
valve development and failure. These methods could be used during various stages of 
valvular development to determine the role of EndMT in ECM deposition and dysregulation 
[289, 351]. Using the multi-modal MALDI-IMS methods developed in this dissertation, the 
glycosaminoglycome and N-glycome of these cells could be explored, in addition to the 
collagen proteome. 
Another potential avenue is to advance these histology-directed techniques on-
tissue towards cell culture models. Recent advances have been made to single-cell and 
cell population IMS applications within cell culture conditions [352-355]. While several cell 
culture models exist for adult fibrocalcific AVS [356-361], there is a not a relevant model 
to pediatric CAVS beyond fresh isolation [331, 362]. A strategy to study the role of HYP in 
a dynamic mechanistic context could be to knock-down prolyl-4-hydroxylase in VICs, 
reducing HYP-modified collagen deposition in culture. MALDI-IMS and IHC can correlate 
HYP modification to molecular markers of interest, such as SPARC (as identified in 
Chapter 4; Figure 15) as well as cell activation, proliferation, and migration, compared to 
normal cells plated on unmodified collagen. Similarly, single-cell MALDI-IMS studies may 
be appropriate to studies of VICs and VECs in culture – potentially as a function of co- vs. 
mono-culture [15, 16, 363], layer specific architecture [131, 361], fluid dynamics [16, 29, 
34, 364-368], or alignment [369-371]. 
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 Finally, Chapter 7 outlined the application of using our ECM targeted MALDI-IMS 
techniques to differentially localize species-specific collagen sequences, as applied to 
human-derived collagen hydrogel injected into mouse myocardium in vivo. This study also 
outlined the application of MALDI-ECM-IMS to student endogenous ECM remodeling as 
a function of therapeutic biomaterials. These techniques have the potential to be applied 
in valvular pathologies and bioengineered solutions. Blum et al recently called for 
mechanistic studies of tissue engineered heart valves [372]. They comment on the current 
need for improved tissue engineered heart valves (TEHV) for pediatric patients, due to 
high incidents of failure in pediatric patients with few studies on mechanism [373-375]. 
While advancements in valve regeneration have been made, few studies characterize the 
role of ECM in TEHV failure or regenerative capacity [373].  MALDI-ECM-IMS may be 
used to study ECM remodeling within TEHV in a species-targeted manner, similar to the 
work outlined in Chapter 6. For example, while decellularized porcine and sheep TEHVs 
may be investigated for cell infiltrate, it is difficult to elucidate collagen-subtype regulation 
and post-translational regulation as a function of scaffold vs. infiltrate remodeling.  Along 
with further clinical characterization, we hope MALDI-ECM-IMS applications outlined in 
this study elucidate mechanisms of failure and inform better bioengineered solutions 





Figure 48: Histology-directed MALDI-IMS workflow. IHC analysis of cell markers 
will identify regions of interest (ROIs). The same tissue section will be taken through 
COLase3 MALDI-IMS to identify the molecular ECM signature of each ROI identified, 






Appendix A: Representative image of unoptimized MALDI-ECM-IMS analysis on aortic 
valve tissue sections. A total of 20 putative peptides were identified from this dataset. 





Appendix B: Laser spot size studies (timsTOF fleX, Bruker LLC). Method development 





Appendix D: Pediatric CAVS valves have high cell density in regions of elastin 
mixing and high total surface area. A. Cell density mask workflow, created in ImageJ. 
B. Cell density mask of SKU DB27 with corresponding Movat’s Pentachrome staining. C. 
Cell density mask of SKU DB16 with corresponding Movat’s Pentachrome staining. E. 
Boxplot of cell density measurements across the valve cohort (in cells/mm2). F. Patient 
specific cell density measurements (in cells/mm2) organized by patient category and 
patient age. *P<0.05, Mann-Whitney U test. G. Boxplot of cross sectional (CS) surface 
area measurements across the valve cohort (in mm2). F. Patient specific CS surface area 
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